<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>KALETRA- lopinavir and ritonavirÂ tablet, film coatedÂ </strong><br>Dispensing Solutions, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use KALETRA safely and effectively. See full prescribing information for KALETRA.<br><br>KALETRA (lopinavir/ritonavir) Tablet, Film Coated for Oral use <br>KALETRA (lopinavir/ritonavir) Solution for Oral use<br>Initial U.S. Approval: 2000</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Warnings and Precautions, Immune Reconstitution Â Â Â  Â Â Â  02/2012 <br>Syndrome. (<a href="#section_5.8">5.8</a>) </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">KALETRA is an HIV-1 protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.  (<a href="#section_1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Tablets: May be taken with or without food, swallowed whole and not chewed, broken, or crushed. (<a href="#section_2">2</a>) </p>
<p class="Highlighta">Oral solution: must be taken with food. (<a href="#section_2">2</a>) </p>
<p class="Highlighta">Do not use once daily administration of KALETRA in: </p>
<ul class="Disc">
<li>HIV-1 infected patients with three or more of the following lopinavir resistance-associated substitutions: L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V. (<a href="#section_2.1">2.1</a>)</li>
<li>Combination with efavirenz, nevirapine, amprenavir, nelfinavir, carbamazepine, phenobarbital, or phenytoin. (<a href="#section_2.1">2.1</a>, <a href="#section_7.3">7.3</a>)</li>
<li>Pediatric patients. (<a href="#section_2.2">2.2</a>)</li>
</ul>
<p class="Highlighta"><span class="Underline">Adult Patients:</span> </p>
<ul class="Disc">
<li>400/100 mg (two 200/50 mg tablets or 5 mL oral solution) twice daily. (<a href="#section_2.1">2.1</a>)<br>or</li>
<li>800/200 mg (four 200/50 mg tablets or 10 mL oral solution) once daily in patients with less than three lopinavir resistance-associated substitutions. (<a href="#section_2.1">2.1</a>) </li>
</ul>
<p class="Highlighta"><span class="Underline">Pediatric Patients (14 days and older):</span> </p>
<ul class="Disc"><li>Twice daily dose is based on body weight or body surface area. (<a href="#section_2.2">2.2</a>)</li></ul>
<p class="Highlighta">Concomitant Therapy in Adults and Pediatric Patients </p>
<ul class="Disc"><li>Dose adjustments of KALETRA may be needed when co-administering with efavirenz, nevirapine, amprenavir, or nelfinavir. (<a href="#section_2.1">2.1</a>,<a href="#section_2.2"> 2.2</a>,<a href="#section_7.3"> 7.3</a>)</li></ul>
<p class="Highlighta">KALETRA oral solution should not be administered to neonates before a postmenstrual age (first day of the motherâ€™s last menstrual period to birth plus the time elapsed after birth) of 42 weeks and a postnatal age of at least 14 days has been attained (<a href="#section_2.2">2.2</a>, <a href="#section_5.2">5.2</a>) </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc">
<li>Film-coated tablets:  200 mg lopinavir and 50 mg ritonavir (<a href="#section_3">3</a>)</li>
<li>Film-coated tablets:  100 mg lopinavir and 25 mg ritonavir (<a href="#section_3">3</a>)</li>
<li>Oral solution:  80 mg lopinavir and 20 mg ritonavir per milliliter (<a href="#section_3">3</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to KALETRA (e.g., <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>) or any of its ingredients, including ritonavir. (<a href="#section_4">4</a>) </p>
<p class="Highlighta">Co-administration with: </p>
<ul class="Disc">
<li>drugs highly dependent on CYP3A for clearance and for which elevated plasma levels may result in serious and/or life-threatening events. (<a href="#section_4">4</a>)</li>
<li>potent CYP3A inducers where significantly reduced lopinavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance and cross resistance. (<a href="#section_4">4</a>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<p class="Highlighta">The following have been observed in patients receiving KALETRA: </p>
<ul class="Disc">
<li>Drug Interactions: Higher plasma concentrations of concomitant medications may occur; consider drug-drug interaction potential to reduce risk of serious or life-threatening adverse reactions. (<a href="#section_5.1">5.1</a>)</li>
<li>Toxicity in preterm neonates: KALETRA oral solution should not be used in preterm neonates in the immediate postnatal period because of possible toxicities. A safe and effective dose of KALETRA oral solution in this patient population has not been established. (<a href="#section_2.2">2.2</a>, <a href="#section_5.2">5.2</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>: Fatalities have occurred; suspend therapy as clinically appropriate. (<a href="#section_5.3">5.3</a>)</li>
<li>Hepatotoxicity: Fatalities have occurred. Monitor liver function before and during therapy, especially in patients with underlying <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C, or marked transaminase elevations. (<a href="#section_5.4">5.4</a>, <a href="#section_8.6">8.6</a>)</li>
<li>PR interval prolongation may occur in some patients.  Cases of second and third degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> have been reported. Use with caution in patients with pre-existing conduction system disease, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, underlying structural heart disease or when administering with other drugs that may prolong the PR interval. (<a href="#section_5.1">5.1</a>, <a href="#section_5.6">5.6</a>, <a href="#section_12.3">12.3</a>)</li>
<li>QT interval prolongation and isolated cases of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> have been reported although causality could not be established. Avoid use in patients with congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>, those with <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, and with other drugs that prolong the QT interval. (<a href="#section_5.1">5.1</a>, <a href="#section_5.7">5.7</a>, <a href="#section_12.3">12.3</a>)</li>
<li>Patients may develop new onset or exacerbations of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> (<a href="#section_5.5">5.5</a>), <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">immune reconstitution syndrome</span>. (<a href="#section_5.8">5.8</a>), redistribution/accumulation of body fat. (<a href="#section_5.9">5.9</a>)</li>
<li>Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides elevations. Monitor prior to therapy and periodically thereafter. (<a href="#section_5.10">5.10</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">Hemophilia</span>: Spontaneous <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may occur, and additional factor VIII may be required. (<a href="#section_5.11">5.11</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (greater than 5%) were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>. (<a href="#section_6.1">6.1</a>, <a href="#section_6.2">6.2</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Abbott Laboratories at 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Co-administration of KALETRA can alter the plasma concentrations of other drugs and other drugs may alter the plasma concentrations of lopinavir. The potential for drug-drug interactions must be considered prior to and during therapy. (<a href="#section_4">4</a>, <a href="#section_5.1">5.1</a>, <a href="#section_7">7</a>, <a href="#section_12.3">12.3</a>) </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 5/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Adult Patients</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Pediatric Patients</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Drug Interactions - CYP3A Enzyme Inhibition</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Toxicity in Preterm Neonates</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Hepatotoxicity</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus/<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 PR Interval Prolongation</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 QT Interval Prolongation</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Fat Redistribution</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Lipid Elevations</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Patients with <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">Hemophilia</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Resistance/Cross-resistance</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Adults - Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Pediatric Patients - Clinical Trials Experience</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Potential for KALETRA to Affect Other Drugs</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Potential for Other Drugs to Affect Lopinavir</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Established and Other Potentially Significant Drug Interactions</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Drugs with No Observed or Predicted Interactions with KALETRA  </a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Patients without Prior Antiretroviral Therapy</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Patients with Prior Antiretroviral Therapy</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Other Studies Supporting Approval</a></h2>
<h2><a href="#section-13.4" class="toc">14.4 Pediatric Studies </a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">16.1 KALETRA Tablets, 200 mg lopinavir/50 mg ritonavir</a></h2>
<h2><a href="#section-14.2" class="toc">16.2 KALETRA Tablets, 100 mg lopinavir/25 mg ritonavir</a></h2>
<h2><a href="#section-14.3" class="toc">16.3 KALETRA Oral Solution</a></h2>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc"></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section_1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First"><a name="p301408"></a>KALETRA is indicated in combination with other antiretroviral agents for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p><a name="p331408"></a>The following points should be considered when initiating therapy with KALETRA:</p>
<ul class="Disc">
<li>The use of other active agents with KALETRA is associated with a greater likelihood of treatment response <span class="Italics">[see Clinical Pharmacology (<a href="#section_12.4">12.4</a>) and Clinical Studies (<a href="#section_14">14</a>)]</span>.</li>
<li>Genotypic or phenotypic testing and/or treatment history should guide the use of KALETRA <span class="Italics">[see Clinical Pharmacology (<a href="#section_12.4">12.4</a>)]</span>. The number of baseline lopinavir resistance-associated substitutions affects the virologic response to KALETRA <span class="Italics">[see Clinical Pharmacology (<a href="#section_12.4">12.4</a>)]</span>.</li>
<li>Once daily administration of KALETRA is not recommended for any pediatric patients.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section_2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"><a name="p2951408"></a><span class="Italics">KALETRA tablets may be taken with or without food.</span> The tablets should be swallowed whole and not chewed, broken, or crushed.</p>
<p><a name="p3011408"></a><span class="Italics">KALETRA oral solution must be taken with food.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section_2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Adult Patients</h2>
<ul class="Disc">
<li>KALETRA tablets 400/100 mg (given as two 200/50 mg tablets) twice daily.</li>
<li>KALETRA oral solution 400/100 mg (5 mL) twice daily.</li>
<li>KALETRA tablets 800/200 mg (given as four 200/50 mg tablets) once daily in patients with less than three lopinavir resistance-associated substitutions.</li>
<li>KALETRA oral solution 800/200 mg (10 mL) once daily in patients with less than three lopinavir resistance-associated substitutions.</li>
</ul>
<p class="First"><a name="p10451408"></a>Once daily administration of KALETRA is not recommended for adult patients with three or more of the following lopinavir resistance-associated substitutions: L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V <span class="Italics">[see Clinical Pharmacology (<a href="#section_12.4"> 12.4</a>)]</span>.</p>
<p><a name="p10581408"></a>KALETRA should not be administered once daily in combination with carbamazepine, phenobarbital, or phenytoin <span class="Italics">[see Drug Interactions (<a href="#section_7">7</a>)]</span>.</p>
<p><a name="p10711408"></a><span class="Italics">Concomitant Therapy: Efavirenz, Nevirapine, Amprenavir or Nelfinavir</span></p>
<p><a name="p12821408"></a><span class="Italics">[see Clinical Pharmacology (<a href="#section_12.3">12.3</a>) and [Drug Interactions (<a href="#section_7.3">7.3</a>)]</span></p>
<p><a name="p12951408"></a><span class="Underline">KALETRA tablets and oral solution should not be administered as a once daily regimen in combination with efavirenz, nevirapine, amprenavir, or nelfinavir.</span></p>
<ul class="Disc">
<li>A dose increase is recommended for all patients who use KALETRA tablets. The recommended dose of KALETRA tablets is 500/125 mg (such as two 200/50 tablets and one 100/25 mg tablet) twice daily in combination with efavirenz, nevirapine, amprenavir or nelfinavir. </li>
<li>A dose increase is recommended for all patients who use KALETRA oral solution. The recommended dose of KALETRA oral solution is 533/133 mg (6.5 mL) twice daily when used in combination with efavirenz, nevirapine, amprenavir or nelfinavir.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Pediatric Patients</h2>
<p class="First"><a name="p13161408"></a>KALETRA tablets and oral solution should not be administered once daily in pediatric patients &lt; 18 years of age.</p>
<p><a name="p502194408"></a>KALETRA oral solution should not be administered to neonates before a postmenstrual age (first day of the motherâ€™s last menstrual period to birth plus the time elapsed after birth) of 42 weeks and a postnatal age of at least 14 days has been attained <span class="Italics">[see Warnings and Precautions (<a href="#section_5.2">5.2</a>)]</span>.</p>
<p><a name="p1544324"></a>KALETRA oral solution contains 42.4% (v/v) alcohol and 15.3% (w/v) propylene glycol. Special attention should be given to accurate calculation of the dose of KALETRA, transcription of the medication order, dispensing information and dosing instructions to minimize the risk for medication errors, and <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. This is especially important for infants and young children.  Total amounts of alcohol and propylene glycol from all medicines that are to be given to pediatric patients 14 days to 6 months of age should be taken into account in order to avoid toxicity from these excipients <span class="Italics">[see Warnings and Precautions (<a href="#section_5.2">5.2</a>) and Overdosage (<a href="#section_10">10</a>)].</span></p>
<p><a name="p15381408"></a><span class="Underline">Prescribers should calculate the appropriate dose of KALETRA for each individual child based on body weight (kg) or body surface area (BSA) to avoid underdosing or exceeding the recommended adult dose.</span></p>
<p><a name="p15451408"></a>Body surface area (BSA) can be calculated as follows:  </p>
<div class="Figure"><img alt="Body surface area equation." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dac2ea61-f5ce-45b8-b4aa-d761c5aecd74&amp;name=kaletra-tablets-bsacalculation.jpg"></div>
<p><a name="p15521408"></a>The KALETRA dose can be calculated based on weight or BSA:</p>
<p><a name="p15551408"></a><span class="Bold">Based on Weight:</span></p>
<p><a name="p15601408"></a>Patient Weight (kg) Ã— Prescribed lopinavir dose (mg/kg) = Administered lopinavir dose (mg) </p>
<p><a name="p15631408"></a><span class="Bold">Based on BSA:</span></p>
<p><a name="p15681408"></a>Patient BSA (m<span class="Sup">2</span>) Ã— Prescribed lopinavir dose (mg/m<span class="Sup">2</span>) = Administered lopinavir dose (mg)</p>
<p><a name="p15811408"></a>If KALETRA oral solution is used, the volume (mL) of KALETRA solution can be determined as follows:</p>
<p><a name="p15841408"></a>Volume of KALETRA solution (mL) = Administered lopinavir dose (mg) Ã· 80 (mg/mL)</p>
<p><a name="p17951408"></a>The dose of the oral solution should be administered using a calibrated dosing syringe.</p>
<p><a name="p18001408"></a>Before prescribing KALETRA 100/25 mg tablets, children should be assessed for the ability to swallow intact tablets. If a child is unable to reliably swallow a KALETRA tablet, the KALETRA oral solution formulation should be prescribed.</p>
<p><a name="p18061408"></a><span class="Italics">14 Days to 6 Months: </span></p>
<p><a name="p18111408"></a>In pediatric patients 14 days to 6 months of age, the recommended dosage of lopinavir/ritonavir using KALETRA oral solution is 16/4 mg/kg or 300/75 mg/m<span class="Sup">2</span> twice daily.  Prescribers should calculate the appropriate dose based on body weight or body surface area. </p>
<p><a name="p18181408"></a>Because no data exists for dosage when administered with efavirenz, nevirapine, amprenavir, or nelfinavir, it is recommended that KALETRA not be administered in combination with these drugs in patients &lt; 6 months of age.</p>
<p><a name="p18221408"></a>6 Months to 18 Years:</p>
<p><a name="p18251408"></a><span class="Italics">Without Concomitant Efavirenz, Nevirapine, Amprenavir or Nelfinavir</span></p>
<p><a name="p18301408"></a><span class="Italics"><span class="Underline">Dosing recommendations using oral solution</span></span></p>
<p><a name="p18371408"></a>In children 6 months to 18 years of age, the recommended dosage of lopinavir/ritonavir using KALETRA oral solution without concomitant efavirenz, nevirapine, amprenavir, or nelfinavir is 230/57.5 mg/m<span class="Sup">2</span> given twice daily, not to exceed the recommended adult dose (400/100 mg [5 mL] twice daily).  If weight-based dosing is preferred, the recommended dosage of lopinavir/ritonavir for patients &lt; 15 kg is 12/3 mg/kg given twice daily and the dosage for patients â‰¥ 15 kg to 40 kg is 10/2.5 mg/kg given twice daily. </p>
<p><a name="p20501408"></a><span class="Italics">Dosing recommendations using tablets</span></p>
<p><a name="p20551408"></a>Table 1 provides the dosing recommendations for pediatric patients 6 months to 18 years of age based on body weight or body surface area for KALETRA tablets.</p>
<a name="table_1"></a><table border="1" frame="box" rules="all" width="100%">
<caption><span>Table 1.  Pediatric Dosing Recommendations for Patients 6 Months to 18 Years of Age Based on Body Weight or Body Surface Area for KALETRA Tablets Without Concomitant Efavirenz, Nevirapine, Amprenavir, or Nelfinavir</span></caption>
<colgroup>
<col width="33%">
<col width="33%">
<col width="34%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Toprule"><span class="Bold">Body Weight (kg)</span></td>
<td class="Toprule" align="center"><span class="Bold">Body Surface Area (m<span class="Sup">2</span>)<span class="Sup">*</span></span></td>
<td class="Toprule" align="center"><span class="Bold">Recommended number of <br>100/25 mg Tablets Twice Daily</span></td>
</tr>
<tr>
<td align="center">15 to 25</td>
<td align="center">â‰¥0.6 to &lt; 0.9</td>
<td align="center">2 </td>
</tr>
<tr>
<td align="center">&gt;25 to 35</td>
<td align="center">â‰¥0.9 to &lt; 1.4</td>
<td align="center">3  </td>
</tr>
<tr>
<td align="center">&gt;35</td>
<td align="center">â‰¥1.4</td>
<td align="center">4 (or two 200/50 mg tablets)</td>
</tr>
<tr class="Last"><td colspan="3">* KALETRA oral solution is available for children with a BSA less than 0.6 m<span class="Sup">2</span> or those who are unable to reliably swallow a tablet. </td></tr>
</tbody>
</table>
<p><a name="p25641408"></a><span class="Italics">Concomitant Therapy: Efavirenz, Nevirapine, Amprenavir, or Nelfinavir</span></p>
<p><a name="p25691408"></a><span class="Italics"><span class="Underline">Dosing recommendations using oral solution</span></span></p>
<p><a name="p25761408"></a>A dose increase of KALETRA to 300/75 mg/m<span class="Sup">2</span> using KALETRA oral solution is needed when co-administered with efavirenz, nevirapine, amprenavir, or nelfinavir in children (both treatment-naÃ¯ve and treatment-experienced) 6 months to 18 years of age, not to exceed the recommended adult dose (533/133 mg [6.5 mL] twice daily). If weight-based dosing is preferred, the recommended dosage for patients &lt;15 kg is 13/3.25 mg/kg given twice daily and the dosage for patients &gt;15 kg to 45 kg is 11/2.75 mg/kg given twice daily. </p>
<p><a name="p25831408"></a><span class="Italics"><span class="Underline">Dosing recommendations using tablets</span></span></p>
<p><a name="p25901408"></a>Table 2 provides the dosing recommendations for pediatric patients 6 months to 18 years of age based on body weight or body surface area for KALETRA tablets when given in combination with efavirenz, nevirapine, amprenavir, or nelfinavir.  </p>
<a name="table_2"></a><table border="1" frame="box" rules="all" width="100%">
<caption><span>Table 2.  Pediatric Dosing Recommendations for Patients 6 Months to 18 Years of Age Based on Body Weight or Body Surface Area for KALETRA Tablets With Concomitant Efavirenz<span class="Sup">â€ </span>, Nevirapine, Amprenavir<span class="Sup">â€ </span> or Nelfinavir<span class="Sup">â€ </span></span></caption>
<colgroup>
<col width="22%">
<col width="34%">
<col width="42%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Toprule"><span class="Bold">Body Weight (kg)</span></td>
<td class="Toprule" align="center"><span class="Bold">Body Surface Area (m<span class="Sup">2</span>)<span class="Sup">*</span></span></td>
<td class="Toprule" align="center"><span class="Bold">Recommended number of<br> 100/25 mg Tablets Twice Daily</span></td>
</tr>
<tr valign="top">
<td align="left">15 to 20</td>
<td align="center">â‰¥0.6 to &lt; 0.8</td>
<td align="center">2  </td>
</tr>
<tr valign="top">
<td align="left">&gt;20 to 30</td>
<td align="center">â‰¥0.8 to &lt; 1.2</td>
<td align="center">3  </td>
</tr>
<tr valign="top">
<td align="left">&gt;30 to 45</td>
<td align="center">â‰¥1.2 to &lt;1.7</td>
<td align="center">4 (or two 200/50 mg tablets)</td>
</tr>
<tr valign="top">
<td align="left">&gt;45</td>
<td align="center">â‰¥1.7</td>
<td align="center">5 [<span class="Italics">see Dosage and Administration</span>, Adult Patients (<a href="#section_2.1">2.1</a>)]</td>
</tr>
<tr class="Last"><td colspan="3">* KALETRA oral solution is available for children with a BSA less than 0.6 m<span class="Sup">2</span> or those who are unable to reliably swallow a tablet.<br><span class="Sup">â€ </span>  Please refer to the individual product labels for appropriate dosing in children. </td></tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section_3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<ul class="Disc">
<li>
<span class="Bold">KALETRA Tablets, 200 mg lopinavir/50 mg ritonavir</span><br>Yellow, film-coated, ovaloid tablets debossed with the corporate Abbott â€œAâ€? logo and the Abbo-Code KA providing 200 mg lopinavir/50 mg ritonavir.</li>
<li>
<span class="Bold">KALETRA Tablets, 100 mg lopinavir/25 mg ritonavir</span><br><span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">Pale</span> yellow, film-coated, ovaloid tablets debossed with the corporate Abbott â€œAâ€? logo and the Abbo-Code KC providing 100 mg lopinavir/25 mg ritonavir.</li>
<li>
<span class="Bold">KALETRA Oral Solution</span><br>Light yellow to orange colored liquid containing 400 mg lopinavir/100 mg ritonavir per 5 mL (80 mg lopinavir/20 mg ritonavir per mL).</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section_4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<ul class="Disc"><li>KALETRA is contraindicated in patients with previously demonstrated clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>) to any of its ingredients, including ritonavir.</li></ul>
<ul class="Disc">
<li>Co-administration of KALETRA is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions.</li>
<li>Co-administration of KALETRA is contraindicated with potent CYP3A inducers where significantly reduced lopinavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance and cross-resistance. These drugs are listed in Table 3.</li>
</ul>
<a name="table_3"></a><table border="1" frame="box" rules="all" width="100%">
<caption><span>TableÂ 3. Drugs That are Contraindicated with KALETRA</span></caption>
<colgroup>
<col width="18%">
<col width="22%">
<col width="48%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Toprule"><span class="Bold">Drug Class</span></td>
<td class="Toprule" align="center"><span class="Bold">Drugs Within Class That are Contraindicated with KALETRA</span></td>
<td class="Toprule" align="center"><span class="Bold">Clinical Comments</span></td>
</tr>
<tr valign="top">
<td>Alpha 1- Adrenoreceptor Antagonist</td>
<td>Alfuzosin</td>
<td>Potentially increased alfuzosin concentrations can result in <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</td>
</tr>
<tr valign="top">
<td>Antimycobacterial</td>
<td>Rifampin</td>
<td>May lead to loss of virologic response and possible resistance to KALETRA or to the class of protease inhibitors or other co-administered antiretroviral agents <span class="Italics">[see Drug Interactions (<a href="#section_7">7</a>)].</span>
</td>
</tr>
<tr valign="top">
<td>Ergot Derivatives</td>
<td>Dihydroergotamine, ergonovine, ergotamine, methylergonovine</td>
<td>Potential for acute ergot toxicity characterized by peripheral <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> and <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities and other tissues.</td>
</tr>
<tr valign="top">
<td>GI Motility Agent</td>
<td>Cisapride</td>
<td>Potential for <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</td>
</tr>
<tr valign="top">
<td>Herbal Products </td>
<td>St. John's Wort (hypericum perforatum)</td>
<td>May lead to loss of virologic response and possible resistance to KALETRA or to the class of protease inhibitors.</td>
</tr>
<tr valign="top">
<td>HMG-CoA Reductase Inhibitors</td>
<td>Lovastatin, simvastatin</td>
<td>Potential for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.</td>
</tr>
<tr valign="top">
<td>PDE5 Enzyme Inhibitor</td>
<td>Sildenafil<span class="Sup">a</span> (Revatio<span class="Sup">Â®</span>) when used for the treatment of <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span></td>
<td>A safe and effective dose has not been established when used with KALETRA. There is an increased potential for sildenafil-associated adverse events, including visual abnormalities, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, prolonged erection,  and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> <span class="Italics">[see Drug Interactions (<a href="#section_7">7</a>)]</span>.</td>
</tr>
<tr valign="top">
<td>Neuroleptic</td>
<td>Pimozide</td>
<td>Potential for <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</td>
</tr>
<tr valign="top">
<td>Sedative/Hypnotics</td>
<td>Triazolam;<br>orally administered midazolam<span class="Sup">b</span>
</td>
<td>Prolonged or increased sedation or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</td>
</tr>
<tr class="Last"><td colspan="3">
<span class="Sup">a</span> see Drug Interactions (7), <span class="Italics"><a href="#table_9">Table 9</a></span> for co-administration of sildenafil in patients with <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>.<br><span class="Sup">b</span>see Drug Interactions (7), <span class="Italics"><a href="#table_9">Table 9</a></span> for parenterally administered midazolam.</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section_5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Drug Interactions - CYP3A Enzyme Inhibition</h2>
<p class="First"><a name="p51591408"></a>KALETRA is a CYP3A inhibitor.  Initiating treatment with KALETRA in patients receiving medications metabolized by CYP3A or initiating medications metabolized by CYP3A in patients already maintained on KALETRA may result in increased plasma concentrations of concomitant medications. Higher plasma concentrations of concomitant medications can result in increased or prolonged therapeutic or adverse effects, potentially leading to severe, life-threatening or fatal events. The potential for drug-drug interactions must be considered prior to and during therapy with KALETRA.  Review of other medications taken by patients and monitoring of patients for adverse effects is recommended during therapy with KALETRA.</p>
<p><a name="p51641408"></a>See Tables <a href="#Table_3">3 </a>and <a href="#Table_9">9</a> for listing of drugs that are contraindicated for use with KALETRA due to potentially life-threatening adverse events, significant drug interactions, or loss of virologic activity<span class="Italics"> [see Contraindications (<a href="#section_7">4</a>) and Drug Interactions (<a href="#section_7">7</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Toxicity in Preterm Neonates</h2>
<p class="First"><a name="p58624224"></a> KALETRA oral solution contains the excipients alcohol (42.4% v/v) and propylene glycol (15.3% w/v). When administered concomitantly with propylene glycol, ethanol competitively inhibits the metabolism of propylene glycol, which may lead to elevated concentrations. Preterm neonates may be at increased risk of propylene glycol-associated adverse events due to diminished ability to metabolize propylene glycol, thereby leading to accumulation and potential adverse events. Postmarketing life-threatening cases of cardiac toxicity (including complete <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>), <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> and respiratory complications leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported, predominantly in preterm neonates receiving KALETRA oral solution.</p>
<p><a name="p58625324"></a>KALETRA oral solution should not be used in preterm neonates in the immediate postnatal period because of possible toxicities. A safe and effective dose of KALETRA oral solution in this patient population has not been established. However, if the benefit of using KALETRA oral solution to treat <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> in infants immediately after birth outweighs the potential risks, infants should be monitored closely for increases in serum <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> and serum creatinine, and for toxicity related to KALETRA oral solution including: hyperosmolality, with or without <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, renal toxicity, <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> (including <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>), <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> and ECG changes, and <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>. Total amounts of alcohol and propylene glycol from all medicines that are to be given to infants should be taken into account in order to avoid toxicity from these excipients <span class="Italics">[see Dosage and Administration (<a href="#section_2.2">2.2</a>) and Overdosage (<a href="#section_10">10</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></h2>
<p class="First"><a name="p53981408"></a><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> has been observed in patients receiving KALETRA therapy, including those who developed marked triglyceride elevations. In some cases, fatalities have been observed. Although a causal relationship to KALETRA has not been established, marked triglyceride elevations are a risk factor for development of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> <span class="Italics">[see Warnings and Precautions (<a href="#section_5.10">5.10</a>)]</span>. Patients with advanced HIV-1 disease may be at increased risk of elevated triglycerides and <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, and patients with a history of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> may be at increased risk for recurrence during KALETRA therapy.</p>
<p><a name="p54091408"></a><span class="Italics"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> should be considered if clinical symptoms (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>) or abnormalities in laboratory values (such as increased serum lipase or amylase values) suggestive of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> occur. Patients who exhibit these signs or symptoms should be evaluated and KALETRA and/or other antiretroviral therapy should be suspended as clinically appropriate.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Hepatotoxicity</h2>
<p class="First"><a name="p54191408"></a>Patients with underlying <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C or marked elevations in transaminase prior to treatment may be at increased risk for developing or worsening of transaminase elevations or hepatic decompensation with use of KALETRA.</p>
<p><a name="p54221408"></a>There have been postmarketing reports of hepatic dysfunction, including some fatalities. These have generally occurred in patients with advanced HIV-1 disease taking multiple concomitant medications in the setting of underlying <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> or cirrhosis. A causal relationship with KALETRA therapy has not been established. </p>
<p><a name="p54251408"></a>Elevated transaminases with or without elevated bilirubin levels have been reported in HIV-1 mono-infected and uninfected patients as early as 7 days after the initiation of KALETRA in conjunction with other antiretroviral agents.  In some cases, the hepatic dysfunction was serious; however, a definitive causal relationship with KALETRA therapy has not been established. </p>
<p><a name="p56361408"></a>Appropriate laboratory testing should be conducted prior to initiating therapy with KALETRA and patients should be monitored closely during treatment. Increased AST/ALT monitoring should be considered in the patients with underlying <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> or cirrhosis, especially during the first several months of KALETRA treatment <span class="Italics">[see Use in Specific Populations (<a href="#section_8.6">8.6</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus/<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></h2>
<p class="First"><a name="p56511408"></a>New onset <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, exacerbation of pre-existing <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> have been reported during post-marketing surveillance in HIV-1 infected patients receiving protease inhibitor therapy. Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. In some cases, <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> has occurred. In those patients who discontinued protease inhibitor therapy, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> persisted in some cases. Because these events have been reported voluntarily during clinical practice, estimates of frequency cannot be made and a causal relationship between protease inhibitor therapy and these events has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 PR Interval Prolongation</h2>
<p class="First"><a name="p56601408"></a>Lopinavir/ritonavir prolongs the PR interval in some patients. Cases of second or third degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span> have been reported. KALETRA should be used with caution in patients with underlying structural heart disease, pre-existing conduction system abnormalities, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span> or cardiomyopathies, as these patients may be at increased risk for developing cardiac conduction abnormalities. </p>
<p><a name="p56631408"></a>The impact on the PR interval of co-administration of KALETRA with other drugs that prolong the PR interval (including calcium channel blockers, beta-adrenergic blockers, digoxin and atazanavir) has not been evaluated. As a result, co-administration of KALETRA with these drugs should be undertaken with caution, particularly with those drugs metabolized by CYP3A. Clinical monitoring is recommended<span class="Italics"> [see Clinical Pharmacology (<a href="#section_12.3">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 QT Interval Prolongation</h2>
<p class="First"><a name="p56791408"></a>Postmarketing cases of QT interval prolongation and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> have been reported although causality of KALETRA could not be established. Avoid use in patients with congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>, those with <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, and with other drugs that prolong the QT interval <span class="Italics">[see Clinical Pharmacology (<a href="#section_12.3">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></h2>
<p class="First"><a name="p59011408"></a><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> has been reported in patients treated with combination antiretroviral therapy, including KALETRA. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> (such as <span class="Italics">Mycobacterium avium</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, cytomegalovirus, <span class="Italics">Pneumocystis jirovecii</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> [PCP], or <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>) which may necessitate further evaluation and treatment.</p>
<p style="border-left:1px solid;"><a name="p53015524"></a><span class="XmChange"><span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune disorders</span> (such as Gravesâ€™ disease, <span class="product-label-link" type="condition" conceptid="80800" conceptname="Polymyositis">polymyositis</span>, and Guillain-BarrÃ© syndrome) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiation of treatment.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Fat Redistribution</h2>
<p class="First"><a name="p59171408"></a>Redistribution/accumulation of body fat including <span class="product-label-link" type="condition" conceptid="4087487" conceptname="Central obesity">central obesity</span>, dorsocervical fat enlargement (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>), peripheral <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, facial <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, and "<span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">cushingoid</span> appearance" have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Lipid Elevations</h2>
<p class="First"><a name="p59251408"></a>Treatment with KALETRA has resulted in large increases in the concentration of total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides <span class="Italics">[see Adverse Reactions (<a href="#section_6.1">6.1</a>)]</span>. Triglyceride and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> testing should be performed prior to initiating KALETRA therapy and at periodic intervals during therapy. Lipid disorders should be managed as clinically appropriate, taking into account any potential drug-drug interactions with KALETRA and HMG-CoA reductase inhibitors <span class="Italics">[see Contraindications (<a href="#section_4">4</a>) and Drug Interactions (<a href="#section_7.3">7.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Patients with <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">Hemophilia</span></h2>
<p class="First"><a name="p61581408"></a>Increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, including spontaneous skin <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> and <span class="product-label-link" type="condition" conceptid="76784" conceptname="Hemarthrosis">hemarthrosis</span> have been reported in patients with <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> type A and B treated with protease inhibitors. In some patients additional factor VIII was given. In more than half of the reported cases, treatment with protease inhibitors was continued or reintroduced. A causal relationship between protease inhibitor therapy and these events has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5.12"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Resistance/Cross-resistance</h2>
<p class="First"><a name="p61661408"></a>Because the potential for HIV cross-resistance among protease inhibitors has not been fully explored in KALETRA-treated patients, it is unknown what effect therapy with KALETRA will have on the activity of subsequently administered protease inhibitors <span class="Italics">[see Clinical Pharmacology (<a href="#section_12.4">12.4</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section_6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First"><a name="p61811408"></a>The following adverse reactions are discussed in greater detail in other sections of the labeling.</p>
<ul class="Disc">
<li>PR Interval Prolongation, QT Interval Prolongation <span class="Italics">[see Warnings and Precautions (<a href="#section_5.6">5.6</a>, <a href="#section_5.7">5.7</a>)]</span>
</li>
<li>Drug Interactions <span class="Italics">[see Warnings and Precautions (<a href="#section_5.1">5.1</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> <span class="Italics">[see Warnings and Precautions (<a href="#section_5.3">5.3</a>)]</span>
</li>
<li>Hepatotoxicity <span class="Italics">[see Warnings and Precautions (<a href="#section_5.4">5.4</a>)]</span>
</li>
</ul>
<p><a name="p64361408"></a>Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Adults - Clinical Trials Experience</h2>
<p class="First"><a name="p66691408"></a>The safety profile of KALETRA in adults is primarily based on 1,964 HIV-1 infected patients in clinical trials.</p>
<p><a name="p66721408"></a>The most common adverse reaction was <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, which was generally of mild to moderate severity. In study 730, the incidence of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> of any severity during 48 weeks of therapy was 60% in patients receiving KALETRA tablets once daily compared to 57% in patients receiving KALETRA tablets twice daily. More patients receiving KALETRA tablets once daily (14, 4.2%) had ongoing <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> at the time of discontinuation as compared to patients receiving KALETRA tablets twice daily (6, 1.8%). In study 730, discontinuations due to any adverse reaction were 4.8% in patients receiving KALETRA tablets once daily as compared to 3% in patients receiving KALETRA tablets twice daily. In study 802, the incidence of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> of any severity during 48 weeks of therapy was 50% in patients receiving KALETRA tablets once daily compared to 39% in patients receiving KALETRA tablets twice daily.  Moderate or severe drug-related <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurred in 14% of patients receiving KALETRA tablets once daily as compared to 11% in patients receiving KALETRA tablets twice daily.   At the time of discontinuation, 19 (6.3%) patients receiving KALETRA tablets once daily had ongoing <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, as compared to 11 (3.7%) patients receiving KALETRA tablets twice daily. Discontinuations due to any adverse reaction occurred in 4.3% of patients receiving KALETRA tablets once daily compared to 7.0% in patients receiving KALETRA tablets twice daily. In study 863, discontinuations of randomized therapy due to adverse reactions were 3.4% in KALETRA-treated and 3.7% in nelfinavir-treated patients. </p>
<p><a name="p66751408"></a>Treatment-emergent clinical adverse reactions of moderate or severe intensity in â‰¥ 2% of patients treated with combination therapy for up to 48 weeks (Studies 863 and 730) and for up to 360 weeks (Study 720) are presented in Table 4 (treatment-naÃ¯ve patients); and for up to 48 weeks (Studies 888 and 802), 84 weeks (Study 957) and 144 weeks (Study 765) in Table 5 (protease inhibitor-experienced patients). </p>
<a name="table_4"></a><table border="1" frame="box" rules="all" width="100%">
<caption><span>TableÂ 4. Percentage of Adult Patients with Selected Treatment-Emergent<span class="Sup">1 </span>Adverse Reactions of Moderate or Severe Intensity Reported in â‰¥ 2% of Adult Antiretroviral-NaÃ¯ve Patients</span></caption>
<colgroup>
<col width="16%">
<col width="12%">
<col width="13%">
<col width="12%">
<col width="13%">
<col width="12%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Toprule">Â </td>
<td class="Toprule" align="center" colspan="2"><span class="Bold">Study 863<br>(48 Weeks)</span></td>
<td class="Toprule" align="center"><span class="Bold">Study 720<br>(360 Weeks)</span></td>
<td class="Toprule" align="center" colspan="2"><span class="Bold">Study 730<br>(48 Weeks)</span></td>
</tr>
<tr valign="top">
<td>Â </td>
<td align="center"><span class="Bold">KALETRA 400/100 mg Twice Daily + d4T + 3TC<br>(N = 326)</span></td>
<td align="center"><span class="Bold">Nelfinavir 750 mg Three Times Daily + d4T + 3TC                  <br>(N = 327)</span></td>
<td align="center"><span class="Bold">KALETRA Twice Daily<span class="Sup">2</span> + d4T + 3TC <br>(N = 100)</span></td>
<td align="center"><span class="Bold">KALETRA  800/200 mg Once Daily + TDF +FTC  (N=333)</span></td>
<td align="center"><span class="Bold">KALETRA 400/100 mg Twice Daily + TDF +FTC (N=331)</span></td>
</tr>
<tr valign="bottom">
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span></span></td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center" colspan="2">Â </td>
</tr>
<tr valign="bottom">
<td>    <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">Hypogonadism</span></td>
<td align="center">0%</td>
<td align="center">0%</td>
<td align="center">2%</td>
<td align="center">0%</td>
<td align="center">0%</td>
</tr>
<tr valign="bottom">
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td>Â </td>
</tr>
<tr valign="bottom">
<td>   <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">16%</td>
<td align="center">17%</td>
<td align="center">28%</td>
<td align="center">17%</td>
<td align="center">15%</td>
</tr>
<tr valign="bottom">
<td>   <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">7%</td>
<td align="center">5%</td>
<td align="center">16%</td>
<td align="center">7%</td>
<td align="center">5%</td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center">2%</td>
<td align="center">2%</td>
<td align="center">6%</td>
<td align="center">3%</td>
<td align="center">4%</td>
</tr>
<tr valign="bottom">
<td> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span> </td>
<td align="center">4%</td>
<td align="center">3%</td>
<td align="center">11%</td>
<td align="center">1%</td>
<td align="center">1%</td>
</tr>
<tr valign="bottom">
<td>    <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center">2%</td>
<td align="center">&lt;1%</td>
<td align="center">6%</td>
<td align="center">0%</td>
<td align="center">0%</td>
</tr>
<tr valign="bottom">
<td>    <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td align="center">2%</td>
<td align="center">1%</td>
<td align="center">4%</td>
<td align="center">1%</td>
<td align="center">1%</td>
</tr>
<tr valign="bottom">
<td><span class="Bold">General Disorders and Administration Site Conditions</span></td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center" colspan="2">Â </td>
</tr>
<tr valign="bottom">
<td>    <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center">4%</td>
<td align="center">3%</td>
<td align="center">9%</td>
<td align="center">&lt;1%</td>
<td align="center">&lt;1%</td>
</tr>
<tr valign="bottom">
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center" colspan="2">Â </td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></td>
<td align="center">0%</td>
<td align="center">0%</td>
<td align="center">2%</td>
<td align="center">0%</td>
<td align="center">&lt;1%</td>
</tr>
<tr valign="bottom">
<td><span class="Bold">Investigations</span></td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center" colspan="2">Â </td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Decreased</span></td>
<td align="center">1%</td>
<td align="center">&lt;1%</td>
<td align="center">2%</td>
<td align="center">0%</td>
<td align="center">&lt;1%</td>
</tr>
<tr valign="bottom">
<td><span class="Bold">Metabolism and Nutrition Disorders</span></td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td>Â </td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="center">1%</td>
<td align="center">&lt;1%</td>
<td align="center">2%</td>
<td align="center">&lt;1%</td>
<td align="center">1%</td>
</tr>
<tr valign="bottom">
<td><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span></td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td>Â </td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td align="center">1%</td>
<td align="center">1%</td>
<td align="center">2%</td>
<td align="center">0%</td>
<td align="center">0%</td>
</tr>
<tr valign="bottom">
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td>Â </td>
</tr>
<tr valign="bottom">
<td>   <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">2%</td>
<td align="center">2%</td>
<td align="center">6%</td>
<td align="center">2%</td>
<td align="center">2%</td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td align="center">1%</td>
<td align="center">1%</td>
<td align="center">2%</td>
<td align="center">0%</td>
<td align="center">0%</td>
</tr>
<tr valign="bottom">
<td><span class="Bold">Psychiatric Disorders</span></td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center" colspan="2">Â </td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center">2%</td>
<td align="center">1%</td>
<td align="center">3%</td>
<td align="center">1%</td>
<td align="center">0%</td>
</tr>
<tr>
<td valign="bottom"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td align="center" valign="bottom">1%</td>
<td align="center" valign="bottom">2%</td>
<td align="center" valign="bottom">0%</td>
<td align="center" valign="bottom">0%</td>
<td align="center">0%</td>
</tr>
<tr>
<td valign="bottom"><span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">Libido Decreased</span></td>
<td align="center" valign="bottom">&lt;1%</td>
<td align="center" valign="bottom">&lt;1%</td>
<td align="center" valign="bottom">2%</td>
<td align="center" valign="bottom">0%</td>
<td align="center">&lt;1%</td>
</tr>
<tr>
<td valign="bottom"><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></td>
<td align="center" valign="bottom">Â </td>
<td align="center" valign="bottom">Â </td>
<td align="center" valign="bottom">Â </td>
<td align="center" valign="bottom">Â </td>
<td>Â </td>
</tr>
<tr>
<td valign="bottom"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center" valign="bottom">1%</td>
<td align="center" valign="bottom">2%</td>
<td align="center" valign="bottom">5%</td>
<td align="center" valign="bottom">&lt;1%</td>
<td align="center">1%</td>
</tr>
<tr>
<td valign="bottom"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span></td>
<td align="center" valign="bottom">Â </td>
<td align="center" valign="bottom">Â </td>
<td align="center" valign="bottom">Â </td>
<td align="center" valign="bottom">Â </td>
<td>Â </td>
</tr>
<tr>
<td valign="bottom">Vasodilation</td>
<td align="center" valign="bottom">0%</td>
<td align="center" valign="bottom">0%</td>
<td align="center" valign="bottom">3%</td>
<td align="center" valign="bottom">0%</td>
<td align="center">0%</td>
</tr>
<tr class="Last"><td colspan="6">1Â Â  Includes adverse reactions of possible or probable relationship to study drug.<br>2 Â Â Includes adverse reaction data from dose group I (200/100 mg twice daily [N = 16] and 400/100 mg twice daily [N = 16]) and dose group II (400/100 mg twice daily [N = 35] and 400/200 mg twice daily [N = 33]).  Within dosing groups, moderate to severe <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> of probable/possible relationship to KALETRA occurred at a higher rate in the 400/200 mg dose arm compared to the 400/100 mg dose arm in group II.<br>Definitions: d4T = Stavudine; 3TC = Lamivudine; TDF = Tenofovir Disoproxil Fumarate; FTC = Emtricitabine   </td></tr>
</tbody>
</table>
<a name="table_5"></a><table border="1" frame="box" rules="all" width="100%">
<caption><span>TableÂ 5. Percentage of Adult Patients with Selected Treatment-Emergent<span class="Sup">1</span> Adverse Reactions of Moderate or Severe Intensity Reported in â‰¥ 2% of Adult Protease Inhibitor-Experienced Patients</span></caption>
<colgroup>
<col width="17%">
<col width="17%">
<col width="17%">
<col width="17%">
<col width="14%">
<col width="10%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Toprule">Â </td>
<td class="Toprule" align="center" colspan="2"><span class="Bold">Study 888<br>(48 Weeks)</span></td>
<td class="Toprule" align="center"><span class="Bold">Study 957<span class="Sup">2</span> and StudyÂ 765<span class="Sup">3</span><br>(84-144 Weeks)</span></td>
<td class="Toprule" align="center" colspan="2"><span class="Bold">Study 802<br>(48 Weeks)</span></td>
</tr>
<tr valign="top">
<td>Â </td>
<td align="center"><span class="Bold">KALETRA 400/100Â mg Twice Daily + NVP + NRTIs                  <br>(N = 148)</span></td>
<td align="center"><span class="Bold">Investigator-Selected Protease Inhibitor(s) + NVP + NRTIs<br>(N = 140)</span></td>
<td align="center"><span class="Bold">KALETRA Twice Daily + NNRTI + NRTIs<br>(N = 127)</span></td>
<td align="center"><span class="Bold">KALETRA 800/200 mg Once Daily +NRTIs<br>(N=300)</span></td>
<td align="center"><span class="Bold">KALETRA 400/100 mg Twice Daily + NRTIs<br>(N=299)</span></td>
</tr>
<tr valign="bottom">
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">7%</td>
<td align="center">9%</td>
<td align="center">23%</td>
<td align="center">14%</td>
<td align="center">11%</td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">7%</td>
<td align="center">16%</td>
<td align="center">5%</td>
<td align="center">3%</td>
<td align="center">7%</td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center">4%</td>
<td align="center">12%</td>
<td align="center">2%</td>
<td align="center">2%</td>
<td align="center">3%</td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td align="center">2%</td>
<td align="center">2%</td>
<td align="center">4%</td>
<td align="center">2%</td>
<td align="center">&lt;1%</td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal Pain Upper</span></td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">1%</td>
<td align="center">2%</td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center">1%</td>
<td align="center">1%</td>
<td align="center">2%</td>
<td align="center">1%</td>
<td align="center">&lt;1%</td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span> </td>
<td align="center">1%</td>
<td align="center">2%</td>
<td align="center">2%</td>
<td align="center">1%</td>
<td align="center">1%</td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">Dysphasia</span></td>
<td align="center">2%</td>
<td align="center">1%</td>
<td align="center">0%</td>
<td align="center">0%</td>
<td align="center">0%</td>
</tr>
<tr valign="bottom">
<td><span class="Bold">General Disorders and Administration Site Conditions</span></td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center">3%</td>
<td align="center">6%</td>
<td align="center">9%</td>
<td align="center">&lt;1%</td>
<td align="center">&lt;1%</td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td align="center">2%</td>
<td align="center">1%</td>
<td align="center">2%</td>
<td align="center">0%</td>
<td align="center">&lt;1%</td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></td>
<td align="center">2%</td>
<td align="center">0%</td>
<td align="center">0%</td>
<td align="center">0%</td>
<td align="center">0%</td>
</tr>
<tr valign="bottom">
<td><span class="Bold">Investigations</span></td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Decreased</span></td>
<td align="center">0%</td>
<td align="center">1%</td>
<td align="center">3%</td>
<td align="center">&lt;1%</td>
<td align="center">&lt;1%</td>
</tr>
<tr valign="bottom">
<td><span class="Bold">Metabolism and Nutrition Disorders</span></td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="center">1%</td>
<td align="center">3%</td>
<td align="center">0%</td>
<td align="center">0%</td>
<td align="center">1%</td>
</tr>
<tr valign="bottom">
<td><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span></td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td align="center">1%</td>
<td align="center">1%</td>
<td align="center">2%</td>
<td align="center">0%</td>
<td align="center">0%</td>
</tr>
<tr valign="bottom">
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">2%</td>
<td align="center">3%</td>
<td align="center">2%</td>
<td align="center">&lt;1%</td>
<td align="center">0%</td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td align="center">0%</td>
<td align="center">1%</td>
<td align="center">2%</td>
<td align="center">0%</td>
<td align="center">0%</td>
</tr>
<tr valign="bottom">
<td><span class="Bold">Psychiatric Disorders</span></td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td align="center">1%</td>
<td align="center">2%</td>
<td align="center">3%</td>
<td align="center">&lt;1%</td>
<td align="center">0%</td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center">0%</td>
<td align="center">2%</td>
<td align="center">2%</td>
<td align="center">0%</td>
<td align="center">&lt;1%</td>
</tr>
<tr valign="bottom">
<td><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr valign="bottom">
<td>    <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center">2%</td>
<td align="center">1%</td>
<td align="center">2%</td>
<td align="center">0%</td>
<td align="center">0%</td>
</tr>
<tr valign="bottom">
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span></td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr valign="bottom">
<td><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td align="center">0%</td>
<td align="center">0%</td>
<td align="center">2%</td>
<td align="center">0%</td>
<td align="center">0%</td>
</tr>
<tr class="Last"><td colspan="6">1Â Â  Includes adverse reactions of possible or probable relationship to study drug.<br>2Â Â  Includes adverse reaction data from patients receiving 400/100 mg twice daily (n = 29) or 533/133 mg twice daily (nÂ =Â 28) for 84 weeks.  Patients received KALETRA in combination with NRTIs and efavirenz.<br>3Â Â  Includes adverse reaction data from patients receiving 400/100 mg twice daily (n = 36) or 400/200 mg twice daily (nÂ =Â 34) for 144 weeks.  Patients received KALETRA in combination with NRTIs and nevirapine.<br>Definitions:  NVP = Nevirapine; NRTI = Nucleoside Reverse Transcriptase Inhibitors; NNRTI = Non-nucleoside Reverse Transcriptase Inhibitors</td></tr>
</tbody>
</table>
<p><a name="p136091408"></a>Less Common Adverse Reactions</p>
<p><a name="p136121408"></a>Treatment-emergent adverse reactions occurring in less than 2% of adult patients receiving KALETRA in the clinical trials supporting approval and of at least moderate intensity are listed below by system organ class.</p>
<p><a name="p136151408"></a><span class="Italics">Blood and Lymphatic System Disorders</span></p>
<p><a name="p138261408"></a><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span>. </p>
<p><a name="p138311408"></a><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span></p>
<p><a name="p138361408"></a><span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">Angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, and <span class="product-label-link" type="condition" conceptid="4006971" conceptname="Tricuspid valve regurgitation">tricuspid valve incompetence</span>.</p>
<p><a name="p138411408"></a><span class="Italics">Ear and Labyrinth Disorders</span></p>
<p><a name="p138461408"></a><span class="product-label-link" type="condition" conceptid="378163" conceptname="Hyperacusis">Hyperacusis</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.</p>
<p><a name="p138511408"></a><span class="Italics"><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span></span></p>
<p><a name="p138561408"></a>Cushing's syndrome and <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>. </p>
<p><a name="p138611408"></a><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span></p>
<p><a name="p138661408"></a><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorder</span> and <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span>. </p>
<p><a name="p138711408"></a><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></p>
<p><a name="p140821408"></a><span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal distension</span>, abdomen <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> lower, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="433516" conceptname="Duodenitis">duodenitis</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">enteritis</span>, <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>, <span class="product-label-link" type="condition" conceptid="4216673" conceptname="Hemorrhagic colitis">enterocolitis hemorrhagic</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">fecal incontinence</span>, <span class="product-label-link" type="condition" conceptid="201891" conceptname="Disorder of stomach">gastric disorder</span>, <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span>, <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">hemorrhoids</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulceration</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="141608" conceptname="Periodontitis">periodontitis</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach discomfort</span>, and <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>.</p>
<p><a name="p140871408"></a><span class="Italics">General Disorders and Administration Site Conditions</span></p>
<p><a name="p140921408"></a><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span>, <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span>, drug interaction, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema peripheral</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>. </p>
<p><a name="p140971408"></a><span class="Italics">Hepatobiliary Disorders</span></p>
<p><a name="p141021408"></a><span class="product-label-link" type="condition" conceptid="195856" conceptname="Cholangitis">Cholangitis</span>, <span class="product-label-link" type="condition" conceptid="192956" conceptname="Cholecystitis">cholecystitis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">cytolytic hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">hepatic steatosis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, and <span class="product-label-link" type="condition" conceptid="4010482" conceptname="Liver tender">liver tenderness</span>. </p>
<p><a name="p141071408"></a><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span></p>
<p><a name="p141121408"></a><span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">Drug hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, and <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">immune reconstitution syndrome</span>.</p>
<p><a name="p141171408"></a><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></p>
<p><a name="p141221408"></a><span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">Bacterial infection</span>, <span class="product-label-link" type="condition" conceptid="256722" conceptname="Bronchopneumonia">bronchopneumonia</span>, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>, <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">furuncle</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, <span class="product-label-link" type="condition" conceptid="4147598" conceptname="Abscess of perineum">perineal abscess</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">sialoadenitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, and <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>.</p>
<p><a name="p141271408"></a><span class="Italics">Investigations</span></p>
<p><a name="p143381408"></a>Drug level increased, glucose tolerance decreased, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span>. </p>
<p><a name="p143431408"></a><span class="Italics">Metabolism and Nutrition Disorders</span></p>
<p><a name="p143481408"></a><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="436658" conceptname="Vitamin deficiency">hypovitaminosis</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, <span class="product-label-link" type="condition" conceptid="4290348" conceptname="Lipomatosis">lipomatosis</span>, and <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>.</p>
<p><a name="p143531408"></a><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span></p>
<p><a name="p143581408"></a><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>, <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">osteonecrosis</span>, and <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span>. </p>
<p><a name="p143631408"></a><span class="Italics">Neoplasms Benign, Malignant and Unspecified (incl <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">Cysts</span> and <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">Polyps</span>)</span></p>
<p><a name="p143681408"></a><span class="product-label-link" type="condition" conceptid="138102" conceptname="Benign neoplasm of skin">Benign neoplasm of skin</span>, <span class="product-label-link" type="condition" conceptid="440358" conceptname="Lipoma">lipoma</span>, and neoplasm.</p>
<p><a name="p143751408"></a><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></p>
<p><a name="p143801408"></a><span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">Ageusia</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>,  <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">balance disorder</span>, <span class="product-label-link" type="condition" conceptid="443454" conceptname="Cerebral infarction">cerebral infarction</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>,  <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorder</span>, <span class="product-label-link" type="condition" conceptid="374923" conceptname="Bell's palsy">facial palsy</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy peripheral</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>. </p>
<p><a name="p143851408"></a><span class="Italics">Psychiatric Disorders</span></p>
<p><a name="p145961408"></a><span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="4197184" conceptname="Pseudobulbar affect">affect lability</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, and <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">thinking abnormal</span>.</p>
<p><a name="p146011408"></a><span class="Italics">Renal and Urinary Disorders</span></p>
<p><a name="p146061408"></a><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span>, <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span>, <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disorder</span>, <span class="product-label-link" type="condition" conceptid="4298419" conceptname="Cloudy urine">urine abnormality</span>, and urine odor abnormal.</p>
<p><a name="p146111408"></a><span class="Italics">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span></span></p>
<p><a name="p146161408"></a><span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">Breast enlargement</span>, <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">ejaculation disorder</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, and <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">menorrhagia</span>. </p>
<p><a name="p146211408"></a><span class="Italics">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></p>
<p><a name="p146261408"></a><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>.</p>
<p><a name="p146311408"></a><span class="Italics">Skin and Subcutaneous Tissue Disorders</span></p>
<p><a name="p146361408"></a><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4299558" conceptname="Acneiform eruption">dermatitis acneiform</span>, <span class="product-label-link" type="condition" conceptid="4070025" conceptname="Cutaneous hypersensitivity">dermatitis allergic</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">dermatitis exfoliative</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="4033870" conceptname="Idiopathic capillaritis">idiopathic capillaritis</span>, <span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">nail disorder</span>, pruritis, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> generalized, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculo-papular, <span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">seborrhea</span>, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>, skin <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">skin striae</span>, <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulcer</span>, and <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">swelling face</span>.</p>
<p><a name="p146411408"></a><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span></p>
<p><a name="p148521408"></a><span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="441644" conceptname="Varicose veins of legs in pregnancy and the puerperium">varicose vein</span>, and <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>.</p>
<p><a name="p148571408"></a><span class="Italics">Laboratory Abnormalities</span></p>
<p><a name="p148621408"></a>The percentages of adult patients treated with combination therapy with Grade 3-4 laboratory abnormalities are presented in Table 6 (treatment-naÃ¯ve patients) and Table 7 (treatment-experienced patients).</p>
<a name="table_6"></a><table border="1" frame="box" rules="all" width="100%">
<caption><span>TableÂ 6. Grade 3-4 Laboratory Abnormalities Reported in â‰¥ 2% of Adult Antiretroviral-NaÃ¯ve Patients</span></caption>
<colgroup>
<col width="7%">
<col width="7%">
<col width="6%">
<col width="6%">
<col width="9%">
<col width="5%">
<col width="5%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
<td class="Toprule" align="center" colspan="2"><span class="Bold">Study 863<br> (48 Weeks)</span></td>
<td class="Toprule" align="center"><span class="Bold">Study 720<br>(360 Weeks) </span></td>
<td class="Toprule" align="center" colspan="2"><span class="Bold">Study 730<br>(48 Weeks)</span></td>
</tr>
<tr valign="top">
<td><span class="Bold">Variable</span></td>
<td><span class="Bold">Limit<span class="Sup">1</span></span></td>
<td align="center"><span class="Bold">KALETRA<br> 400/100 mg Twice Daily + d4T +3TC<br>(N = 326)</span></td>
<td align="center"><span class="Bold">Nelfinavir<br> 750 mg Three Times Daily + d4T + 3TC<br>(N = 327)</span></td>
<td align="center"><span class="Bold">KALETRA<br> Twice Daily + d4T + 3TC<br>(N = 100)</span></td>
<td align="center"><span class="Bold">KALETRA<br> Once Daily + TDF +FTC <br>(N=333)</span></td>
<td align="center"><span class="Bold">KALETRA <br>Twice Daily + TDF +FTC<br>(N=331)</span></td>
</tr>
<tr valign="top">
<td><span class="Bold">Chemistry</span></td>
<td><span class="Bold">High</span></td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center" colspan="2">Â </td>
</tr>
<tr valign="top">
<td> Glucose  </td>
<td> &gt; 250 mg/dL  </td>
<td align="center">2%</td>
<td align="center">2%</td>
<td align="center">4%</td>
<td align="center">0%</td>
<td align="center">&lt;1%</td>
</tr>
<tr valign="top">
<td> Uric Acid  </td>
<td> &gt; 12 mg/dL  </td>
<td align="center">2%</td>
<td align="center">2%</td>
<td align="center">5%</td>
<td align="center">&lt;1%</td>
<td align="center">1%</td>
</tr>
<tr valign="top">
<td> <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>/<br>AST<span class="Sup">2</span>
</td>
<td> &gt; 180 U/L  </td>
<td align="center">2%</td>
<td align="center">4%</td>
<td align="center">10%</td>
<td align="center">1%</td>
<td align="center">2%</td>
</tr>
<tr valign="top">
<td> SGPT/<br>ALT<span class="Sup">2 </span>
</td>
<td>&gt;215 U/L</td>
<td align="center">4%</td>
<td align="center">4%</td>
<td align="center">11%</td>
<td align="center">1%</td>
<td align="center">1%</td>
</tr>
<tr valign="top">
<td>GGT</td>
<td>&gt;300 U/L</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">10%</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
</tr>
<tr valign="top">
<td>Total<br><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></td>
<td>&gt;300 mg/dL</td>
<td align="center">9%</td>
<td align="center">5%</td>
<td align="center">27%</td>
<td align="center">4%</td>
<td align="center">3%</td>
</tr>
<tr valign="top">
<td>Triglycerides</td>
<td>&gt;750 mg/dL</td>
<td align="center">9%</td>
<td align="center">1%</td>
<td align="center">29%</td>
<td align="center">3%</td>
<td align="center">6%</td>
</tr>
<tr valign="top">
<td>Amylase</td>
<td>&gt;2 x ULN</td>
<td align="center">3%</td>
<td align="center">2%</td>
<td align="center">4%</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
</tr>
<tr valign="top">
<td>Lipase</td>
<td>&gt;2 x ULN</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">3%</td>
<td align="center">5%</td>
</tr>
<tr valign="top">
<td><span class="Bold">Chemistry</span></td>
<td><span class="Bold">Low</span></td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr valign="top">
<td>Calculated Creatinine Clearance</td>
<td>&lt;50 mL/min</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">2%</td>
<td align="center">2%</td>
</tr>
<tr valign="top">
<td><span class="Bold">Hematology</span></td>
<td><span class="Bold">Low</span></td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center" colspan="2">Â </td>
</tr>
<tr valign="top">
<td> <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span></td>
<td>&lt;0.75 x 10<span class="Sup">9</span>/L</td>
<td align="center">1%</td>
<td align="center">3%</td>
<td align="center">5%</td>
<td align="center">2%</td>
<td align="center">1%</td>
</tr>
<tr class="Last"><td colspan="7">1 Â Â ULN = upper limit of the normal range; N/A = Not Applicable.<br>2 Â Â Criterion for Study 730 was &gt;5x ULN (AST/ALT). </td></tr>
</tbody>
</table>
<a name="table_7"></a><table border="1" frame="box" rules="all" width="100%">
<caption><span>TableÂ 7. Grade 3-4 Laboratory Abnormalities Reported in â‰¥ 2% of Adult Protease Inhibitor-Experienced Patients</span></caption>
<colgroup>
<col width="11%">
<col width="7%">
<col width="13%">
<col width="12%">
<col width="10%">
<col width="10%">
<col width="10%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Toprule" align="center">Â </td>
<td class="Toprule" align="center">Â </td>
<td class="Toprule" align="center" colspan="2"><span class="Bold">Study 888<br> (48 Weeks)</span></td>
<td class="Toprule" align="center"><span class="Bold">Study 957<span class="Sup">2</span> and Study 765<span class="Sup">3</span><br>(84-144 Weeks)</span></td>
<td class="Toprule" align="center" colspan="2"><span class="Bold">Study 802<br> (48 Weeks)</span></td>
</tr>
<tr valign="top">
<td><span class="Bold">Variable</span></td>
<td><span class="Bold">Limit<span class="Sup">1</span></span></td>
<td align="center"><span class="Bold">KALETRA<br> 400/100 mg Twice Daily + NVP + NRTIs<br>(N = 148)</span></td>
<td align="center"><span class="Bold">Investigator-Selected Protease Inhibitor(s) + NVP + NRTIs<br>(N = 140)</span></td>
<td align="center"><span class="Bold">KALETRA<br> Twice Daily + NNRTI + NRTIs<br>(N = 127)</span></td>
<td align="center"><span class="Bold">KALETRA<br> 800/200 mg Once Daily +NRTIs<br>(N=300)</span></td>
<td align="center"><span class="Bold">KALETRA <br>400/100 mg Twice Daily +NRTIs<br>(N=299)</span></td>
</tr>
<tr valign="top">
<td><span class="Bold">Chemistry</span></td>
<td><span class="Bold">High</span></td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr valign="top">
<td>    Glucose</td>
<td>&gt;250 mg/dL</td>
<td align="center">1%</td>
<td align="center">2%</td>
<td align="center">5%</td>
<td align="center">2%</td>
<td align="center">2%</td>
</tr>
<tr valign="top">
<td>    Total Bilirubin</td>
<td>&gt;3.48 mg/dL</td>
<td align="center">1%</td>
<td align="center">3%</td>
<td align="center">1%</td>
<td align="center">1%</td>
<td align="center">1%</td>
</tr>
<tr valign="top">
<td>    <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>/AST<span class="Sup">4</span>
</td>
<td>&gt;180 U/L</td>
<td align="center">5%</td>
<td align="center">11%</td>
<td align="center">8%</td>
<td align="center">3%</td>
<td align="center">2%</td>
</tr>
<tr valign="top">
<td>    SGPT/ALT<span class="Sup">4</span>
</td>
<td>&gt;215 U/L</td>
<td align="center">6%</td>
<td align="center">13%</td>
<td align="center">10%</td>
<td align="center">2%</td>
<td align="center">2%</td>
</tr>
<tr valign="top">
<td>    GGT</td>
<td>&gt;300 U/L</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">29%</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
</tr>
<tr valign="top">
<td>    Total    <br><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></td>
<td>&gt;300 mg/dL</td>
<td align="center">20%</td>
<td align="center">21%</td>
<td align="center">39%</td>
<td align="center">6%</td>
<td align="center">7%</td>
</tr>
<tr valign="top">
<td>    Triglycerides</td>
<td>&gt;750 mg/dL</td>
<td align="center">25%</td>
<td align="center">21%</td>
<td align="center">36%</td>
<td align="center">5%</td>
<td align="center">6%</td>
</tr>
<tr valign="top">
<td>    Amylase</td>
<td>&gt;2 x ULN</td>
<td align="center">4%</td>
<td align="center">8%</td>
<td align="center">8%</td>
<td align="center">4%</td>
<td align="center">4%</td>
</tr>
<tr valign="top">
<td>    Lipase</td>
<td>&gt;2 x ULN</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">4%</td>
<td align="center">1%</td>
</tr>
<tr valign="top">
<td>    Creatine <br>Phosphokinase</td>
<td>&gt;4 x ULN</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">4%</td>
<td align="center">5%</td>
</tr>
<tr valign="top">
<td><span class="Bold">Chemistry</span></td>
<td><span class="Bold">Low</span></td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr valign="top">
<td>    Calculated<br>Creatinine <br> Clearance</td>
<td>&lt;50 mL/min</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">3%</td>
<td align="center">3%</td>
</tr>
<tr valign="top">
<td>    Inorganic <br>Phosphorus</td>
<td>&lt;1.5 mg/dL</td>
<td align="center">1%</td>
<td align="center">0%</td>
<td align="center">2%</td>
<td align="center">1%</td>
<td align="center">&lt;1%</td>
</tr>
<tr valign="top">
<td><span class="Bold">Hematology</span></td>
<td><span class="Bold">Low</span></td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr valign="top">
<td>    <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span></td>
<td>&lt;0.75 x 10<span class="Sup">9</span>/L</td>
<td align="center">1%</td>
<td align="center">2%</td>
<td align="center">4%</td>
<td align="center">3%</td>
<td align="center">4%</td>
</tr>
<tr valign="top">
<td>    Hemoglobin</td>
<td>&lt;80 g/L</td>
<td align="center">1%</td>
<td align="center">1%</td>
<td align="center">1%</td>
<td align="center">1%</td>
<td align="center">2%</td>
</tr>
<tr class="Last"><td colspan="7">1 Â Â ULN = upper limit of the normal range; N/A = Not Applicable.<br>2 Â Â Includes clinical laboratory data from patients receiving 400/100 mg twice daily (n = 29) or 533/133 mg twice daily (n = 28) for 84 weeks.  Patients received KALETRA in combination with NRTIs and efavirenz.<br>3 Â Â Includes clinical laboratory data from patients receiving 400/100 mg twice daily (n = 36) or 400/200 mg twice daily (n = 34) for 144 weeks.  Patients received KALETRA in combination with NRTIs and nevirapine.<br>4   Criterion for Study 802 was &gt;5x ULN (AST/ALT). </td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Pediatric Patients - Clinical Trials Experience</h2>
<p class="First"><a name="p202361408"></a>KALETRA oral solution dosed up to 300/75 mg/m<span class="Sup">2</span> has been studied in 100 pediatric patients 6 months to 12 years of age. The adverse reaction profile seen during Study 940 was similar to that for adult patients. </p>
<p><a name="p202431408"></a><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span> (22%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (21%), and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (12%) were the most common adverse reactions of any severity reported in pediatric patients treated with combination therapy for up to 48 weeks in Study 940.  A total of 8 patients experienced adverse reactions of moderate to severe intensity.  The adverse reactions meeting these criteria and reported for the 8 subjects include: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (characterized by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> increased, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>.  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> was the only event of those listed that occurred in 2 or more subjects (N = 3).</p>
<p><a name="p202461408"></a>KALETRA oral solution dosed at 300/75 mg/m<span class="Sup">2 </span>has been studied in 31 pediatric patients 14 days to 6 months of age. The adverse reaction profile in Study 1030 was similar to that observed in older children and adults. No adverse reaction was reported in greater than 10% of subjects. Adverse drug reactions of moderate to severe intensity occurring in 2 or more subjects included decreased neutrophil count (N=3), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (N=2), high potassium (N=2), and low sodium (N=2).  </p>
<p><a name="p202531408"></a>KALETRA oral solution and soft gelatin capsules dosed at higher than recommended doses including 400/100 mg/m<span class="Sup">2</span> (without concomitant NNRTI) and 480/120 mg/m<span class="Sup">2</span> (with concomitant NNRTI) have been studied in 26 pediatric patients 7 to 18 years of age in Study 1038. Patients also had saquinavir mesylate added to their regimen at Week 4. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> (12%), <span class="product-label-link" type="condition" conceptid="45763616" conceptname="Serum cholesterol abnormal">blood cholesterol abnormal</span> (12%) and blood triglycerides abnormal (12%) were the only adverse reactions reported in greater than 10% of subjects. Adverse drug reactions of moderate to severe intensity occurring in 2 or more subjects included <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (N=3), blood triglycerides abnormal (N=3), and <span class="product-label-link" type="condition" conceptid="4008859" conceptname="Prolonged QT interval">electrocardiogram QT prolonged</span> (N=2). Both subjects with QT prolongation had additional predisposing conditions such as electrolyte abnormalities, concomitant medications, or pre-existing cardiac abnormalities.</p>
<p><a name="p202641408"></a><span class="Italics">Laboratory Abnormalities</span></p>
<p><a name="p202691408"></a>The percentages of pediatric patients treated with combination therapy including KALETRA with Grade 3-4 laboratory abnormalities are presented in Table 8.</p>
<a name="table_8"></a><table border="1" frame="box" rules="all" width="100%">
<caption><span>TableÂ 8. Grade 3-4 Laboratory Abnormalities Reported in â‰¥ 2% Pediatric Patients in Study 940</span></caption>
<colgroup>
<col width="28%">
<col width="35%">
<col width="36%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Toprule"><span class="Bold">Variable</span></td>
<td class="Toprule" align="center"><span class="Bold">Limit<span class="Sup">1</span></span></td>
<td class="Toprule" align="center"><span class="Bold">KALETRA Twice Daily + RTIs<br>(N = 100)</span></td>
</tr>
<tr valign="top">
<td><span class="Bold">Chemistry</span></td>
<td align="center"><span class="Bold">High</span></td>
<td align="center">Â </td>
</tr>
<tr valign="top">
<td>Â Â Â Â Â Sodium</td>
<td align="center">&gt; 149 mEq/L</td>
<td align="center">3%</td>
</tr>
<tr valign="top">
<td>Â Â Â Â Â Total Bilirubin</td>
<td align="center">â‰¥ 3.0 x ULN</td>
<td align="center">3%</td>
</tr>
<tr valign="top">
<td>Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>/AST</td>
<td align="center">&gt; 180 U/L</td>
<td align="center">8%</td>
</tr>
<tr valign="top">
<td>Â Â Â Â Â SGPT/ALT</td>
<td align="center">&gt; 215 U/L</td>
<td align="center">7%</td>
</tr>
<tr valign="top">
<td>Â Â Â Â Â Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></td>
<td align="center">&gt; 300 mg/dL</td>
<td align="center">3%</td>
</tr>
<tr valign="top">
<td>Â Â Â Â Â Amylase</td>
<td align="center">&gt; 2.5 x ULN</td>
<td align="center">7%<span class="Sup">2</span>
</td>
</tr>
<tr valign="top">
<td><span class="Bold">Chemistry</span></td>
<td align="center"><span class="Bold">Low</span></td>
<td align="center">Â </td>
</tr>
<tr valign="top">
<td>Â Â Â Â Â Sodium</td>
<td align="center">&lt; 130 mEq/L</td>
<td align="center">3%</td>
</tr>
<tr valign="top">
<td><span class="Bold">Hematology</span></td>
<td align="center"><span class="Bold">Low</span></td>
<td align="center">Â </td>
</tr>
<tr valign="top">
<td>Â Â Â Â Â Platelet Count</td>
<td align="center">&lt; 50 x 10<span class="Sup">9</span>/L</td>
<td align="center">4%</td>
</tr>
<tr valign="top">
<td>Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span></td>
<td align="center">&lt; 0.40 x 10<span class="Sup">9</span>/L</td>
<td align="center">2%</td>
</tr>
<tr class="Last"><td colspan="3">1 Â Â ULN = upper limit of the normal range.<br>2 Â Â Subjects with Grade 3-4 amylase confirmed by elevations in pancreatic amylase.</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_6.3"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Postmarketing Experience</h2>
<p class="First"><a name="p215281408"></a>The following adverse reactions have been reported during postmarketing use of KALETRA. Because these reactions are reported voluntarily from a population of unknown size, it is not possible to reliably estimate their frequency or establish a causal relationship to KALETRA exposure.</p>
<p><a name="p215311408"></a><span class="Italics">Body as a Whole</span><br> Redistribution/accumulation of body fat has been reported <span class="Italics">[see Warnings and Precautions (<a href="#section_5.9">5.9</a>)]</span>.</p>
<p><a name="p215461408"></a><span class="Italics">Cardiovascular</span><br> <span class="product-label-link" type="condition" conceptid="4228448" conceptname="Bradyarrhythmia">Bradyarrhythmias</span>. First-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>, second-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>, third-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>, QTc interval prolongation, torsades (torsade) de pointes <span class="Italics">[see Warnings and Precautions (<a href="#section_5.6">5.6</a>, <a href="#section_5.7">5.7</a>)]</span>.</p>
<p><a name="p217711408"></a><span class="Italics">Skin and Appendages</span><br><span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">Toxic epidermal necrolysis</span> (TEN), <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section_7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First"><a name="p217831408"></a><span class="Italics">See also Contraindications (<a href="#section_4">4</a>), Warnings and Precautions (<a href="#section_5.1">5.1</a>),  Clinical Pharmacology (<a href="#section_12.3">12.3</a>)</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section_7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Potential for KALETRA to Affect Other Drugs</h2>
<p class="First"><a name="p220341408"></a>Lopinavir/ritonavir is an inhibitor of CYP3A and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (&gt; 3-fold) when co-administered with KALETRA. Thus, co-administration of KALETRA with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated. Co-administration with other CYP3A substrates may require a dose adjustment or additional monitoring as shown in Table 9.</p>
<p><a name="p220371408"></a>Additionally, KALETRA induces glucuronidation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Potential for Other Drugs to Affect Lopinavir</h2>
<p class="First"><a name="p220451408"></a>Lopinavir/ritonavir is a CYP3A substrate; therefore, drugs that induce CYP3A may decrease lopinavir plasma concentrations and reduce KALETRAâ€™s therapeutic effect.  Although not observed in the KALETRA/ketoconazole drug interaction study, co-administration of KALETRA and other drugs that inhibit CYP3A may increase lopinavir plasma concentrations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Established and Other Potentially Significant Drug Interactions</h2>
<p class="First"><a name="p220531408"></a>Table 9 provides a listing of established or potentially clinically significant drug interactions. Alteration in dose or regimen may be recommended based on drug interaction studies or predicted interaction <span class="Italics">[see Clinical Pharmacology (<a href="#section_12.3">12.3</a>) for magnitude of interaction]</span>.</p>
<a name="table_9"></a><table border="1" frame="box" rules="all" width="100%">
<caption><span>TableÂ 9.Â Established and Other Potentially Significant Drug Interactions</span></caption>
<colgroup>
<col width="26%">
<col width="22%">
<col width="51%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Toprule">
<span class="Bold">Concomitant Drug Class:</span><br><span class="Bold">DrugÂ Name</span>
</td>
<td class="Toprule"><span class="Bold">Effect on Concentration of Lopinavir or Concomitant Drug</span></td>
<td class="Toprule" align="center"><span class="Bold">Clinical Comments</span></td>
</tr>
<tr><td align="center" colspan="3"><span class="Italics"><span class="Bold">HIV-1 Antiviral Agents</span></span></td></tr>
<tr valign="top">
<td>Non-nucleoside Reverse Transcriptase Inhibitors:<br>efavirenz*,<br>nevirapine*</td>
<td>â†“ lopinavir</td>
<td>KALETRA dose increase is recommended in all patients <span class="Italics">[see Dosage and Administration (<a href="#section_2.1">2.1</a>) and Clinical Pharmacology (<a href="#section_12.3">12.3</a>)]</span>.<br>Increasing the dose of KALETRA tablets to 500/125 mg (given as two 200/50 mg tablets and one 100/25 mg tablet) twice daily co-administered with efavirenz resulted in similar lopinavir concentrations compared to KALETRA tablets 400/100 mg (given as two 200/50 mg tablets) twice daily without efavirenz.<br>Increasing the dose of KALETRA tablets to 600/150 mg (given as three 200/50 mg tablets) twice daily co-administered with efavirenz resulted in significantly higher lopinavir plasma concentrations compared to KALETRA tablets 400/100 mg twice daily without efavirenz. <br>KALETRA should not be administered once daily in combination with efavirenz or nevirapine<br><span class="Italics">[see Dosage and Administration (<a href="#section_2.1">2.1</a>) and Clinical Pharmacology (<a href="#section_12.3">12.3</a>)]</span>.</td>
</tr>
<tr valign="top">
<td>Non-nucleoside Reverse Transcriptase Inhibitor:<br>delavirdine</td>
<td>â†‘ lopinavir</td>
<td>Appropriate doses of the combination with respect to safety and efficacy have not been established.</td>
</tr>
<tr valign="top">
<td>Nucleoside Reverse Transcriptase Inhibitor:<br>didanosine</td>
<td>Â </td>
<td>KALETRA tablets can be administered simultaneously with didanosine without food.<br>For KALETRA oral solution, it is recommended that didanosine be administered on an empty stomach; therefore, didanosine should be given one hour before or two hours after KALETRA oral solution (given with food).</td>
</tr>
<tr valign="top">
<td>Nucleoside Reverse Transcriptase Inhibitor:<br>tenofovir</td>
<td>â†‘ tenofovir</td>
<td>KALETRA increases tenofovir concentrations.  The mechanism of this interaction is unknown.  Patients receiving KALETRA and tenofovir should be monitored for adverse reactions associated with tenofovir.</td>
</tr>
<tr valign="top">
<td>Nucleoside Reverse Transcriptase Inhibitor:<br>abacavir<br>zidovudine</td>
<td>â†“ abacavir<br>â†“ zidovudine</td>
<td>KALETRA induces glucuronidation; therefore,  KALETRA has the potential to reduce zidovudine and abacavir plasma concentrations. The clinical significance of this potential interaction is unknown. </td>
</tr>
<tr valign="top">
<td>HIV-1 Protease Inhibitor:<br>amprenavir*</td>
<td>â†‘ amprenavir <br>â†“Â lopinavir</td>
<td>KALETRA should not be administered once daily in combination with amprenavir <br><span class="Italics">[see Dosage and Administration (<a href="#section_2.1">2.1</a>)]</span>.</td>
</tr>
<tr valign="top">
<td>HIV-1 Protease Inhibitor:<br>fosamprenavir/ritonavir</td>
<td>â†“Â amprenavir <br>â†“Â lopinavir</td>
<td>An increased rate of adverse reactions has been observed with co-administration of these medications.  Appropriate doses of the combinations with respect to safety and efficacy have not been established.</td>
</tr>
<tr valign="top">
<td>HIV-1 Protease Inhibitor:<br>indinavir*</td>
<td>â†‘ indinavir </td>
<td>Decrease indinavir dose to 600 mg twice daily, when co-administered with KALETRA 400/100 mg twice daily <span class="Italics">[see Clinical Pharmacology (<a href="#section_12.3">12.3</a>)]</span>.  KALETRA once daily has not been studied in combination with indinavir.</td>
</tr>
<tr valign="top">
<td>HIV-1 Protease Inhibitor:<br>nelfinavir*</td>
<td>â†‘ nelfinavir <br>â†‘ M8 metabolite of nelfinavir<br>â†“ lopinavir</td>
<td>KALETRA should not be administered once daily in combination with nelfinavir<br><span class="Italics">[see Dosage and Administration (<a href="#section_2.1">2.1</a>) and Clinical Pharmacology (<a href="#section_12.3">12.3</a>)]</span>.<br><br>
</td>
</tr>
<tr valign="top">
<td>HIV-1 Protease Inhibitor:<br>ritonavir*</td>
<td>â†‘ lopinavir</td>
<td>Appropriate doses of additional ritonavir in combination with KALETRA with respect to safety and efficacy have not been established.</td>
</tr>
<tr valign="top">
<td>HIV-1 Protease Inhibitor:<br>saquinavir*</td>
<td>â†‘ saquinavir </td>
<td>The saquinavir dose is 1000 mg twice daily, when co-administered with KALETRAÂ 400/100Â mgÂ twice daily. <br>KALETRA once daily has not been studied in combination with saquinavir.   </td>
</tr>
<tr valign="top">
<td>HIV-1 Protease Inhibitor:<br>tipranavir</td>
<td>â†“ lopinavir AUC and C<span class="Sub">min</span>
</td>
<td>KALETRA should not be administered with tipranavir (500 mg twice daily) co-administered with ritonavir (200 mg twice daily).</td>
</tr>
<tr valign="top">
<td>HIV CCR5 â€“ Antagonist:<br> maraviroc</td>
<td>â†‘ maraviroc</td>
<td>Concurrent administration of maraviroc with KALETRA will increase plasma levels of maraviroc.   When co-administered, patients should receive 150 mg twice daily of maraviroc.  For further details see complete prescribing information for Selzentry<span class="Sup">Â®</span> (maraviroc).  </td>
</tr>
<tr valign="top"><td align="center" colspan="3"><span class="Italics"><span class="Bold">Other Agents</span></span></td></tr>
<tr valign="top">
<td>Antiarrhythmics:<br>amiodarone,<br>bepridil,<br>lidocaine (systemic),<br>quinidine</td>
<td>â†‘ antiarrhythmics</td>
<td>Caution is warranted and therapeutic concentration monitoring (if available) is recommended for antiarrhythmics when co-administered with KALETRA.</td>
</tr>
<tr valign="top">
<td>Anticancer Agents: <br>vincristine,<br>vinblastine,<br>dasatinib,  <br>nilotinib</td>
<td>â†‘ anticancer agents</td>
<td>Concentrations of these drugs may be increased when co-administered with KALETRA resulting in the potential for increased adverse events usually associated with these anticancer agents.  <br>For vincristine and vinblastine, consideration should be given to temporarily withholding the ritonavir-containing antiretroviral regimen in patients who develop significant hematologic or gastrointestinal side effects when KALETRA is administered concurrently with vincristine or vinblastine. If the antiretroviral regimen must be withheld for a prolonged period, consideration should be given to initiating a revised regimen that does not include a CYP3A or P-gp inhibitor.<br>  A decrease in the dosage or an adjustment of the dosing interval of nilotinib and dasatinib may be necessary for patients requiring co-administration with strong CYP3A inhibitors such as KALETRA.  Please refer to the nilotinib and dasatinib prescribing information for dosing instructions.</td>
</tr>
<tr valign="top">
<td>Anticoagulant:<br>warfarin</td>
<td>Â </td>
<td>Concentrations of warfarin may be affected.  It is recommended that INR (international normalized ratio) be monitored.</td>
</tr>
<tr valign="top">
<td>Anticonvulsants:<br>carbamazepine,<br>phenobarbital,<br>phenytoin</td>
<td>â†“ lopinavir<br>â†“ phenytoin</td>
<td>KALETRA may be less effective due to decreased lopinavir plasma concentrations in patients taking these agents concomitantly and should be used with caution.<br>KALETRA should not be administered once daily in combination with carbamazepine, phenobarbital, or phenytoin.<br><br>In addition, co-administration of phenytoin and KALETRA may cause decreases in steady-state phenytoin concentrations.  Phenytoin levels should be monitored when co-administering with KALETRA. </td>
</tr>
<tr valign="top">
<td>Antidepressant: <br>bupropion</td>
<td>â†“ bupropion<br>â†“ active metabolite, <br>hydroxybupropion</td>
<td>Concurrent administration of bupropion with KALETRA may decrease plasma levels of both bupropion and its active metabolite (hydroxybupropion).  Patients receiving KALETRA and bupropion concurrently should be monitored for an adequate clinical response to bupropion.  </td>
</tr>
<tr valign="top">
<td>Antidepressant:<br>trazodone<br>
</td>
<td>â†‘ trazodone</td>
<td>Concomitant use of trazodone and KALETRA may increase concentrations of trazodone.  Adverse reactions of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> have been observed following co-administration of trazodone and ritonavir.  If trazodone is used with a CYP3A4 inhibitor such as ritonavir, the combination should be used with caution and a lower dose of trazodone should be considered.</td>
</tr>
<tr valign="top">
<td>Anti-infective:<br>clarithromycin</td>
<td>â†‘ clarithromycin</td>
<td>For patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the following dosage adjustments should be considered: <br>â€ƒâ€ƒâ€¢â€ƒFor patients with CL<span class="Sub">CR</span> 30 to 60Â mL/min the dose <br>â€ƒâ€ƒ â€ƒof clarithromycin should be reduced by 50%.<br>â€ƒâ€ƒâ€¢â€ƒFor patients with CL<span class="Sub">CR</span> &lt;Â 30Â mL/min the dose <br>â€ƒâ€ƒ â€ƒof clarithromycin should be decreased by 75%.<br><br>No dose adjustment for patients with normal renal function is necessary.</td>
</tr>
<tr valign="top">
<td>Antifungals:<br>ketoconazole*,<br>itraconazole,<br>voriconazole</td>
<td>â†‘ ketoconazole<br>â†‘Â itraconazole<br>â†“ voriconazole </td>
<td>High doses of ketoconazole (&gt;200 mg/day) or itraconazole (&gt;Â 200Â mg/day) are not recommended.  <br>Co-administration of voriconazole with KALETRA has not been studied.  However, a study has been shown that administration of voriconazole with ritonavir 100 mg every 12 hours decreased voriconazole steady-state AUC by an average of 39%; therefore, co-administration of KALETRA and voriconazole may result in decreased voriconazole concentrations and the potential for decreased voriconazole effectiveness and should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole.  Otherwise, alternative antifungal therapies should be considered in these patients.  </td>
</tr>
<tr valign="top">
<td>Anti-<span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>: <br>colchicine</td>
<td>â†‘ colchicine</td>
<td>Patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should not be given colchicine with KALETRA.  <br><br><span class="Underline">Treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span>-co-administration of colchicine in patients on KALETRA:</span><br><br>0.6 mg (1 tablet) x 1 dose, followed by 0.3 mg (half tablet) 1 hour later. Dose to be repeated no earlier than 3 days.<br><br><span class="Underline">Prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span>-co-administration of colchicine in patients on KALETRA:</span><br><br>If the original colchicine regimen was 0.6 mg twice a day, the regimen should be adjusted to 0.3 mg once a day.  <br><br>If the original colchicine regimen was 0.6 mg once a day, the regimen should be adjusted to 0.3 mg once every other day. <br><br><span class="Underline">Treatment of familial Mediterranean <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (FMF)-co-administration of colchicine in patients on KALETRA:</span><br><br>Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day).</td>
</tr>
<tr valign="top">
<td>Antimycobacterial:<br>rifabutin*</td>
<td>â†‘ rifabutin and rifabutin metabolite</td>
<td>Dosage reduction of rifabutin by at least 75% of the usual dose of 300 mg/day is recommended (i.e., a maximum dose of 150 mg every other day or three times per week).  Increased monitoring for adverse reactions is warranted in patients receiving the combination.  Further dosage reduction of rifabutin may be necessary.</td>
</tr>
<tr valign="top">
<td>Antimycobacterial:<br>rifampin</td>
<td>â†“ lopinavir</td>
<td>May lead to loss of virologic response and possible resistance to KALETRA or to the class of protease inhibitors or other co-administered antiretroviral agents.  A study evaluated combination of rifampin 600 mg once daily, with KALETRA 800/200 mg twice daily or KALETRA 400/100Â mg + ritonavir 300 mg twice daily.  Pharmacokinetic and safety results from this study do not allow for a dose recommendation.  Nine subjects (28%) experienced a â‰¥Â grade 2 increase in ALT/AST, of which seven (21%) prematurely discontinued study per protocol.  Based on the study design, it is not possible to determine whether the frequency or magnitude of the ALT/AST elevations observed is higher than what would be seen with rifampin alone <span class="Italics">[see Clinical Pharmacology (<a href="#section_12.3">12.3</a>) for magnitude of interaction]</span>.</td>
</tr>
<tr valign="top">
<td>Antiparasitic:<br>atovaquone</td>
<td>â†“ atovaquone</td>
<td>Clinical significance is unknown; however, increase in atovaquone doses may be needed.</td>
</tr>
<tr valign="top">
<td>Benzodiazepines: parenterally administered midazolam</td>
<td>â†‘ midazolam</td>
<td>Midazolam is extensively metabolized by CYP3A4. Increases in the concentration of midazolam are expected to be significantly higher with oral than parenteral administration.  Therefore, KALETRA should not be given with orally administered midazolam <span class="Italics">[see Contraindications (<a href="#section_4">4</a>)]</span>. If KALETRA is co-administered with parenteral midazolam, close clinical monitoring for <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and/or prolonged sedation should be exercised and dosage adjustment should be considered.</td>
</tr>
<tr valign="top">
<td>Calcium Channel Blockers:<br> dihydropyridine,<br>felodipine,<br>nifedipine,<br>nicardipine</td>
<td>â†‘ dihydropyridine calcium channel blockers</td>
<td>Caution is warranted and clinical monitoring of patients is recommended.</td>
</tr>
<tr valign="top">
<td>Contraceptive:<br>ethinyl estradiol*</td>
<td>â†“ ethinyl estradiol</td>
<td>Because contraceptive steroid concentrations may be altered when KALETRA is co-administered with oral contraceptives or with the contraceptive patch, alternative methods of nonhormonal contraception are recommended.</td>
</tr>
<tr valign="top">
<td>Corticosteroid:<br>dexamethasone<br><br>
</td>
<td>â†“ lopinavir</td>
<td>Use with caution.  KALETRA may be less effective due to decreased lopinavir plasma concentrations in patients taking these agents concomitantly.<br><br><br>
</td>
</tr>
<tr valign="top">
<td>disulfiram/metronidazole</td>
<td>Â </td>
<td>KALETRA oral solution contains alcohol, which can produce disulfiram-like reactions when co-administered with disulfiram or other drugs that produce this reaction (e.g., metronidazole).</td>
</tr>
<tr valign="top">
<td>Endothelin Receptor Antagonists: <br>bosentan</td>
<td>â†‘ bosentan</td>
<td>
<span class="Underline">Co-administration of bosentan in patients on KALETRA:</span><br><br>In patients who have been receiving KALETRA for at least 10 days, start bosentan at 62.5 mg once daily or every other day based upon individual tolerability.  <br><br><span class="Underline">Co-administration of KALETRA in patients on bosentan:</span><br><br>Discontinue use of bosentan at least 36 hours prior to initiation of KALETRA.   <br><br>After at least 10 days following the initiation of KALETRA, resume bosentan at 62.5 mg once daily or every other day based upon individual tolerability.</td>
</tr>
<tr valign="top">
<td>HMG-CoA Reductase Inhibitors:<br>atorvastatin<br>rosuvastatin</td>
<td>â†‘ atorvastatin<br>â†‘ rosuvastatin</td>
<td>Use atorvastatin with caution and at the lowest necessary dose. Titrate rosuvastatin dose carefully and use the lowest necessary dose; do not exceed rosuvastatin 10 mg/day. See Drugs with No Observed or Predicted Interactions with KALETRA <span class="Italics">(<a href="#section_7.4">7.4</a>) </span>and Clinical Pharmacology <span class="Italics">(<a href="#section_12.3">12.3</a>)</span> for drug interaction data with other HMG-CoA reductase inhibitors.</td>
</tr>
<tr valign="top">
<td>Immunosuppressants:<br>cyclosporine,<br>tacrolimus,<br>rapamycin</td>
<td>â†‘ immunosuppressants</td>
<td>Therapeutic concentration monitoring is recommended for immunosuppressant agents when co-administered with KALETRA.</td>
</tr>
<tr valign="top">
<td>Inhaled Steroid:<br>fluticasone</td>
<td>â†‘ fluticasone</td>
<td>Concomitant use of fluticasone propionate and KALETRA may increase plasma concentrations of fluticasone propionate, resulting in significantly reduced serum cortisol concentrations. Systemic corticosteroid effects including Cushing's syndrome and adrenal suppression have been reported during post-marketing use in patients receiving ritonavir and inhaled or intranasally administered fluticasone propionate. Co-administration of fluticasone propionate and KALETRA is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effect.  </td>
</tr>
<tr valign="top">
<td>Long-acting beta-adrenoceptor Agonist: <br>salmeterol</td>
<td>â†‘ salmeterol</td>
<td>Concurrent administration of salmeterol and KALETRA is not recommended. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span> and <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">sinus tachycardia</span>.</td>
</tr>
<tr valign="top">
<td>Narcotic Analgesic:<br>methadone*<br>fentanyl</td>
<td>â†“ methadone<br>â†‘ fentanyl</td>
<td>Dosage of methadone may need to be increased when co-administered with KALETRA.<br>Concentrations of fentanyl are expected to increase.  Careful monitoring of therapeutic and adverse effects (including potentially fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>) is recommended when fentanyl is concomitantly administered with KALETRA.</td>
</tr>
<tr valign="top">
<td>PDE5 inhibitors: <br>sildenafil, <br>tadalafil, <br>vardenafil </td>
<td>â†‘ sildenafil <br>â†‘ tadalafil <br>â†‘ vardenafil </td>
<td>Particular caution should be used when prescribing sildenafil, tadalafil, or vardenafil in patients receiving KALETRA. Co-administration of KALETRA with these drugs is expected to substantially increase their concentrations and may result in an increase in PDE5 inhibitor associated adverse reactions including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, visual changes and prolonged erection.<br><br>Use of PDE5 inhibitors for <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span> (PAH):  <br><br>Sildenafil (Revatio<span class="Sup">Â®</span>) is contraindicated when used for the treatment of <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span> (PAH) because a safe and effective dose has not been established when used with KALETRA <span class="Italics">[see Contraindications (<a href="#section_4">4</a>)]</span>. <br><br>The following dose adjustments are recommended for use of tadalafil (Adcirca<span class="Sup">Â®</span>) with KALETRA:  <br><br><span class="Underline">Co-administration of ADCIRCA in patients on KALETRA:</span><br><br>In patients receiving KALETRA for at least one week, start ADCIRCA at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability.  <br><br><span class="Underline">Co-administration of KALETRA in patients on ADCIRCA:</span><br><br>Avoid use of ADCIRCA during the initiation of KALETRA. Stop ADCIRCA at least 24 hours prior to starting KALETRA. After at least one week following the initiation of KALETRA, resume ADCIRCA at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability.  <br><br>Use of PDE5 inhibitors for <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>:  <br><br>It is recommended not to exceed the following doses:<br>â€ƒâ€ƒâ€¢â€ƒSildenafil: 25 mg every 48 hours<br>â€ƒâ€ƒâ€¢â€ƒTadalafil: 10 mg every 72 hours<br>â€ƒâ€ƒâ€¢â€ƒVardenafil: 2.5 mg every 72 hours<br><br>Use with increased monitoring for adverse events.</td>
</tr>
<tr class="Last"><td colspan="3">*  Â Â <span class="Italics">see Clinical Pharmacology (<a href="#section_12.3">12.3</a>)</span> for magnitude of interaction.</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Drugs with No Observed or Predicted Interactions with KALETRA  </h2>
<p class="First"><a name="p266521408"></a>Drug interaction studies reveal no clinically significant interaction between KALETRA and desipramine (CYP2D6 probe), pitavastatin, pravastatin, stavudine, lamivudine, omeprazole, or ranitidine.</p>
<p><a name="p266551408"></a>Based on known metabolic profiles, clinically significant drug interactions are not expected between KALETRA and dapsone, trimethoprim/sulfamethoxazole, azithromycin, erythromycin, or fluconazole.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section_8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><a name="p268911408"></a>Pregnancy Category C.</p>
<p><a name="p269001408"></a><span class="Underline"><span class="Italics">Antiretroviral Pregnancy Registry</span></span>: To monitor maternal-fetal outcomes of pregnant women exposed to KALETRA, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263.</p>
<p><a name="p61971324"></a><span class="Italics">Human Data:</span></p>
<p><a name="p542991024"></a> There are no adequate and well-controlled studies in pregnant women. KALETRA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>
<p><a name="p55067624"></a><span class="Italics">Antiretroviral Pregnancy Registry: </span>As of January 2011, the Antiretroviral Pregnancy Registry (APR) has received prospective reports of 2458 exposures to lopinavir containing regimens (738 exposed in the first trimester and 1720 exposed in the second and third trimester). <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth defects</span> occurred in 16 of the 738 (2.2%) live births (first trimester exposure) and 41 of the 1720 (2.4%) live births (second/third trimester exposure). Among pregnant women in the U.S. reference population, the background rate of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> is 2.7%. There was no association between lopinavir and overall <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> observed in the APR.</p>
<p><a name="p61968624"></a><span class="Italics">Animal Data: </span></p>
<p><a name="p268941408"></a>No treatment-related malformations were observed when lopinavir in combination with ritonavir was administered to pregnant rats or rabbits. Embryonic and fetal developmental toxicities (early resorption, decreased fetal viability, decreased fetal body weight, increased incidence of skeletal variations and skeletal ossification delays) occurred in rats at a maternally toxic dosage. Based on AUC measurements, the drug exposures in rats at the toxic doses were approximately 0.7-fold for lopinavir and 1.8-fold for ritonavir for males and females that of the exposures in humans at the recommended therapeutic dose (400/100 mg twice daily). In a peri- and postnatal study in rats, a developmental toxicity (a decrease in survival in pups between birth and postnatal Day 21) occurred.</p>
<p><a name="p268971408"></a>No embryonic and fetal developmental toxicities were observed in rabbits at a maternally toxic dosage. Based on AUC measurements, the drug exposures in rabbits at the toxic doses were approximately 0.6-fold for lopinavir and 1.0-fold for ritonavir that of the exposures in humans at the recommended therapeutic dose (400/100 mg twice daily). </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section_8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First"><a name="p269131408"></a><span class="Underline">The Centers for Disease Control and Prevention recommend that HIV-1 infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV-1</span>.  Studies in rats have demonstrated that lopinavir is secreted in milk.  It is not known whether lopinavir is secreted in human milk.  Because of both the potential for HIV-1 transmission and the potential for serious adverse reactions in nursing infants, mothers should be instructed <span class="Underline">not to breastfeed if they are receiving KALETRA</span>.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section_8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First"><a name="p269281408"></a>The safety, efficacy, and pharmacokinetic profiles of KALETRA in pediatric patients below the age of 14 days have not been established. KALETRA once daily has not been evaluated in pediatric patients.</p>
<p><a name="p271371408"></a>An open-label, multi-center, dose-finding trial was performed to evaluate the pharmacokinetic profile, tolerability, safety and efficacy of KALETRA oral solution containing lopinavir 80 mg/mL and ritonavir 20 mg/mL at a dose of 300/75 mg/m<span class="Sup">2</span>  twice daily plus two NRTIs in HIV-infected infants â‰¥14 days and &lt; 6 months of age.  Results revealed that infants younger than 6 months of age generally had lower lopinavir AUC<span class="Sub">12</span> than older children (6 months to 12 years of age), however, despite the lower lopinavir drug exposure observed, antiviral activity was demonstrated as reflected in the proportion of subjects who achieved HIV-1 RNA &lt;400 copies/mL at Week 24 <span class="Italics">[see Adverse Reactions (<a href="#section_6.2">6.2</a>), Clinical Pharmacology (<a href="#section_12.3">12.3</a>), Clinical Studies (<a href="#section_14.4">14.4</a>)]</span>.</p>
<p><a name="p271641408"></a>Safety and efficacy in pediatric patients &gt; 6 months of age was demonstrated in a clinical trial in 100 patients.  The clinical trial was an open-label, multicenter trial evaluating the pharmacokinetic profile, tolerability, safety, and efficacy of KALETRA oral solution containing lopinavir 80 mg/mL and ritonavir 20 mg/mL in 100 antiretroviral naÃ¯ve and experienced pediatric patients ages 6 months to 12 years. Dose selection for patients 6 months to 12 years of age was based on the following results.  The 230/57.5 mg/m<span class="Sup">2</span> oral solution twice daily regimen without nevirapine and the 300/75 mg/m<span class="Sup">2</span> oral solution twice daily regimen with nevirapine provided lopinavir plasma concentrations similar to those obtained in adult patients receiving the 400/100 mg twice daily regimen (without nevirapine) <span class="Italics">[see Adverse Reactions (<a href="#section_6.2">6.2</a>), Clinical Pharmacology (<a href="#section_12.3">12.3</a>), Clinical Studies (<a href="#section_14.4">14.4</a>)]</span>.</p>
<p><a name="p273971408"></a>A prospective multicenter, open-label trial evaluated the pharmacokinetic profile, tolerability, safety and efficacy of high-dose KALETRA with or without concurrent NNRTI therapy (Group 1: 400/100 mg/m<span class="Sup">2</span> twice daily + â‰¥ 2 NRTIs; Group 2: 480/120 mg/m<span class="Sup">2</span> twice daily + â‰¥ 1 NRTI + 1 NNRTI) in children and adolescents â‰¥ 2 years to &lt; 18 years of age who had failed prior therapy. Patients also had saquinavir mesylate added to their regimen. This strategy was intended to assess whether higher than approved doses of KALETRA could overcome protease inhibitor cross-resistance. High doses of KALETRA exhibited a safety profile similar to those observed in previous trials; changes in HIV-1 RNA were less than anticipated; three patients had HIV-1 RNA &lt;400 copies/mL at Week 48. CD4+ cell count increases were noted in the eight patients who remained on treatment for 48 weeks <span class="Italics">[see Adverse Reactions (<a href="#section_6.2">6.2</a>), Clinical Pharmacology (<a href="#section_12.3">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section_8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First"><a name="p274251408"></a>Clinical studies of KALETRA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.  In general, appropriate caution should be exercised in the administration and monitoring of KALETRA in elderly patients reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First"><a name="p274331408"></a>KALETRA is principally metabolized by the liver; therefore, caution should be exercised when administering this drug to patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, because lopinavir concentrations may be increased <span class="Italics">[see Warnings and Precautions (<a href="#section_5.4">5.4</a>) and Clinical Pharmacology (<a href="#section_12.3">12.3</a>)]</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section_10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First"><a name="p276591408"></a><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdoses</span> with KALETRA oral solution have been reported. One of these reports described fatal <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span> in a 2.1 kg infant who received a single dose of 6.5 mL of KALETRA oral solution (520 mg lopinavir, approximately 10-fold above the recommended lopinavir dose) nine days prior. The following events have been reported in association with unintended <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> in preterm neonates: complete <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> <span class="Italics">[see Warnings and Precautions (<a href="#section_5.2">5.2</a>)]</span>. Healthcare professionals should be aware that KALETRA oral solution is highly concentrated and therefore, should pay special attention to accurate calculation of the dose of KALETRA, transcription of the medication order, dispensing information and dosing instructions to minimize the risk for medication errors and <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.  This is especially important for infants and young children.</p>
<p><a name="p276621408"></a>KALETRA oral solution contains 42.4% alcohol (v/v) and 15.3% propylene glycol (w/v). Ingestion of the product over the recommended dose by an infant or a young child could result in significant toxicity and could potentially be lethal. </p>
<p><a name="p276661408"></a>Human experience of acute overdosage with KALETRA is limited.  Treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with KALETRA should consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient.  There is no specific antidote for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with KALETRA.  If indicated, elimination of unabsorbed drug should be achieved by gastric lavage.  Administration of activated charcoal may also be used to aid in removal of unabsorbed drug.  Since lopinavir is highly protein bound, dialysis is unlikely to be beneficial in significant removal of the drug. However, dialysis can remove both alcohol and propylene glycol in the case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with KALETRA oral solution.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section_11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First"><a name="p276741408"></a>KALETRA (lopinavir/ritonavir) is a co-formulation of lopinavir and ritonavir. Lopinavir is an inhibitor of the HIV-1 protease. As co-formulated in KALETRA, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.</p>
<p><a name="p276771408"></a>Lopinavir is chemically designated as [1<span class="Italics">S</span>-[1<span class="Italics">R</span>*,(<span class="Italics">R</span>*), 3<span class="Italics">R</span>*, 4<span class="Italics">R</span>*]]-<span class="Italics">N</span>-[4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2<span class="Italics">H</span>)-pyrimidineacetamide.  Its molecular formula is C<span class="Sub">37</span>H<span class="Sub">48</span>N<span class="Sub">4</span>O<span class="Sub">5</span>, and its molecular weight is 628.80.  Lopinavir is a white to light tan powder. It is freely soluble in methanol and ethanol, soluble in isopropanol and practically insoluble in water.  Lopinavir has the following structural formula:</p>
<div class="Figure"><img alt="Chemical structure for lopinavir." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dac2ea61-f5ce-45b8-b4aa-d761c5aecd74&amp;name=kaletra-tablets-oral-structure1.jpg"></div>
<p><a name="p279341408"></a>Ritonavir is chemically designated as 10-hydroxy-2-methyl-5-(1-methylethyl)-1- [2-(1-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-2,4,7,12-tetraazatridecan-13-oic acid, 5-thiazolylmethyl ester, [5<span class="Italics">S</span>-(5<span class="Italics">R</span>*,8<span class="Italics">R</span>*,10<span class="Italics">R</span>*,11<span class="Italics">R</span>*)]. Its molecular formula is C<span class="Sub">37</span>H<span class="Sub">48</span>N<span class="Sub">6</span>O<span class="Sub">5</span>S<span class="Sub">2</span>, and its molecular weight is 720.95. Ritonavir is a white to light tan powder. It is freely soluble in methanol and ethanol, soluble in isopropanol and practically insoluble in water.  Ritonavir has the following structural formula:</p>
<div class="Figure"><img alt="Chemical structure for ritonavir." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dac2ea61-f5ce-45b8-b4aa-d761c5aecd74&amp;name=kaletra-tablets-oral-structure2.jpg"></div>
<p><a name="p281871408"></a>KALETRA film-coated tablets are available for oral administration in two strengths: </p>
<ul class="Disc">
<li>Yellow tablets containing 200 mg of lopinavir and 50 mg of ritonavir</li>
<li><span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">Pale</span> yellow tablets containing 100 mg of lopinavir and 25 mg of ritonavir.</li>
</ul>
<p><a name="p281981408"></a>The yellow, 200 mg lopinavir/50 mg ritonavir, tablets contain the following inactive ingredients: copovidone, sorbitan monolaurate, colloidal silicon dioxide, and sodium stearyl fumarate. The following are the ingredients in the film coating: hypromellose, titanium dioxide, polyethylene glycol 400, hydroxypropyl cellulose, talc, colloidal silicon dioxide, polyethylene glycol 3350, yellow ferric oxide E172, and polysorbate 80.  </p>
<p><a name="p282011408"></a>The <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, 100 mg lopinavir/25 mg ritonavir, tablets contain the following inactive ingredients: copovidone, sorbitan monolaurate, colloidal silicon dioxide, and sodium stearyl fumarate. The following are the ingredients in the film coating: polyvinyl alcohol, titanium dioxide, talc, polyethylene glycol 3350, and yellow ferric oxide E172.</p>
<p><a name="p282041408"></a>KALETRA oral solution is available for oral administration as 80 mg lopinavir and 20 mg ritonavir per milliliter with the following inactive ingredients: acesulfame potassium, alcohol, artificial cotton candy flavor, citric acid, glycerin, high fructose corn syrup, Magnasweet-110 flavor, menthol, natural &amp; artificial vanilla flavor, peppermint oil, polyoxyl 40 hydrogenated castor oil, povidone, propylene glycol, saccharin sodium, sodium chloride, sodium citrate, and water.  </p>
<p><a name="p282071408"></a><span class="Underline">KALETRA oral solution contains 42.4% alcohol (v/v).</span></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section_12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section_12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First"><a name="p284301408"></a>Lopinavir is an antiviral drug <span class="Italics">[see Clinical Pharmacology (<a href="#section_12.4">12.4</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section_12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><a name="p284461408"></a>The pharmacokinetic properties of lopinavir co-administered with ritonavir have been evaluated in healthy adult volunteers and in HIV-1 infected patients; no substantial differences were observed between the two groups.  Lopinavir is essentially completely metabolized by CYP3A.  Ritonavir inhibits the metabolism of lopinavir, thereby increasing the plasma levels of lopinavir.  Across studies, administration of KALETRA 400/100 mg twice daily yields mean steady-state lopinavir plasma concentrations 15-Â to 20-fold higher than those of ritonavir in HIV-1 infected patients.  The plasma levels of ritonavir are less than 7% of those obtained after the ritonavir dose of 600 mg twice daily.  The <span class="Italics">in vitro</span> antiviral EC<span class="Sub">50</span> of lopinavir is approximately 10-fold lower than that of ritonavir.  Therefore, the antiviral activity of KALETRA is due to lopinavir.</p>
<p><a name="p284581408"></a>Figure 1 displays the mean steady-state plasma concentrations of lopinavir and ritonavir after KALETRA 400/100 mg twice daily with food for 3 weeks from a pharmacokinetic study in HIV-1 infected adult subjects (n = 19).  </p>
<p><a name="p284611408"></a><span class="Bold">FigureÂ 1. Mean Steady-State Plasma Concentrations with 95% Confidence Intervals (CI) for HIV-1 Infected Adult Subjects (N = 19)</span></p>
<div class="Figure"><img alt="Figure displays steady-state plasma concentrations for lopinavir and ritonavir." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dac2ea61-f5ce-45b8-b4aa-d761c5aecd74&amp;name=kaletra-tablets-oral-figure1.jpg"></div>
<p><a name="p286771408"></a><span class="Italics">Absorption</span><br>In a pharmacokinetic study in HIV-1 positive subjects (n = 19), multiple dosing with 400/100 mg KALETRA twice daily with food for 3 weeks produced a mean Â± SD lopinavir peak plasma concentration (C<span class="Sub">max</span>) of 9.8 Â± 3.7 Âµg/mL, occurring approximately 4 hours after administration.  The mean steady-state trough concentration prior to the morning dose was 7.1 Â± 2.9 Âµg/mL and minimum concentration within a dosing interval was 5.5Â Â±Â 2.7 Âµg/mL.  Lopinavir AUC over a 12 hour dosing interval averaged 92.6Â Â±Â 36.7Â Âµg<span class="Bold">â€¢</span>h/mL.  The absolute bioavailability of lopinavir co-formulated with ritonavir in humans has not been established.  Under nonfasting conditions (500 kcal, 25% from fat), lopinavir concentrations were similar following administration of KALETRA co-formulated capsules and oral solution.  When administered under fasting conditions, both the mean AUC and C<span class="Sub">max</span> of lopinavir were 22% lower for the KALETRA oral solution relative to the capsule formulation.</p>
<p><a name="p286961408"></a>Plasma concentrations of lopinavir and ritonavir after administration of two 200/50 mg KALETRA tablets are similar to three 133.3/33.3 mg KALETRA capsules under fed conditions with less pharmacokinetic variability.</p>
<p><a name="p286991408"></a><span class="Italics">Effects of Food on Oral Absorption</span><br><span class="Underline">KALETRA Tablets</span><br>No clinically significant changes in C<span class="Sub">max</span> and AUC were observed following administration of KALETRA tablets under fed conditions compared to fasted conditions. Relative to fasting, administration of KALETRA tablets with a moderate fat meal (500 - 682 Kcal, 23 to 25% calories from fat) increased lopinavir AUC and C<span class="Sub">max</span> by 26.9% and 17.6%, respectively. Relative to fasting, administration of KALETRA tablets with a high fat meal (872 Kcal, 56% from fat) increased lopinavir AUC by 18.9% but not C<span class="Sub">max</span>. Therefore, KALETRA tablets may be taken with or without food.<br><span class="Underline">KALETRA Oral Solution</span><br>Relative to fasting, administration of KALETRA oral solution with a moderate fat meal (500 - 682 Kcal, 23 to 25% calories from fat) increased lopinavir AUC and C<span class="Sub">max</span> by 80 and 54%, respectively.  Relative to fasting, administration of KALETRA oral solution with a high fat meal (872 Kcal, 56% from fat) increased lopinavir AUC and C<span class="Sub">max</span> by 130% and 56%, respectively.  To enhance bioavailability and minimize pharmacokinetic variability KALETRA oral solution should be taken with food.</p>
<p><a name="p289421408"></a><span class="Italics">Distribution</span><br>At steady state, lopinavir is approximately 98-99% bound to plasma proteins. Lopinavir binds to both alpha-1-acid glycoprotein (AAG) and albumin; however, it has a higher affinity for AAG. At steady state, lopinavir protein binding remains constant over the range of observed concentrations after 400/100 mg KALETRA twice daily, and is similar between healthy volunteers and HIV-1 positive patients.  </p>
<p><a name="p289491408"></a><span class="Italics">Metabolism</span><br><span class="Italics">In vitro</span> experiments with human hepatic microsomes indicate that lopinavir primarily undergoes oxidative metabolism. Lopinavir is extensively metabolized by the hepatic cytochrome P450 system, almost exclusively by the CYP3A isozyme. Ritonavir is a potent CYP3A inhibitor which inhibits the metabolism of lopinavir, and therefore increases plasma levels of lopinavir. A <span class="Sup">14</span>C-lopinavir study in humans showed that 89% of the plasma radioactivity after a single 400/100 mg KALETRA dose was due to parent drug. At least 13 lopinavir oxidative metabolites have been identified in man. Ritonavir has been shown to induce metabolic enzymes, resulting in the induction of its own metabolism. Pre-dose lopinavir concentrations decline with time during multiple dosing, stabilizing after approximately 10 to 16 days.</p>
<p><a name="p289631408"></a><span class="Italics">Elimination</span><br>Following a 400/100 mg <span class="Sup">14</span>C-lopinavir/ritonavir dose, approximately 10.4 Â± 2.3% and 82.6 Â± 2.5% of an administered dose of <span class="Sup">14</span>C-lopinavir can be accounted for in urine and feces, respectively, after 8 days. Unchanged lopinavir accounted for approximately 2.2 and 19.8% of the administered dose in urine and feces, respectively. After multiple dosing, less than 3% of the lopinavir dose is excreted unchanged in the urine. The apparent oral clearance (CL/F) of lopinavir is 5.98 Â± 5.75 L/hr (mean Â± SD, n = 19).</p>
<p><a name="p291841408"></a><span class="Italics">Once Daily Dosing</span><br> The pharmacokinetics of once daily KALETRA have been evaluated in HIV-1 infected subjects naÃ¯ve to antiretroviral treatment. KALETRA 800/200 mg was administered in combination with emtricitabine 200 mg and tenofovir DF 300 mg as part of a once daily regimen. Multiple dosing of 800/200 mg KALETRA once daily for 4 weeks with food (n = 24) produced a mean Â± SD lopinavir peak plasma concentration (C<span class="Sub">max</span>) of 11.8 Â± 3.7 Âµg/mL, occurring approximately 6 hours after administration. The mean steady-state lopinavir trough concentration prior to the morning dose was 3.2 Â± 2.1 Âµg/mL and minimum concentration within a dosing interval was 1.7 Â± 1.6 Âµg/mL. Lopinavir AUC over a 24 hour dosing interval averaged 154.1 Â± 61.4 Âµgâ€¢ h/mL.</p>
<p><a name="p291951408"></a>The pharmacokinetics of once daily KALETRA has also been evaluated in treatment experienced HIV-1 infected subjects.  Lopinavir exposure (C<span class="Sub">max</span>, AUC<span class="Sub">[0-24h]</span>, C<span class="Sub">trough</span>) with once daily KALETRA administration in treatment experienced subjects is comparable to the once daily lopinavir exposure in treatment naÃ¯ve subjects.</p>
<p><a name="p292101408"></a><span class="Italics">Effects on Electrocardiogram</span></p>
<p><a name="p292151408"></a> QTcF interval was evaluated in a randomized, placebo and active (moxifloxacin 400 mg once daily) controlled crossover study in 39 healthy adults, with 10 measurements over 12 hours on Day 3. The maximum mean time-matched (95% upper confidence bound) differences in QTcF interval from placebo after baseline-correction were 5.3 (8.1) and 15.2 (18.0) mseconds (msec) for 400/100 mg twice daily and supratherapeutic 800/200 mg twice daily KALETRA, respectively. KALETRA 800/200 mg twice daily resulted in a Day 3 mean C<span class="Sub">max</span> approximately 2-fold higher than the mean C<span class="Sub">max </span>observed with the approved once daily and twice daily KALETRA doses at steady state.  </p>
<p><a name="p292261408"></a>PR interval prolongation was also noted in subjects receiving KALETRA in the same study on Day 3. The maximum mean (95% upper confidence bound) difference from placebo in the PR interval after baseline-correction were 24.9 (21.5, 28.3) and 31.9 (28.5, 35.3) msec for 400/100 mg twice daily and supratherapeutic 800/200 mg twice daily KALETRA, respectively <span class="Italics">[see Warnings and Precautions (<a href="#section_5.6">5.6</a>, <a href="#section_5.7">5.7</a>)]</span>.</p>
<p><a name="p294471408"></a>Special Populations</p>
<p><a name="p294501408"></a><span class="Italics">Gender, Race and Age</span><br>No gender related pharmacokinetic differences have been observed in adult patients.  No clinically important pharmacokinetic differences due to race have been identified. Lopinavir pharmacokinetics have not been studied in elderly patients. </p>
<p><a name="p294571408"></a><span class="Italics">Pediatric Patients</span><br>The pharmacokinetics of KALETRA oral solution 300/75 mg/m<span class="Sup">2</span> twice daily and 230/57.5 mg/m<span class="Sup">2</span> twice daily have been studied in a total of 53 pediatric patients in Study 940, ranging in age from 6 months to 12 years <span class="Italics">[see Clinical Studies (<a href="#section_14.4">14.4</a>)]</span>.  The 230/57.5 mg/m<span class="Sup">2</span> twice daily regimen without nevirapine and the 300/75 mg/m<span class="Sup">2</span> twice daily regimen with nevirapine provided lopinavir plasma concentrations similar to those obtained in adult patients receiving the 400/100 mg twice daily regimen (without nevirapine).</p>
<p><a name="p294891408"></a>The mean steady-state lopinavir AUC, C<span class="Sub">max</span>, and C<span class="Sub">min</span> were 72.6 Â± 31.1 Âµg<span class="Bold">â€¢</span>h/mL, 8.2Â Â±Â 2.9 and 3.4 Â± 2.1 Âµg/mL, respectively after KALETRA oral solution 230/57.5Â mg/m<span class="Sup">2</span> twice daily without nevirapine (n = 12), and were 85.8Â Â±Â 36.9Â Âµg<span class="Bold">â€¢</span> h/mL, 10.0 Â± 3.3 and 3.6Â Â±Â 3.5Â Âµg/mL, respectively, after 300/75 mg/m<span class="Sup">2</span> twice daily with nevirapine (n = 12).  The nevirapine regimen was 7 mg/kg twice daily (6 months to 8 years) or 4 mg/kg twice daily (&gt; 8 years).</p>
<p><a name="p297221408"></a>The pharmacokinetics of KALETRA oral solution at approximately 300/75 mg/m<span class="Sup">2</span> twice daily have also been evaluated in infants at approximately 6 weeks of age (n = 9) and between 6 weeks and 6 months of age (n = 18) in Study 1030. The mean steady-state lopinavir AUC<span class="Sub">12</span>, C<span class="Sub">max</span>, and C<span class="Sub">12</span> were 43.4 Â± 14.8 Âµgâ€¢ h/mL, 5.2 Â± 1.8 Âµg/mL and 1.9 Â± 1.1 Âµg/mL, respectively, in infants at approximately 6 weeks of age, and 74.5 Â± 37.9 Âµgâ€¢ h/mL, 9.4 Â± 4.9 and 3.1 Â± 1.8 Âµg/mL, respectively, in infants between 6 weeks and 6 months of age after KALETRA oral solution was administered at approximately 300/75 mg/m<span class="Sup">2</span> twice daily without concomitant NNRTI therapy.</p>
<p><a name="p297451408"></a>The pharmacokinetics of KALETRA soft gelatin capsule and oral solution (Group 1: 400/100 mg/m<span class="Sup">2</span> twice daily + 2 NRTIs; Group 2: 480/120 mg/m<span class="Sup">2</span> twice daily + â‰¥ 1 NRTI + 1 NNRTI) have been evaluated in children and adolescents age â‰¥ 2 years to &lt; 18 years of age who had failed prior therapy (n=26) in Study 1038. KALETRA doses of 400/100 and 480/120 mg/m<span class="Sup">2</span> resulted in high lopinavir exposure, as almost all subjects had lopinavir AUC<span class="Sub">12</span> above 100 Âµgâ€¢h/mL. Both groups of subjects also achieved relatively high average minimum lopinavir concentrations.</p>
<p><a name="p299701408"></a>KALETRA once daily has not been evaluated in pediatric patients.</p>
<p><a name="p299731408"></a><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span><br>Lopinavir pharmacokinetics have not been studied in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>; however, since the renal clearance of lopinavir is negligible, a decrease in total body clearance is not expected in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. </p>
<p><a name="p299801408"></a><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span><br>Lopinavir is principally metabolized and eliminated by the liver.  Multiple dosing of KALETRA 400/100 mg twice daily to HIV-1 and HCV co-infected patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (n = 12) resulted in a 30% increase in lopinavir AUC and 20% increase in C<span class="Sub">max</span> compared to HIV-1 infected subjects with normal hepatic function (nÂ =Â 12).  Additionally, the plasma protein binding of lopinavir was statistically significantly lower in both mild and moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> compared to controls (99.09 vs. 99.31%, respectively).  Caution should be exercised when administering KALETRA to subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.  KALETRA has not been studied in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see Warnings and Precautions (<a href="#section_5.4">5.4</a>) and Use in Specific Populations (<a href="#section_8.6">8.6</a>)]</span>.</p>
<p><a name="p302091408"></a>Drug Interactions</p>
<p><a name="p302131408"></a>KALETRA is an inhibitor of the P450 isoform CYP3A <span class="Italics">in vitro</span>.  Co-administration of KALETRA and drugs primarily metabolized by CYP3A may result in increased plasma concentrations of the other drug, which could increase or prolong its therapeutic and adverse effects <span class="Italics">[see Contraindications (<a href="#section_4">4</a>) and Drug Interactions (<a href="#section_7">7</a>)]</span>.</p>
<p><a name="p302331408"></a>KALETRA does not inhibit CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP2B6 or CYP1A2 at clinically relevant concentrations.</p>
<p><a name="p302371408"></a>KALETRA has been shown <span class="Italics">in vivo</span> to induce its own metabolism and to increase the biotransformation of some drugs metabolized by cytochrome P450 enzymes and by glucuronidation.</p>
<p><a name="p302451408"></a>KALETRA is metabolized by CYP3A.  Drugs that induce CYP3A activity would be expected to increase the clearance of lopinavir, resulting in lowered plasma concentrations of lopinavir.  Although not noted with concurrent ketoconazole, co-administration of KALETRA and other drugs that inhibit CYP3A may increase lopinavir plasma concentrations.</p>
<p><a name="p302491408"></a>Drug interaction studies were performed with KALETRA and other drugs likely to be co-administered and some drugs commonly used as probes for <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span>.  The effects of co-administration of KALETRA on the AUC, C<span class="Sub">max</span> and C<span class="Sub">min</span> are summarized in Table 10 (effect of other drugs on lopinavir) and Table 11 (effect of KALETRA on other drugs).  The effects of other drugs on ritonavir are not shown since they generally correlate with those observed with lopinavir (if lopinavir concentrations are decreased, ritonavir concentrations are decreased) unless otherwise indicated in the table footnotes.  For information regarding clinical recommendations, see Table 9 in <span class="Italics">Drug Interactions (<a href="#section_7">7</a>)</span>.</p>
<a name="t52776324"></a><table border="1" frame="box" rules="all" width="100%">
<caption><span>Table 10. Drug Interactions: Pharmacokinetic Parameters for Lopinavir in the Presence of the Co-administered Drug for Recommended Alterations in Dose or Regimen </span></caption>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Toprule"><span class="Bold">Co-administered Drug </span></td>
<td class="Toprule" align="center"><span class="Bold">Dose of Co-administered Drug <br>    (mg)</span></td>
<td class="Toprule" align="center"><span class="Bold">Dose of KALETRA <br>    (mg)</span></td>
<td class="Toprule" align="center"><span class="Bold">n</span></td>
<td class="Toprule" align="center" colspan="3"><span class="Bold">Ratio (in combination with Co-administered drug/alone) of Lopinavir Pharmacokinetic Parameters (90% CI); No Effect = 1.00 </span></td>
</tr>
<tr valign="top">
<td>Â </td>
<td>Â </td>
<td>Â </td>
<td align="center">Â </td>
<td align="center"><span class="Bold">C<span class="Sub">max</span></span></td>
<td align="center"><span class="Bold">AUC </span></td>
<td align="center"><span class="Bold">C<span class="Sub">min</span></span></td>
</tr>
<tr valign="top">
<td>Amprenavir</td>
<td align="center">750 twice daily, 10 d</td>
<td align="center">400/100 capsule twice daily, 21 d</td>
<td align="center">12</td>
<td align="center">0.72<br>(0.65, 0.79) </td>
<td align="center">0.62<br>(0.56, 0.70) </td>
<td align="center">0.43<br>(0.34, 0.56) </td>
</tr>
<tr valign="top">
<td>Efavirenz<span class="Sup">1,2</span>
</td>
<td align="center">600 at bedtime, 9 d </td>
<td align="center">400/100 capsule twice daily, 9 d</td>
<td align="center">11, 7*</td>
<td align="center">0.97<br>(0.78, 1.22) </td>
<td align="center">0.81<br>(0.64, 1.03) </td>
<td align="center">0.61<br>(0.38, 0.97) </td>
</tr>
<tr valign="top">
<td>Â </td>
<td align="center">600 at bedtime, 9 d</td>
<td align="center">500/125 tablet <br>twice daily, 10 d </td>
<td align="center">19</td>
<td align="center">1.12<br>(1.02, 1.23) </td>
<td align="center">1.06<br>(0.96, 1.17) </td>
<td align="center">0.90<br>(0.78, 1.04) </td>
</tr>
<tr valign="top">
<td>Â </td>
<td align="center">600 at bedtime, 9 d</td>
<td align="center">600/150 tablet<br>twice daily, 10 d </td>
<td align="center">23</td>
<td align="center">1.36<br>(1.28, 1.44) </td>
<td align="center">1.36<br>(1.28, 1.44) </td>
<td align="center">1.32<br>(1.21, 1.44) </td>
</tr>
<tr valign="top">
<td>Fosamprenavir<span class="Sup">3</span>
</td>
<td align="center">700 twice daily plus ritonavir 100 twice daily, 14 d</td>
<td align="center">400/100 capsule twice daily, 14 d</td>
<td align="center">18</td>
<td align="center">1.30<br>(0.85, 1.47) </td>
<td align="center">1.37<br>(0.80, 1.55) </td>
<td align="center">1.52<br>(0.72, 1.82) </td>
</tr>
<tr valign="top">
<td>Ketoconazole</td>
<td align="center">200 single dose</td>
<td align="center">400/100 capsule twice daily, 16 d</td>
<td align="center">12</td>
<td align="center">0.89<br>(0.80, 0.99) </td>
<td align="center">0.87<br>(0.75, 1.00) </td>
<td align="center">0.75<br>(0.55, 1.00) </td>
</tr>
<tr valign="top">
<td>Nelfinavir</td>
<td align="center">1000 twice daily, <br>10 d </td>
<td align="center">400/100 capsule twice daily, 21 d</td>
<td align="center">13</td>
<td align="center">0.79<br>    (0.70, 0.89) </td>
<td align="center">0.73<br>    (0.63, 0.85) </td>
<td align="center">0.62<br>    (0.49, 0.78) </td>
</tr>
<tr valign="top">
<td>Nevirapine</td>
<td align="center">200 twice daily, steady-state<br>(&gt; 1 yr)<span class="Sup">4#</span>
</td>
<td align="center">400/100 capsule twice daily,<br>steady-state </td>
<td align="center">22, 19*</td>
<td align="center">0.81<br>(0.62, 1.05) </td>
<td align="center">0.73<br>(0.53, 0.98) </td>
<td align="center">0.49<br>(0.28, 0.74) </td>
</tr>
<tr valign="top">
<td>Â </td>
<td align="center">7 mg/kg or 4 mg/kg once daily, 2 wk; twice daily 1 wk<span class="Sup">5</span>
</td>
<td align="center">(&gt; 1 yr) 300/75 mg/m2<br>oral solution<br>twice daily, 3 wk </td>
<td align="center">12, 15*</td>
<td align="center">0.86<br>(0.64, 1.16) </td>
<td align="center">0.78<br>(0.56, 1.09) </td>
<td align="center">0.45<br>(0.25, 0.81) </td>
</tr>
<tr valign="top">
<td>Omeprazole</td>
<td align="center">40 once daily, 5 d</td>
<td align="center">400/100 tablet twice daily, 10 d</td>
<td align="center">12</td>
<td align="center">1.08<br>(0.99, 1.17) </td>
<td align="center">1.07<br>(0.99, 1.15) </td>
<td align="center">1.03<br>(0.90, 1.18) </td>
</tr>
<tr valign="top">
<td>Â </td>
<td align="center">40 once daily, 5 d</td>
<td align="center">800/200 tablet once daily, 10 d</td>
<td align="center">12</td>
<td align="center">0.94<br>(0.88, 1.00) </td>
<td align="center">0.92<br>(0.86, 0.99) </td>
<td align="center">0.71<br>(0.57, 0.89) </td>
</tr>
<tr>
<td>Pitavastatin<span class="Sup">6</span>
</td>
<td align="center" valign="top">4 mg once daily, 5 d</td>
<td>400/100 tablet twice daily, 16 d </td>
<td align="center" valign="top">23</td>
<td align="center" valign="top">0.93<br>(0.88-0.98) </td>
<td align="center" valign="top">0.91<br>(0.86-0.97)</td>
<td align="center" valign="top">NA</td>
</tr>
<tr valign="top">
<td>Pravastatin </td>
<td align="center">20 once daily, 4 d</td>
<td align="center">400/100 capsule twice daily, 14 d</td>
<td align="center">12</td>
<td align="center">0.98<br>(0.89, 1.08) </td>
<td align="center">0.95<br>(0.85, 1.05) </td>
<td align="center">0.88<br>(0.77, 1.02) </td>
</tr>
<tr valign="top">
<td>Rifabutin</td>
<td align="center">150 once daily, 10 d</td>
<td align="center">400/100 capsule twice daily, 20 d</td>
<td align="center">14</td>
<td align="center">1.08<br>(0.97, 1.19) </td>
<td align="center">1.17<br>(1.04, 1.31) </td>
<td align="center">1.20<br>(0.96, 1.65) </td>
</tr>
<tr valign="top">
<td>Ranitidine</td>
<td align="center">150 single dose</td>
<td align="center">400/100 tablet twice daily, 10 d</td>
<td align="center">12</td>
<td align="center">0.99<br>(0.95, 1.03) </td>
<td align="center">0.97<br>(0.93, 1.01) </td>
<td align="center">0.90<br>(0.85, 0.95) </td>
</tr>
<tr valign="top">
<td>Â </td>
<td align="center">150 single dose</td>
<td align="center">800/200 tablet once daily, 10 d</td>
<td align="center">10</td>
<td align="center">0.97<br>(0.95, 1.00) </td>
<td align="center">0.95<br>(0.91, 0.99) </td>
<td align="center">0.82<br>(0.74, 0.91) </td>
</tr>
<tr valign="top">
<td>Rifampin</td>
<td align="center">600 once daily,<br>    10 d </td>
<td align="center">400/100 capsule twice daily, 20 d</td>
<td align="center">22</td>
<td align="center">0.45<br>(0.40, 0.51) </td>
<td align="center">0.25<br>(0.21, 0.29) </td>
<td align="center">0.01<br>(0.01, 0.02) </td>
</tr>
<tr valign="top">
<td>Â </td>
<td align="center">600 once daily,<br>    14 d </td>
<td align="center">800/200 capsule twice daily, 9 d<span class="Sup">7</span>
</td>
<td align="center">10</td>
<td align="center">1.02<br>(0.85, 1.23) </td>
<td align="center">0.84<br>(0.64, 1.10) </td>
<td align="center">0.43<br>(0.19, 0.96) </td>
</tr>
<tr valign="top">
<td>Â </td>
<td align="center">600 once daily,<br>    14 d </td>
<td align="center">400/400 capsule twice daily, 9 d<span class="Sup">8</span>
</td>
<td align="center">9</td>
<td align="center">0.93<br>(0.81, 1.07) </td>
<td align="center">0.98<br>(0.81, 1.17) </td>
<td align="center">1.03<br>(0.68, 1.56) </td>
</tr>
<tr valign="top">
<td>Â </td>
<td>Â </td>
<td>Â </td>
<td>Â </td>
<td>Â </td>
<td align="center" colspan="2">Co-administration of KALETRA and rifampin is contraindicated.<br>    [see Contraindications (<a href="#section_4">4</a>)]</td>
</tr>
<tr valign="top">
<td>Ritonavir<span class="Sup">4</span>
</td>
<td align="center">100 twice daily,<br>    3-4 wk<span class="Sup">#</span>
</td>
<td align="center">400/100 capsule twice daily,<br>    3-4 wk </td>
<td align="center">8, 21*</td>
<td align="center">1.28<br>    (0.94, 1.76) </td>
<td align="center">1.46<br>    (1.04, 2.06) </td>
<td align="center">2.16<br>    (1.29, 3.62) </td>
</tr>
<tr valign="top">
<td>Tenofovir<span class="Sup">9</span>
</td>
<td align="center">300 mg once daily, <br>    14 d </td>
<td align="center">400/100 capsule twice daily, 14 d</td>
<td align="center">24</td>
<td align="center">NC<span class="Sup">â€ </span>
</td>
<td align="center">NC<span class="Sup">â€ </span>
</td>
<td align="center">NC<span class="Sup">â€ </span>
</td>
</tr>
<tr valign="top">
<td>Tipranavir/ritonavir<span class="Sup">4</span>
</td>
<td align="center">500/200 mg twice daily (28 doses)<span class="Sup">#</span>
</td>
<td align="center">400/100 capsule twice daily<br>    (27 doses) </td>
<td align="center">21 <br>    69 </td>
<td align="center">0.53<br>    (0.40, 0.69)<span class="Sup">10</span>
</td>
<td align="center">0.45<br>    (0.32, 0.63)<span class="Sup">10</span>
</td>
<td align="center">0.30 (0.17, 0.51)<span class="Sup">10</span><br>    0.48 (0.40, 0.58)<span class="Sup">11</span>
</td>
</tr>
<tr class="Last"><td colspan="7">All interaction studies conducted in healthy, HIV-1 negative subjects unless otherwise indicated.<br> 1â€ƒThe pharmacokinetics of ritonavir are unaffected by concurrent efavirenz.<br>2â€ƒReference for comparison is lopinavir/ritonavir 400/100 mg twice daily without efavirenz. <br> 3â€ƒData extracted from the fosamprenavir package insert.<br> 4â€ƒStudy conducted in HIV-1 positive adult subjects.<br> 5â€ƒStudy conducted in HIV-1 positive pediatric subjects ranging in age from 6 months to 12 years.<br>6â€ƒData extracted from the pitavastatin package insert and results presented at the 2011 International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (Morgan<span class="Italics">, et al, poster #MOPE170)</span>.<br> 7â€ƒTitrated to 800/200 twice daily as 533/133 twice daily x 1 d, 667/167 twice daily x 1 d, then 800/200 twice daily x 7 d, compared to 400/100 twice daily x 10 days alone. <br> 8â€ƒTitrated to 400/400 twice daily as 400/200 twice daily x 1 d, 400/300 twice daily x 1 d, then 400/400 twice daily x 7 d, compared to 400/100 twice daily x 10 days alone. <br> 9â€ƒData extracted from the tenofovir package insert.<br> 10â€ƒIntensive PK analysis.<br> 11â€ƒDrug levels obtained at 8-16 hrs post-dose.<br> *â€ƒParallel group design; n for KALETRA + co-administered drug, n for KALETRA alone.<br> â€ â€ƒNC = No change.<br> # For the nevirapine 200 mg twice daily study, ritonavir, and tipranavir/ritonavir studies, KALETRA was administered with or without food. For all other studies, KALETRA was administered with food. </td></tr>
</tbody>
</table>
<a name="table_11"></a><table border="1" frame="box" rules="all" width="100%">
<caption><span>TableÂ 11. Drug Interactions:  Pharmacokinetic Parameters for Co-administered Drug in the Presence of KALETRA for Recommended Alterations in Dose or Regimen</span></caption>
<colgroup>
<col width="17%">
<col width="17%">
<col width="14%">
<col width="9%">
<col width="12%">
<col width="13%">
<col width="14%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="bottom">
<td class="Toprule" valign="top"><span class="Bold">Co-administered Drug</span></td>
<td class="Toprule" align="center" valign="top"><span class="Bold">Dose of Co-administered Drug                <br>(mg)</span></td>
<td class="Toprule" align="center" valign="top"><span class="Bold">Dose of KALETRA                <br>(mg)</span></td>
<td class="Toprule" align="center" valign="top">Â <span class="Bold">n</span>
</td>
<td class="Toprule" align="center" colspan="3" valign="top"><span class="Bold">Ratio (in combination with KALETRA/alone) of Co-administered Drug Pharmacokinetic Parameters (90%Â CI); No Effect = 1.00</span></td>
</tr>
<tr valign="top">
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center"><span class="Bold">C<span class="Sub">max</span></span></td>
<td align="center"><span class="Bold">AUC</span></td>
<td align="center"><span class="Bold">C<span class="Sub">min</span></span></td>
</tr>
<tr valign="top">
<td>Amprenavir<span class="Sup">1</span>
</td>
<td align="center">750 twice daily, 10 d combo vs. 1200 twice daily, 14 d alone</td>
<td align="center">400/100Â <br>capsule twice daily, 21 d</td>
<td align="center">11</td>
<td align="center">1.12<br>(0.91, 1.39)</td>
<td align="center">1.72<br>(1.41, 2.09)</td>
<td align="center">4.57<br>(3.51, 5.95)</td>
</tr>
<tr valign="top">
<td>Desipramine<span class="Sup">2</span>
</td>
<td align="center">100 single dose</td>
<td align="center">400/100Â <br>capsule twice daily, 10 d</td>
<td align="center">15</td>
<td align="center">0.91<br>(0.84, 0.97)</td>
<td align="center">1.05<br>(0.96, 1.16)</td>
<td align="center">N/A</td>
</tr>
<tr valign="top">
<td>Efavirenz</td>
<td align="center">600 at bedtime, 9 d</td>
<td align="center">400/100Â <br>capsule twice daily, 9 d</td>
<td align="center">11, 12*</td>
<td align="center">0.91<br>(0.72, 1.15)</td>
<td align="center">0.84<br>(0.62, 1.15)</td>
<td align="center">0.84<br>(0.58, 1.20)</td>
</tr>
<tr valign="top">
<td>Ethinyl Estradiol</td>
<td align="center">35 Âµg once daily, 21 d<br> (Ortho Novum<span class="Sup">Â®</span>)</td>
<td align="center">400/100Â <br>capsule twice daily, 14 d</td>
<td align="center">12</td>
<td align="center">0.59<br>(0.52, 0.66)</td>
<td align="center">0.58<br>(0.54, 0.62)</td>
<td align="center">0.42<br>(0.36, 0.49)</td>
</tr>
<tr valign="top">
<td>Fosamprenavir<span class="Sup">3</span>
</td>
<td align="center">700 twice daily plus ritonavir 100 twice daily, 14 d</td>
<td align="center">400/100Â <br>capsule twice daily, 14 d</td>
<td align="center">18</td>
<td align="center">0.42<br>(0.30, 0.58)</td>
<td align="center">0.37<br>(0.28, 0.49)</td>
<td align="center">0.35<br>(0.27, 0.46)</td>
</tr>
<tr valign="top">
<td>Indinavir<span class="Sup">1</span>
</td>
<td align="center">600 twice daily, 10 d combo nonfasting vs. 800 three times daily, 5 d alone fasting</td>
<td align="center">400/100Â <br>capsule twice daily, <br>15 d</td>
<td align="center">13</td>
<td align="center">0.71<br>(0.63, 0.81)</td>
<td align="center">0.91<br>(0.75, 1.10)</td>
<td align="center">3.47<br>(2.60, 4.64)</td>
</tr>
<tr valign="top">
<td>Ketoconazole</td>
<td align="center">200 single dose</td>
<td align="center">400/100Â <br>capsule twice daily, 16 d</td>
<td align="center">12</td>
<td align="center">1.13<br>(0.91, 1.40)</td>
<td align="center">3.04<br>(2.44, 3.79)</td>
<td align="center">N/A</td>
</tr>
<tr valign="top">
<td>Methadone</td>
<td align="center">5 single dose</td>
<td align="center">400/100Â <br>capsule twice daily, 10 d</td>
<td align="center">11</td>
<td align="center">0.55<br>(0.48, 0.64)</td>
<td align="center">0.47<br>(0.42, 0.53)</td>
<td align="center">N/A</td>
</tr>
<tr valign="top">
<td>Nelfinavir<span class="Sup">1</span>
</td>
<td align="center">1000 twice daily, 10 d combo vs. 1250Â twice daily 14 d alone</td>
<td align="center">400/100Â <br>capsule twice daily, 21 d</td>
<td align="center">13</td>
<td align="center">0.93<br>(0.82, 1.05)</td>
<td align="center">1.07<br>(0.95, 1.19)</td>
<td align="center">1.86<br>(1.57, 2.22)</td>
</tr>
<tr valign="top">
<td>M8 metabolite</td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">2.36<br>(1.91, 2.91)</td>
<td align="center">3.46<br>(2.78, 4.31)</td>
<td align="center">7.49<br>(5.85, 9.58)</td>
</tr>
<tr valign="top">
<td>Nevirapine</td>
<td align="center">200 once daily, 14 d; twice daily, 6 d</td>
<td align="center">400/100Â <br>capsule twice daily, 20 d</td>
<td align="center">5, 6*</td>
<td align="center">1.05<br>(0.72, 1.52)</td>
<td align="center">1.08<br>(0.72, 1.64)</td>
<td align="center">1.15<br>(0.71, 1.86)</td>
</tr>
<tr valign="top">
<td>Norethindrone</td>
<td align="center">1 once daily, 21 d <br>(Ortho Novum<span class="Sup">Â®</span>)</td>
<td align="center">400/100Â <br>capsule twice daily, 14 d</td>
<td align="center">12</td>
<td align="center">0.84<br>(0.75, 0.94)</td>
<td align="center">0.83<br>(0.73, 0.94)</td>
<td align="center">0.68<br>(0.54, 0.85)</td>
</tr>
<tr>
<td>Pitavastatin<span class="Sup">4</span>
</td>
<td align="center" valign="top">4 mg once daily , 5 d</td>
<td align="center" valign="top">400/100 tablet twice daily, 16 d </td>
<td align="center" valign="top">23</td>
<td align="center" valign="top">0.96<br>(0.84-1.10)</td>
<td align="center" valign="top">0.80<br>(0.73-0.87) </td>
<td align="center" valign="top">N/A</td>
</tr>
<tr valign="top">
<td>Pravastatin</td>
<td align="center">20 once daily, 4 d</td>
<td align="center">400/100 capsule twice daily, 14 d</td>
<td align="center">12</td>
<td align="center">1.26<br>(0.87, 1.83)</td>
<td align="center">1.33<br>(0.91, 1.94)</td>
<td align="center">N/A</td>
</tr>
<tr valign="top">
<td>Rifabutin</td>
<td align="center">150 once daily, 10 d; combo vs. 300 once daily, 10 d; alone</td>
<td align="center">400/100 capsule twice daily, 10 d</td>
<td align="center">12</td>
<td align="center">2.12<br>(1.89, 2.38)</td>
<td align="center">3.03<br>(2.79, 3.30)</td>
<td align="center">4.90<br>(3.18, 5.76)</td>
</tr>
<tr valign="top">
<td>25-<span class="Italics">O</span>-desacetyl rifabutin</td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">23.6<br>(13.7, 25.3)</td>
<td align="center">47.5<br>(29.3, 51.8)</td>
<td align="center">94.9<br>(74.0, 122)</td>
</tr>
<tr valign="top">
<td>Rifabutin + 25-<span class="Italics">O</span>-desacetyl rifabutin<span class="Sup">5</span>
</td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
<td align="center">3.46<br>(3.07, 3.91)</td>
<td align="center">5.73<br>(5.08, 6.46)</td>
<td align="center">9.53<br>(7.56, 12.01)</td>
</tr>
<tr valign="top">
<td>Rosuvastatin<span class="Sup">6</span>
</td>
<td align="center">20 mg once daily, 7 d</td>
<td align="center">400/100 tablet twice daily, 7 d</td>
<td align="center">15</td>
<td align="center">4.66<br>(3.4, 6.4)</td>
<td align="center">2.08<br>(1.66, 2.6)</td>
<td align="center">1.04<br>(0.9, 1.2)</td>
</tr>
<tr valign="top">
<td>Tenofovir<span class="Sup">7</span>
</td>
<td align="center">300 mg once daily, 14 d</td>
<td align="center">400/100 capsule twice daily, 14 d</td>
<td align="center">24</td>
<td align="center">NC<span class="Sup">â€ </span>
</td>
<td align="center">1.32<br>(1.26, 1.38)</td>
<td align="center">1.51<br>(1.32, 1.66)</td>
</tr>
<tr class="Last"><td colspan="7">All interaction studies conducted in healthy, HIV-1 negative subjects unless otherwise indicated.<br>1 Â Â Ratio of parameters for amprenavir, indinavir, and nelfinavir, are not normalized for dose.<br>2 Â Â Desipramine is a probe substrate for assessing effects on CYP2D6-mediated metabolism.<br>3 Â Â Data extracted from the fosamprenavir package insert.<br>4 Â Data extracted from the pitavastatin package insert and results presented at the 2011 International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (Morgan<span class="Italics">, et al, poster #MOPE170</span>). <br>5 Â Â Effect on the dose-normalized sum of rifabutin parent and 25-<span class="Italics">O</span>-desacetyl rifabutin active metabolite.<br>6   Kiser, et al. J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):570-8.<br>7 Â Â Data extracted from the tenofovir package insert.<br>* Â Â Parallel group design; n for KALETRA + co-administered drug, n for co-administered drug alone.<br>N/A = Not available.<br>â€  Â Â NC = No change.</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="section_12.4"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First"><a name="p386791408"></a><span class="Italics">Mechanism of Action</span></p>
<p><a name="p386841408"></a>Lopinavir, an inhibitor of the HIV-1 protease, prevents cleavage of the Gag-Pol polyprotein, resulting in the production of immature, non-infectious viral particles.</p>
<p><a name="p386871408"></a><span class="Italics">Antiviral Activity</span></p>
<p><a name="p386921408"></a>The antiviral activity of lopinavir against laboratory HIV <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> and clinical HIV-1 isolates was evaluated in acutely infected lymphoblastic cell lines and peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, respectively. In the absence of human serum, the mean 50% effective concentration (EC<span class="Sub">50</span>) values of lopinavir against five different HIV-1 subtype B laboratory <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> ranged from 10-27 nM (0.006-0.017 Âµg/mL, 1 Âµg/mL = 1.6 ÂµM) and ranged from 4-11 nM (0.003-0.007 Âµg/mL) against several HIV-1 subtype B clinical isolates (n = 6). In the presence of 50% human serum, the mean EC<span class="Sub">50</span> values of lopinavir against these five HIV-1 laboratory <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> ranged from 65-289 nM (0.04-0.18 Âµg/mL), representing a 7 to 11-fold attenuation. Combination antiviral drug activity studies with lopinavir in cell cultures demonstrated additive to antagonistic activity with nelfinavir and additive to synergistic activity with amprenavir, atazanavir, indinavir, saquinavir and tipranavir.  The EC<span class="Sub">50</span> values of lopinavir against three different HIV-2 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> ranged from 12-180 nM (0.008-113 Î¼g/mL).</p>
<p><a name="p389131408"></a><span class="Italics">Resistance</span></p>
<p><a name="p389181408"></a>HIV-1 isolates with reduced susceptibility to lopinavir have been selected in cell culture. The presence of ritonavir does not appear to influence the selection of lopinavir-resistant viruses in cell culture. </p>
<p><a name="p389211408"></a>The selection of resistance to KALETRA in antiretroviral treatment naÃ¯ve patients has not yet been characterized. In a study of 653 antiretroviral treatment naÃ¯ve patients (Study 863), plasma viral isolates from each patient on treatment with plasma HIV-1 RNA &gt; 400 copies/mL at Week 24, 32, 40 and/or 48 were analyzed. No evidence of resistance to KALETRA was observed in 37 evaluable KALETRA-treated patients (0%). Evidence of genotypic resistance to nelfinavir, defined as the presence of the D30N and/or L90M substitution in HIV-1 protease, was observed in 25/76 (33%) of evaluable nelfinavir-treated patients. The selection of resistance to KALETRA in antiretroviral treatment naÃ¯ve pediatric patients (Study 940) appears to be consistent with that seen in adult patients (Study 863).</p>
<p><a name="p389251408"></a>Resistance to KALETRA has been noted to emerge in patients treated with other protease inhibitors prior to KALETRA therapy. In studies of 227 antiretroviral treatment naÃ¯ve and protease inhibitor experienced patients, isolates from 4 of 23 patients with quantifiable (&gt; 400 copies/mL) viral RNA following treatment with KALETRA for 12 to 100 weeks displayed significantly reduced susceptibility to lopinavir compared to the corresponding baseline viral isolates. Three of these patients had previously received treatment with a single protease inhibitor (indinavir, nelfinavir, or saquinavir) and one patient had received treatment with multiple protease inhibitors (indinavir, ritonavir, and saquinavir). All four of these patients had at least 4 substitutions associated with protease inhibitor resistance immediately prior to KALETRA therapy. Following viral rebound, isolates from these patients all contained additional substitutions, some of which are recognized to be associated with protease inhibitor resistance. However, there are insufficient data at this time to identify patterns of lopinavir resistance-associated substitutions in isolates from patients on KALETRA therapy. The assessment of these patterns is under study.</p>
<p><a name="p389281408"></a><span class="Italics">Cross-resistance - Preclinical Studies</span></p>
<p><a name="p389331408"></a>Varying degrees of cross-resistance have been observed among HIV-1 protease inhibitors. Little information is available on the cross-resistance of viruses that developed decreased susceptibility to lopinavir during KALETRA therapy.</p>
<p><a name="p389361408"></a>The antiviral activity in cell culture of lopinavir against clinical isolates from patients previously treated with a single protease inhibitor was determined. Isolates that displayed &gt; 4-fold reduced susceptibility to nelfinavir (n = 13) and saquinavir (n = 4), displayed &lt; 4-fold reduced susceptibility to lopinavir. Isolates with &gt; 4-fold reduced susceptibility to indinavir (n = 16) and ritonavir (n = 3) displayed a mean of 5.7- and 8.3-fold reduced susceptibility to lopinavir, respectively. Isolates from patients previously treated with two or more protease inhibitors showed greater reductions in susceptibility to lopinavir, as described in the following paragraph.</p>
<p><a name="p389391408"></a><span class="Italics">Clinical Studies - Antiviral Activity of KALETRA in Patients with Previous Protease Inhibitor Therapies</span></p>
<p><a name="p389441408"></a>The clinical relevance of reduced susceptibility in cell culture to lopinavir has been examined by assessing the virologic response to KALETRA therapy in treatment-experienced patients, with respect to baseline viral genotype in three studies and baseline viral phenotype in one study.</p>
<p><a name="p389471408"></a>Virologic response to KALETRA has been shown to be affected by the presence of three or more of the following amino acid substitutions in protease at baseline: L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V.  Table 12 shows the 48-week virologic response (HIV-1 RNA &lt;400 copies/mL) according to the number of the above protease inhibitor resistance-associated substitutions at baseline in studies 888 and 765 <span class="Italics">[see Clinical Studies (<a href="#section_14.2">14.2</a>) and (<a href="#section_14.3">14.3</a>)]</span> and study 957 (see below). Once daily administration of KALETRA for adult patients with three or more of the above substitutions is not recommended.</p>
<a name="table_12"></a><table border="1" frame="box" rules="all" width="100%">
<caption><span>Table 12. Virologic Response (HIV-1 RNA &lt;400 copies/mL) at Week 48 by Baseline KALETRA Susceptibility and by Number of Protease Substitutions Associated with Reduced Response to KALETRA<span class="Sup">1</span></span></caption>
<colgroup>
<col width="4243*">
<col width="4509*">
<col width="4244*">
<col width="25%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Toprule"><span class="Bold">Number of protease inhibitor substitutions at baseline<span class="Sup">1</span></span></td>
<td class="Toprule" align="center"><span class="Bold">Study 888 (Single protease inhibitor-experienced<span class="Sup">2</span>, NNRTI-naÃ¯ve) n=130</span></td>
<td class="Toprule" align="center"><span class="Bold">Study 765 (Single protease inhibitor-experienced<span class="Sup">3</span>, NNRTI-naÃ¯ve) n=56</span></td>
<td class="Toprule" align="center"><span class="Bold">Study 957 (Multiple protease inhibitor-experienced<span class="Sup">4</span>, NNRTI-naÃ¯ve) n=50</span></td>
</tr>
<tr valign="top">
<td align="left">0-2</td>
<td align="center">76/103 (74%)</td>
<td align="center">34/45 (76%)</td>
<td align="center">19/20 (95%)</td>
</tr>
<tr valign="top">
<td align="left">3-5</td>
<td align="center">13/26 (50%)</td>
<td align="center">8/11 (73%)</td>
<td align="center">18/26 (69%)</td>
</tr>
<tr valign="top">
<td align="left">6 or more</td>
<td align="center">0/1 (0%)</td>
<td align="center">N/A</td>
<td align="center">1/4 (25%)</td>
</tr>
<tr class="Last"><td colspan="4">1Â Â  Substitutions considered in the analysis included L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V.<br>2Â Â  43% indinavir, 42% nelfinavir, 10% ritonavir, 15% saquinavir.<br>3 Â Â 41% indinavir, 38% nelfinavir, 4% ritonavir, 16% saquinavir.<br>4Â Â Â 86% indinavir, 54% nelfinavir, 80% ritonavir, 70% saquinavir.</td></tr>
</tbody>
</table>
<p><a name="p397051408"></a>Virologic response to KALETRA therapy with respect to phenotypic susceptibility to lopinavir at baseline was examined in Study 957. In this study 56 NNRTI-naÃ¯ve patients with HIV-1 RNA &gt;1,000 copies/mL despite previous therapy with at least two protease inhibitors selected from indinavir, nelfinavir, ritonavir, and saquinavir were randomized to receive one of two doses of KALETRA in combination with efavirenz and nucleoside reverse transcriptase inhibitors (NRTIs). The EC<span class="Sub">50</span> values of lopinavir against the 56 baseline viral isolates ranged from 0.5- to 96-fold the wild-type EC<span class="Sub">50</span> value. Fifty-five percent (31/56) of these baseline isolates displayed &gt;4-fold reduced susceptibility to lopinavir. These 31 isolates had a median reduction in lopinavir susceptibility of 18-fold.  Response to therapy by baseline lopinavir susceptibility is shown in Table 13.</p>
<a name="table_13"></a><table border="1" frame="box" rules="all" width="100%">
<caption><span>Table 13. HIV-1 RNA Response at Week 48 by Baseline Lopinavir Susceptibility<span class="Sup">1</span></span></caption>
<colgroup>
<col width="4277*">
<col width="4505*">
<col width="4238*">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Toprule"><span class="Bold">Lopinavir susceptibility<span class="Sup">2</span> at baseline</span></td>
<td class="Toprule" align="center"><span class="Bold">HIV-1 RNA &lt;400 copies/mL (%)</span></td>
<td class="Toprule" align="center"><span class="Bold">HIV-1 RNA &lt;50 copies/mL (%)</span></td>
</tr>
<tr valign="top">
<td>&lt; 10 fold </td>
<td align="center">25/27 (93%)</td>
<td align="center">22/27 (81%)</td>
</tr>
<tr valign="top">
<td>&gt; 10 and &lt; 40 fold</td>
<td align="center">11/15 (73%)</td>
<td align="center">9/15 (60%)</td>
</tr>
<tr valign="top">
<td>â‰¥ 40 fold</td>
<td align="center">2/8 (25%)</td>
<td align="center">2/8 (25%)</td>
</tr>
<tr class="Last"><td colspan="3">1Â Â  Lopinavir susceptibility was determined by recombinant phenotypic technology performed by Virologic.<br>2Â Â  Fold change in susceptibility from wild type.</td></tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section_13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section_13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><a name="p62240224"></a><span class="Bold">Carcinogenesis</span></p>
<p><a name="p402311408"></a>Lopinavir/ritonavir combination was evaluated for carcinogenic potential by oral gavage administration to mice and rats for up to 104 weeks. Results showed an increase in the incidence of benign <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> and an increase in the combined incidence of <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> plus carcinoma in both males and females in mice and males in rats at doses that produced approximately 1.6-2.2 times (mice) and 0.5 times (rats) the human exposure (based on AUC<span class="Sub">0-24hr</span> measurement) at the recommended dose of 400/100 mg KALETRA twice daily. Administration of lopinavir/ritonavir did not cause a statistically significant increase in the incidence of any other benign or malignant neoplasm in mice or rats.</p>
<p><a name="p402381408"></a>Carcinogenicity studies in mice and rats have been carried out on ritonavir. In male mice, there was a dose dependent increase in the incidence of both <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and combined <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and carcinomas in the liver. Based on AUC measurements, the exposure at the high dose was approximately 4-fold for males that of the exposure in humans with the recommended therapeutic dose (400/100 mg KALETRA twice daily). There were no carcinogenic effects seen in females at the dosages tested. The exposure at the high dose was approximately 9-fold for the females that of the exposure in humans. There were no carcinogenic effects in rats. In this study, the exposure at the high dose was approximately 0.7-fold that of the exposure in humans with the 400/100 mg KALETRA twice daily regimen. Based on the exposures achieved in the animal studies, the significance of the observed effects is not known. </p>
<p><a name="p62245124"></a><span class="Bold">Mutagenesis</span></p>
<p><a name="p62250124"></a>Neither lopinavir nor ritonavir was found to be mutagenic or clastogenic in a battery of <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> assays including the Ames bacterial reverse mutation assay using <span class="Italics">S. typhimurium</span> and <span class="Italics">E. coli</span>, the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, the mouse micronucleus test and chromosomal aberration assays in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>.</p>
<p><a name="p55329324"></a><span class="Bold">Impairment of Fertility</span></p>
<p><a name="p404631408"></a>Lopinavir in combination with ritonavir at a 2:1 ratio produced no effects on fertility in male and female rats at levels of 10/5, 30/15 or 100/50 mg/kg/day. Based on AUC measurements, the exposures in rats at the high doses were approximately 0.7-fold for lopinavir and 1.8-fold for ritonavir of the exposures in humans at the recommended therapeutic dose (400/100 mg twice daily).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section_14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section_14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Patients without Prior Antiretroviral Therapy</h2>
<p class="First"><a name="p404781408"></a><span class="Italics">Study 863: KALETRA Capsules twice daily + stavudine + lamivudine compared to nelfinavir three times daily + stavudine + lamivudine</span></p>
<p><a name="p404831408"></a>Study 863 was a randomized, double-blind, multicenter trial comparing treatment with KALETRA capsules (400/100 mg twice daily) plus stavudine and lamivudine versus nelfinavir (750 mg three times daily) plus stavudine and lamivudine in 653 antiretroviral treatment naÃ¯ve patients. Patients had a mean age of 38 years (range: 19 to 84), 57% were Caucasian, and 80% were male. Mean baseline CD4+ cell count was 259 cells/mm<span class="Sup">3</span> (range: 2 to 949 cells/mm<span class="Sup">3</span>) and mean baseline plasma HIV-1 RNA was 4.9 log<span class="Sub">10</span> copies/mL (range: 2.6 to 6.8 log<span class="Sub">10</span> copies/mL).</p>
<p><a name="p407081408"></a>Treatment response and outcomes of randomized treatment are presented in Table 14.</p>
<a name="table_14"></a><table border="1" frame="box" rules="all" width="100%">
<caption><span>TableÂ 14. Outcomes of Randomized Treatment Through Week 48 (StudyÂ 863)</span></caption>
<colgroup>
<col width="41%">
<col width="29%">
<col width="29%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="bottom">
<td class="Toprule" align="center" valign="top"><span class="Bold">Outcome</span></td>
<td class="Toprule" align="center"><span class="Bold">KALETRA+d4T+3TC            <br>(N = 326)</span></td>
<td class="Toprule" align="center"><span class="Bold">Nelfinavir+d4T+3TC            <br>(N = 327)</span></td>
</tr>
<tr>
<td>Responder<span class="Sup">1</span>
</td>
<td align="center">75%</td>
<td align="center">62%</td>
</tr>
<tr>
<td>Virologic failure<span class="Sup">2</span><br> Â Â Â Â  Rebound<br> Â Â Â Â Â Never suppressed through Week 48</td>
<td align="center">9%<br>7%<br>2%</td>
<td align="center">25%<br>15%<br>9%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td align="center">2%</td>
<td align="center">1%</td>
</tr>
<tr>
<td>Discontinued due to adverse events</td>
<td align="center">4%</td>
<td align="center">4%</td>
</tr>
<tr>
<td>Discontinued for other reasons<span class="Sup">3</span>
</td>
<td align="center">10%</td>
<td align="center">8%</td>
</tr>
<tr class="Last"><td colspan="3">1 Â Â Patients achieved and maintained confirmed HIV-1 RNA &lt; 400 copies/mL through Week 48.<br>2 Â Â Includes confirmed viral rebound and failure to achieve confirmed &lt; 400 copies/mL through Week 48.<br>3Â Â  Includes lost to follow-up, patient's withdrawal, non-compliance, protocol violation and other reasons.  Overall discontinuation through Week 48, including patients who discontinued subsequent to virologic failure, was 17% in the KALETRA arm and 24% in the nelfinavir arm.</td></tr>
</tbody>
</table>
<p><a name="p412611408"></a>Through 48 weeks of therapy, there was a statistically significantly higher proportion of patients in the KALETRA arm compared to the nelfinavir arm with HIV-1 RNA &lt; 400 copies/mL (75% vs. 62%, respectively) and HIV-1 RNA &lt; 50 copies/mL (67% vs. 52%, respectively). Treatment response by baseline HIV-1 RNA level subgroups is presented in Table 15.</p>
<a name="table_15"></a><table border="1" frame="box" rules="all" width="100%">
<caption><span>TableÂ 15. Proportion of Responders Through Week 48 by Baseline Viral Load (Study 863)</span></caption>
<colgroup>
<col width="27%">
<col width="14%">
<col width="14%">
<col width="4%">
<col width="14%">
<col width="14%">
<col width="5%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="bottom">
<td class="Toprule" valign="top"><span class="Bold">Baseline Viral Load (HIV-1 RNA copies/mL)</span></td>
<td class="Toprule" align="center" colspan="3" valign="top"><span class="Bold">KALETRA +d4T+3TC</span></td>
<td class="Toprule" align="center" colspan="3" valign="top"><span class="Bold">Nelfinavir +d4T+3TC</span></td>
</tr>
<tr valign="top">
<td align="center">Â </td>
<td align="center"><span class="Bold">&lt;400 copies/mL  <span class="Sup">1</span></span></td>
<td align="center"><span class="Bold">&lt;50 copies/mL  <span class="Sup">2</span></span></td>
<td align="center"><span class="Bold">n  </span></td>
<td align="center"><span class="Bold">&lt;400 copies/mL  <span class="Sup">1</span></span></td>
<td align="center"><span class="Bold">&lt;50 copies/mL  <span class="Sup">2</span></span></td>
<td align="center"><span class="Bold">n  </span></td>
</tr>
<tr valign="top">
<td>&lt; 30,000</td>
<td align="center">74%</td>
<td align="center">71%</td>
<td align="center">82</td>
<td align="center">79%</td>
<td align="center">72%</td>
<td align="center">87</td>
</tr>
<tr valign="top">
<td>â‰¥ 30,000 to &lt; 100,000</td>
<td align="center">81%</td>
<td align="center">73%</td>
<td align="center">79</td>
<td align="center">67%</td>
<td align="center">54%</td>
<td align="center">79</td>
</tr>
<tr valign="top">
<td>â‰¥ 100,000 to &lt; 250,000</td>
<td align="center">75%</td>
<td align="center">64%</td>
<td align="center">83</td>
<td align="center">60%</td>
<td align="center">47%</td>
<td align="center">72</td>
</tr>
<tr valign="top">
<td>â‰¥ 250,000</td>
<td align="center">72%</td>
<td align="center">60%</td>
<td align="center">82</td>
<td align="center">44%</td>
<td align="center">33%</td>
<td align="center">89</td>
</tr>
<tr class="Last"><td colspan="7">1 Â Â Patients achieved and maintained confirmed HIV-1 RNA &lt; 400 copies/mL through Week 48.<br>2 Â Â Patients achieved HIV-1 RNA &lt; 50 copies/mL at Week 48.</td></tr>
</tbody>
</table>
<p><a name="p425011408"></a>Through 48 weeks of therapy, the mean increase from baseline in CD4+ cell count was 207 cells/mm<span class="Sup">3</span> for the KALETRA arm and 195 cells/mm<span class="Sup">3</span> for the nelfinavir arm.</p>
<p><a name="p425141408"></a><span class="Italics">Study 730:  KALETRA Tablets once daily + tenofovir DF + emtricitabine compared to KALETRA Tablets twice daily + tenofovir DF + emtricitabine</span>. </p>
<p><a name="p425201408"></a>Study 730 was a randomized, open-label, multicenter trial comparing treatment with KALETRA 800/200 mg once daily plus tenofovir DF and emtricitabine versus KALETRA 400/100 mg twice daily plus tenofovir DF and emtricitabine in 664 antiretroviral treatment-naÃ¯ve patients. Patients were randomized in a 1:1 ratio to receive either KALETRA 800/200 mg once daily (n = 333) or KALETRA 400/100 mg twice daily (n = 331).  Further stratification within each group was 1:1 (tablet vs. capsule).  Patients administered the capsule were switched to the tablet formulation at Week 8 and maintained on their randomized dosing schedule.  Patients were administered emtricitabine 200 mg once daily and tenofovir DF 300 mg once daily. Mean age of patients enrolled was 39 years (range: 19 to 71); 75% were Caucasian, and 78% were male. Mean baseline CD4+ cell count was 216 cells/mm<span class="Sup">3 </span>(range: 20 to 775 cells/mm<span class="Sup">3</span>) and mean baseline plasma HIV-1 RNA was 5.0 log<span class="Sub">10</span> copies/mL (range: 1.7 to 7.0 log<span class="Sub">10</span> copies/mL).  </p>
<p><a name="p425391408"></a>Treatment response and outcomes of randomized treatment through Week 48 are presented in Table 16. </p>
<a name="table_16"></a><table border="1" frame="box" rules="all" width="100%">
<caption><span>TableÂ 16. Outcomes of Randomized Treatment Through Week 48 (StudyÂ 730)</span></caption>
<colgroup>
<col width="45%">
<col width="27%">
<col width="27%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="bottom">
<td class="Toprule" valign="top"><span class="Bold">Outcome</span></td>
<td class="Toprule" align="center">
<span class="Bold">KALETRA Once Daily + TDF + FTC</span><br><span class="Bold">(n = 333)</span>
</td>
<td class="Toprule" align="center">
<span class="Bold">KALETRA Twice Daily + TDF + FTC</span><br><span class="Bold">(n = 331)</span>
</td>
</tr>
<tr valign="top">
<td>Responder<span class="Sup">1</span>
</td>
<td align="center">78%</td>
<td align="center">77%</td>
</tr>
<tr valign="top">
<td>Virologic failure<span class="Sup">2</span><br> Â Â Â Â  Rebound<br> Â Â Â Â Â Never suppressed through Week 48</td>
<td align="center">10%<br>5%<br>5%</td>
<td align="center">8%<br>5%<br>3%</td>
</tr>
<tr valign="top">
<td><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td align="center">1%</td>
<td align="center">&lt;1%</td>
</tr>
<tr valign="top">
<td>Discontinued due to adverse events</td>
<td align="center">4%</td>
<td align="center">3%</td>
</tr>
<tr valign="top">
<td>Discontinued for other reasons<span class="Sup">3</span>
</td>
<td align="center">8%</td>
<td align="center">11%</td>
</tr>
<tr class="Last"><td colspan="3">1 Â Â Patients achieved and maintained confirmed HIV-1 RNA &lt; 50 copies/mL through Week 48.<br>2 Â Â Includes confirmed viral rebound and failure to achieve confirmed &lt; 50 copies/mL through Week 48.<br>3 Â Â Includes lost to follow-up, patient's withdrawal, non-compliance, protocol violation and other reasons.</td></tr>
</tbody>
</table>
<p><a name="p433041408"></a>Through 48 weeks of therapy, 78% in the KALETRA once daily arm and 77% in the KALETRA twice daily arm achieved and maintained HIV-1 RNA &lt; 50 copies/mL (95% confidence interval for the difference, -5.9% to 6.8%). Mean CD4+ cell count increases at Week 48 were 186 cells/mm<span class="Sup">3</span> for the KALETRA once daily arm and 198 cells/mm<span class="Sup">3</span> for the KALETRA twice daily arm.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Patients with Prior Antiretroviral Therapy</h2>
<p class="First"><a name="p435261408"></a><span class="Italics">Study 888: KALETRA Capsules twice daily + nevirapine + NRTIs compared to investigator-selected protease inhibitor(s) + nevirapine + NRTIs </span></p>
<p><a name="p435311408"></a>Study 888 was a randomized, open-label, multicenter trial comparing treatment with KALETRA capsules (400/100 mg twice daily) plus nevirapine and nucleoside reverse transcriptase inhibitors versus investigator-selected protease inhibitor(s) plus nevirapine and nucleoside reverse transcriptase inhibitors in 288 single protease inhibitor-experienced, non-nucleoside reverse transcriptase inhibitor (NNRTI)-naÃ¯ve patients. Patients had a mean age of 40 years (range: 18 to 74), 68% were Caucasian, and 86% were male. Mean baseline CD4+ cell count was 322 cells/mm<span class="Sup">3</span> (range: 10 to 1059 cells/mm<span class="Sup">3</span>) and mean baseline plasma HIV-1 RNA was 4.1 log<span class="Sub">10</span> copies/mL (range:  2.6 to 6.0 log<span class="Sub">10</span> copies/mL). </p>
<p><a name="p435501408"></a>Treatment response and outcomes of randomized treatment through Week 48 are presented in Table 17. </p>
<a name="table_17"></a><table border="1" frame="box" rules="all" width="100%">
<caption><span>TableÂ 17. Outcomes of Randomized Treatment Through Week 48 (Study 888)</span></caption>
<colgroup>
<col width="41%">
<col width="29%">
<col width="29%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Toprule" align="center"><span class="Bold">Outcome</span></td>
<td class="Toprule" align="center"><span class="Bold">KALETRA + nevirapine +Â NRTIs   <br>(n = 148)</span></td>
<td class="Toprule" align="center"><span class="Bold">Investigator-Selected Protease Inhibitor(s) +Â nevirapine + NRTIs  <br>(n = 140)</span></td>
</tr>
<tr valign="top">
<td>Responder<span class="Sup">1</span>
</td>
<td align="center">57%</td>
<td align="center">33%</td>
</tr>
<tr valign="top">
<td>Virologic failure<span class="Sup">2</span><br> Â Â Â Â  Rebound<br> Â Â Â Â Â Never suppressed through Week 48</td>
<td align="center">24%<br>11%<br>13%</td>
<td align="center">41%<br>19%<br>23%</td>
</tr>
<tr valign="top">
<td><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td align="center">1%</td>
<td align="center">2%</td>
</tr>
<tr valign="top">
<td>Discontinued due to adverse events </td>
<td align="center">5%</td>
<td align="center">11%</td>
</tr>
<tr valign="top">
<td>Discontinued for other reasons<span class="Sup">3</span>
</td>
<td align="center">14%</td>
<td align="center">13%</td>
</tr>
<tr class="Last"><td colspan="3">1Â Â  Patients achieved and maintained confirmed HIV-1 RNA &lt; 400 copies/mL through Week 48.<br>2 Â Â Includes confirmed viral rebound and failure to achieve confirmed &lt; 400 copies/mL through Week 48.<br>3 Â Â Includes lost to follow-up, patient's withdrawal, non-compliance, protocol violation and other reasons.</td></tr>
</tbody>
</table>
<p><a name="p443091408"></a>Through 48 weeks of therapy, there was a statistically significantly higher proportion of patients in the KALETRA arm compared to the investigator-selected protease inhibitor(s) arm with HIV-1 RNA &lt; 400 copies/mL (57% vs. 33%, respectively).</p>
<p><a name="p443121408"></a>Through 48 weeks of therapy, the mean increase from baseline in CD4+ cell count was 111 cells/mm<span class="Sup">3</span> for the KALETRA arm and 112 cells/mm<span class="Sup">3</span> for the investigator-selected protease inhibitor(s) arm.</p>
<p><a name="p443241408"></a><span class="Italics">Study 802: KALETRA Tablets 800/200 mg Once Daily Versus 400/100 mg Twice Daily when Co-administered with Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced, HIV-1 Infected Subjects </span></p>
<p><a name="p443291408"></a>M06-802 was a randomized open-label study comparing the safety, tolerability, and antiviral activity of once daily and twice daily dosing of KALETRA tablets in 599 subjects with detectable viral loads while receiving their current antiviral therapy.  Of the enrolled subjects, 55% on both treatment arms had not been previously treated with a protease inhibitor and 81 â€“ 88% had received prior NNRTIs as part of their anti-HIV treatment regimen. Patients were randomized in a 1:1 ratio to receive either KALETRA 800/200 mg once daily (n = 300) or KALETRA 400/100 mg twice daily (n = 299).  Patients were administered at least two nucleoside/nucleotide reverse transcriptase inhibitors selected by the investigator.  Mean age of patients enrolled was 41 years (range: 21 to 73); 51% were Caucasian, and 66% were male. Mean baseline CD4+ cell count was 254 cells/mm<span class="Sup">3</span> (range: 4 to 952 cells/mm<span class="Sup">3</span>) and mean baseline plasma HIV-1 RNA was 4.3 log<span class="Sub">10</span> copies/mL (range: 1.7 to 6.6 log<span class="Sub">10</span> copies/mL).</p>
<p><a name="p445551408"></a>Treatment response and outcomes of randomized treatment through Week 48 are presented in Table 18.</p>
<a name="table_18"></a><table border="1" frame="box" rules="all" width="100%">
<caption><span>Table 18. Outcomes of Randomized Treatment Through Week 48 (Study 802) </span></caption>
<colgroup>
<col width="41%">
<col width="29%">
<col width="29%">
</colgroup>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Toprule" align="center"><span class="Bold">Outcome</span></td>
<td class="Toprule" align="center"><span class="Bold">KALETRA Once Daily + NRTIs         <br>(n = 300)</span></td>
<td class="Toprule" align="center"><span class="Bold">KALETRA Twice Daily + NRTIs          <br>(n = 299)</span></td>
</tr>
<tr valign="top">
<td align="left">Virologic Success (HIV-1 RNA &lt;50 copies/mL) </td>
<td align="center">57%</td>
<td align="center">54%</td>
</tr>
<tr valign="top">
<td align="left">Virologic failure<span class="Sup">1</span>
</td>
<td align="center">22%</td>
<td align="center">24%</td>
</tr>
<tr valign="top">
<td>No virologic data in Week 48 window</td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr valign="top">
<td>Discontinued study due to adverse event or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span><span class="Sup">2</span>
</td>
<td align="center">5%</td>
<td align="center">7%</td>
</tr>
<tr valign="top">
<td>Discontinued study for other reasons<span class="Sup">3</span>
</td>
<td align="center">13%</td>
<td align="center">12%</td>
</tr>
<tr valign="top">
<td>Missing data during window but on study</td>
<td align="center">3%</td>
<td align="center">3%</td>
</tr>
<tr class="Last"><td colspan="3">1   Includes patients who discontinued prior to Week 48 for lack or loss of efficacy and patients with HIV-1 RNA â‰¥ 50 copies/mL at Week 48.<br>2   Includes patients who discontinued due to adverse events or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> at any time from Day 1 through Week 48 if this resulted in no virologic data on treatment at Week 48.<br> 3   Includes withdrawal of consent, loss to follow-up, non-compliance, protocol violation and other reasons.</td></tr>
</tbody>
</table>
<p><a name="p451021408"></a>Through 48 weeks of treatment, the mean change from baseline for CD4 + cell count was 135 cells/mm<span class="Sup">3</span> for the once daily group and 122 cells/mm<span class="Sup">3</span>  for the twice daily group.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_14.3"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Other Studies Supporting Approval</h2>
<p class="First"><a name="p453241408"></a><span class="Italics">Study 720:  KALETRA twice daily + stavudine + lamivudine<br>Study 765:  KALETRA twice daily + nevirapine + NRTIs</span></p>
<p><a name="p453311408"></a>Study 720 (patients <span class="Underline">without</span> prior antiretroviral therapy) and study 765 (patients <span class="Underline">with</span> prior protease inhibitor therapy) were randomized, blinded, multi-center trials evaluating treatment with KALETRA at up to three dose levels (200/100 mg twice daily [720 only], 400/100 mg twice daily, and 400/200 mg twice daily). In Study 720, all patients switched to 400/100 mg twice daily between Weeks 48-72. Patients in study 720 had a mean age of 35 years, 70% were Caucasian, and 96% were male, while patients in study 765 had a mean age of 40 years, 73% were Caucasian, and 90% were male. Mean (range) baseline CD4+ cell counts for patients in study 720 and study 765 were 338 (3-918) and 372 (72-807) cells/mm<span class="Sup">3</span>, respectively. Mean (range) baseline plasma HIV-1 RNA levels for patients in study 720 and study 765 were 4.9 (3.3 to 6.3) and 4.0 (2.9 to 5.8) log<span class="Sub">10</span> copies/mL, respectively.</p>
<p><a name="p453501408"></a>Through 360 weeks of treatment in study 720, the proportion of patients with HIV-1 RNA &lt; 400 (&lt; 50) copies/mL was 61% (59%) [n = 100]. Among patients completing 360 weeks of treatment with CD4+ cell count measurements [n=60], the mean (median) increase in CD4+ cell count was 501 (457) cells/mm<span class="Sup">3</span>. Thirty-nine patients (39%) discontinued the study, including 13 (13%) discontinuations due to adverse reactions and 1 (1%) <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </p>
<p><a name="p453571408"></a>Through 144 weeks of treatment in study 765, the proportion of patients with HIV-1 RNA &lt; 400 (&lt; 50) copies/mL was 54% (50%) [n = 70], and the corresponding mean increase in CD4+ cell count was 212 cells/mm<span class="Sup">3</span>. Twenty-seven patients (39%) discontinued the study, including 5 (7%) discontinuations secondary to adverse reactions and 2 (3%) <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GN78093"></a><a name="section-13.4"></a><p></p>
<h2>14.4 Pediatric Studies </h2>
<p class="First"><a name="p455751408"></a>Study 1030 was an open-label, multicenter, dose-finding trial evaluating the pharmacokinetic profile, tolerability, safety and efficacy of KALETRA oral solution containing lopinavir 80 mg/mL and ritonavir 20 mg/mL at a dose of 300/75 mg/m<span class="Sup">2</span> twice daily plus 2 NRTIs in HIV-1 infected infants â‰¥14 days and &lt;6 months of age.</p>
<p><a name="p455821408"></a>Ten infants, â‰¥14 days and &lt;6 wks of age, were enrolled at a median (range) age of 5.7 (3.6-6.0) weeks and all completed 24 weeks.  At entry, median (range) HIV-1 RNA was 6.0 (4.7-7.2) log<span class="Sub">10</span> copies/mL.  Seven of 10 infants had HIV-1 RNA &lt;400 copies/mL at Week 24.  At entry, median (range) CD4+ percentage was 41 (16-59) with a median decrease of 1% (95% CI: -10, 18) from baseline to week 24 in 6 infants with available data.</p>
<p><a name="p455891408"></a>Twenty-one infants, between 6 weeks and 6 months of age, were enrolled at a median (range) age of 14.7 (6.9-25.7) weeks and 19 of 21 infants completed 24 weeks.  At entry, median (range) HIV RNA level was 5.8 (3.7-6.9) log<span class="Sub">10</span> copies/mL.  Ten of 21 infants had HIV RNA &lt;400 copies/mL at Week 24.  At entry, the median (range) CD4+ percentage was 32 (11-54) with a median increase of 4% (95% CI: -1, 9) from baseline to week 24 in 19 infants with available data.</p>
<p><a name="p455961408"></a><span class="Italics">See Clinical Pharmacology (<a href="#section_12.3">12.3</a>) for pharmacokinetic results</span>.</p>
<p><a name="p456061408"></a>Study 940 was an open-label, multicenter trial evaluating the pharmacokinetic profile, tolerability, safety and efficacy of KALETRA oral solution containing lopinavir 80 mg/mL and ritonavir 20 mg/mL in 100 antiretroviral naÃ¯ve (44%) and experienced (56%) pediatric patients. All patients were non-nucleoside reverse transcriptase inhibitor naÃ¯ve. Patients were randomized to either 230 mg lopinavir/57.5 mg ritonavir per m<span class="Sup">2</span> or 300 mg lopinavir/75 mg ritonavir per m<span class="Sup">2</span>. NaÃ¯ve patients also received lamivudine and stavudine. Experienced patients received nevirapine plus up to two nucleoside reverse transcriptase inhibitors.</p>
<p><a name="p456171408"></a>Safety, efficacy and pharmacokinetic profiles of the two dose regimens were assessed after three weeks of therapy in each patient. After analysis of these data, all patients were continued on the 300 mg lopinavir/75 mg ritonavir per m<span class="Sup">2</span> dose. Patients had a mean age of 5 years (range 6 months to 12 years) with 14% less than 2 years. Mean baseline CD4+ cell count was 838 cells/mm<span class="Sup">3</span> and mean baseline plasma HIV-1 RNA was 4.7 log<span class="Sub">10</span> copies/mL. </p>
<p><a name="p458381408"></a>Through 48 weeks of therapy, the proportion of patients who achieved and sustained an HIV-1 RNA &lt; 400 copies/mL was 80% for antiretroviral naÃ¯ve patients and 71% for antiretroviral experienced patients. The mean increase from baseline in CD4+ cell count was 404 cells/mm<span class="Sup">3</span> for antiretroviral naÃ¯ve and 284 cells/mm<span class="Sup">3</span> for antiretroviral experienced patients treated through 48 weeks. At 48 weeks, two patients (2%) had prematurely discontinued the study. One antiretroviral naÃ¯ve patient prematurely discontinued secondary to an adverse reaction, while one antiretroviral experienced patient prematurely discontinued secondary to an HIV-1 related event. </p>
<p><a name="p458491408"></a>Dose selection in pediatric patients was based on the following:</p>
<ul class="Disc">
<li>Among patients 14 days to 6 months of age receiving 300/75 mg/m<span class="Sup">2</span> twice daily without nevirapine, plasma concentrations were lower than those observed in adults or in older children. This dose resulted in HIV-1 RNA &lt; 400 copies/mL in 55% of patients (70% in those initiating treatment at &lt;6 weeks of age).</li>
<li> Among patients 6 months to 12 years of age, the 230/57.5 mg/m<span class="Sup">2</span> oral solution twice daily regimen without nevirapine and the 300/75 mg/m<span class="Sup">2</span> oral solution twice daily regimen with nevirapine provided lopinavir plasma concentrations similar to those obtained in adult patients receiving the 400/100 mg twice daily regimen (without nevirapine). These doses resulted in treatment benefit (proportion of patients with HIV-1 RNA &lt; 400 copies/mL) similar to that seen in the adult clinical trials.</li>
<li>Among patients 12 to 18 years of age receiving 400/100 mg/m<span class="Sup">2</span> or 480/120 mg/m<span class="Sup">2</span> (with efavirenz) twice daily, plasma concentrations were 60-100% higher than among 6 to 12 year old patients receiving 230/57.5 mg/m<span class="Sup">2</span>.  Mean apparent clearance was similar to that observed in adult patients receiving standard dose and in patients 6 to 12 years of age. Although changes in HIV-1 RNA in patients with prior treatment failure were less than anticipated, the pharmacokinetic data supports use of similar dosing as in patients 6 to 12 years of age, not to exceed the recommended adult dose. </li>
<li>For all age groups, the body surface area dosing was converted to body weight dosing using the patientâ€™s prescribed lopinavir dose.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section_16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><a name="p461021408"></a>KALETRA<span class="Sup">Â®</span> (lopinavir/ritonavir) Film-Coated tablets and Oral Solution are available in the following strengths and package sizes:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section_16.1"></a><a name="section-14.1"></a><p></p>
<h2>16.1 KALETRA Tablets, 200 mg lopinavir/50 mg ritonavir</h2>
<p class="First"><a name="p461141408"></a>Yellow film-coated ovaloid tablets debossed with the corporate Abbott â€œAâ€? logo and the Abbo-Code KA:</p>
<p><a name="p461171408"></a>Bottles of 120 tablets â€¦.â€¦â€¦â€¦â€¦â€¦ (NDC 0074-6799-22)</p>
<p><a name="p461201408"></a>Recommended Storage</p>
<p><a name="p461231408"></a>Store KALETRA film-coated tablets at 20Â°-25Â°C (68Â°-77Â°F); excursions permitted to 15Â°-30Â°C (59Â° to 86Â°F)[see USP controlled room temperature]. Dispense in original container or USP equivalent tight container (250 mL or less).  For patient use:  exposure of this product to high humidity outside the original container or USP equivalent tight container (250 mL or less) for longer than 2 weeks is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_16.2"></a><a name="section-14.2"></a><p></p>
<h2>16.2 KALETRA Tablets, 100 mg lopinavir/25 mg ritonavir</h2>
<p class="First"><a name="p463371408"></a><span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">Pale</span> yellow film-coated ovaloid tablets debossed with the corporate Abbott â€œAâ€? logo and the Abbo-Code KC:</p>
<p><a name="p463401408"></a>Bottles of 60 tablets â€¦.â€¦â€¦â€¦â€¦â€¦ (NDC 0074-0522-60) </p>
<p><a name="p463431408"></a>Recommended Storage</p>
<p><a name="p463461408"></a>Store KALETRA film-coated tablets at 20Â°-25Â°C (68Â°-77Â°F); excursions permitted to 15Â°-30Â°C (59Â° to 86Â°F)[see USP controlled room temperature]. Dispense in original container or USP equivalent tight container (100 mL or less).  For patient use:  exposure of this product to high humidity outside the original container or USP equivalent tight container (100 mL or less) for longer than 2 weeks is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_16.3"></a><a name="section-14.3"></a><p></p>
<h2>16.3 KALETRA Oral Solution</h2>
<p class="First"><a name="p463541408"></a>KALETRA (lopinavir/ritonavir) oral solution is a light yellow to orange colored liquid supplied in amber-colored multiple-dose bottles containing 400 mg lopinavir/100 mg ritonavir per 5 mL (80 mg lopinavir/20 mg ritonavir per mL) packaged with a marked dosing cup in the following size:</p>
<p><a name="p463581408"></a>160 mL bottleâ€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦.(NDC 0074-3956-46)</p>
<p><a name="p463611408"></a>Recommended Storage</p>
<p><a name="p463641408"></a>Store KALETRA oral solution at 2Â°-8Â°C (36Â°-46Â°F) until dispensed.  Avoid exposure to excessive heat.  For patient use, refrigerated KALETRA oral solution remains stable until the expiration date printed on the label.  If stored at room temperature up to 25Â°C (77Â°F), oral solution should be used within 2 months.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section_17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><a name="p463721408"></a>See FDA-approved patient labeling (Medication Guide)</p>
<p><a name="p62464124"></a><span class="Bold">Information For Patients</span></p>
<p><a name="p62467124"></a><span class="Bold">Patients or parents of patients should be informed that:</span></p>
<p><a name="p62469124"></a><span class="Underline">General Information</span></p>
<p><a name="p62480124"></a>ï?± They should pay special attention to accurate administration of their dose to minimize the risk of accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> or underdose of KALETRA.   </p>
<p><a name="p62471824"></a>ï?± They should inform their healthcare provider if their childrenâ€™s weight changes in order to make sure that the childâ€™s KALETRA dose is the correct one.</p>
<p><a name="p62482124"></a>ï?± They should take the prescribed dose of KALETRA as directed and to set up a daily routine in order to do so.</p>
<p><a name="p62484124"></a> ï?± KALETRA tablets may be taken with or without food. KALETRA oral solution should be taken with food to enhance absorption.</p>
<p><a name="p55841724"></a>ï?± Sustained decreases in plasma HIV-1 RNA have been associated with a reduced risk of progression to AIDS and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Patients should remain under the care of a physician while using KALETRA. Patients should be advised to take KALETRA and other concomitant antiretroviral therapy every day as prescribed. KALETRA must always be used in combination with other antiretroviral drugs. Patients should not alter the dose or discontinue therapy without consulting with their doctor. If a dose of KALETRA is missed patients should take the dose as soon as possible and then return to their normal schedule. However, if a dose is skipped the patient should not double the next dose. </p>
<p><a name="p62486324"></a>ï?± KALETRA is not a cure for HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and patients may continue to experience illnesses associated with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. Patients should remain under the care of a physician when using KALETRA. </p>
<p><a name="p62495324"></a>Patients should be advised to avoid doing things that can spread HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others. </p>
<ul class="Disc">
<li><span class="Bold">Do not share needles or other injection equipment.</span></li>
<li><span class="Bold">Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</span></li>
<li>
<span class="Bold">Do not have any kind of sex without protection</span>. Always practice safe sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood.</li>
<li>
<span class="Bold">Do not breastfeed</span>. We do not know if KALETRA can be passed to the baby through breast milk and whether it could harm the baby. Also, mothers with HIV-1 should not breastfeed because HIV-1 can be passed to the baby in the breast milk.</li>
</ul>
<p><a name="p62497324"></a><span class="Underline">Drug Interactions</span></p>
<p><a name="p63002124"></a>ï?± KALETRA may interact with some drugs; therefore, patients should be advised to report to their doctor the use of any other prescription, non-prescription medication or herbal products, particularly St. John's Wort.</p>
<p><a name="p63004124"></a>ï?± KALETRA tablets can be taken at the same time as didanosine without food. Patients taking didanosine should take didanosine one hour before or two hours after KALETRA oral solution. </p>
<p><a name="p62499324"></a>ï?± If they are receiving sildenafil, tadalafil, or vardenafil, there may be an increased risk of associated adverse reactions including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, visual changes, and sustained erection, and should promptly report any symptoms to their doctor.  </p>
<p><a name="p62501324"></a>ï?± If they are receiving estrogen-based hormonal contraceptives, additional or alternate contraceptive measures should be used during therapy with KALETRA. </p>
<p><a name="p629981524"></a>ï?± If they are taking or before they begin using Serevent<span class="Sup">Â® </span>(salmeterol) and KALETRA, they should talk to their doctor about problems these two medications may cause when taken together. The doctor may choose not to keep someone on Serevent<span class="Sup">Â® </span>(salmeterol).</p>
<p><a name="p625111124"></a>ï?± If they are taking or before they begin taking Advair<span class="Sup">Â®</span> (salmeterol in combination with fluticasone propionate) and KALETRA, they should talk to their doctor about problems these two medications may cause when taken together. The doctor may choose not to keep someone on AdvairÂ® (salmeterol in combination with fluticasone propionate).</p>
<p><a name="p63000124"></a><span class="Underline">Potential Adverse Effects </span></p>
<p><a name="p63025124"></a>ï?± <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rashes</span> ranging in severity from mild to <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span> have been reported in patients receiving KALETRA or its components lopinavir and/or ritonavir. Patients should be advised to contact their healthcare provider if they develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> while taking KALETRA. The healthcare provider will determine if treatment should be continued or an alternative antiretroviral regimen used.  </p>
<p><a name="p63233124"></a>ï?± Patients should be advised that appropriate liver function testing will be conducted prior to initiating and during therapy with KALETRA. Pre-existing liver disease including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B or C can worsen with use of KALETRA. This can be seen as worsening of transaminase elevations or hepatic decompensation. Patients should be advised that their liver function tests will need to be monitored closely especially during the first several months of KALETRA treatment and that they should notify their healthcare provider if they develop the signs and symptoms of worsening liver disease including loss of appetite, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy skin</span>.  </p>
<p><a name="p63235124"></a>ï?± New onset of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or exacerbation of pre-existing <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> have been reported during KALETRA use. Patients should be advised to notify their healthcare provider if they develop the signs and symptoms of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus including frequent urination, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">excessive thirst</span>, extreme <span class="product-label-link" type="condition" conceptid="4205415" conceptname="Hungry">hunger</span> or unusual <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> and/or an increased blood sugar while on KALETRA as they may require a change in their <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> treatment or new treatment.  </p>
<p><a name="p63237124"></a>ï?± KALETRA might produce changes in the electrocardiogram (e.g., PR and/or QT prolongation). Patients should consult their physician if they experience symptoms such as <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, abnormal heart rhythm or <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>.  </p>
<p><a name="p63253124"></a>ï?± They should seek medical assistance immediately if they develop a sustained penile erection lasting more than 4 hours while taking KALETRA and a PDE 5 Inhibitor such as Viagra, Cialis or Levitra.  </p>
<p><a name="p63239124"></a>ï?± Redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy and that the cause and long term health effects of these conditions are not known at this time.</p>
<p><a name="p63017124"></a>ï?± Patients should be informed that there may be a greater chance of developing <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> with the once daily regimen as compared with the twice daily regimen. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="GN78357"></a><a name="section-15.1"></a><p></p>
<h2></h2>
<p class="First"><a name="p468711408"></a>KALETRA Tablets, 200 mg lopinavir/50 mg ritonavir</p>
<p><a name="p468741408"></a>Manufactured by Abbott Pharmaceuticals PR Ltd., Barceloneta, PR 00617</p>
<p><a name="p468771408"></a>for Abbott Laboratories, North Chicago, IL 60064 USA</p>
<br><p><a name="p468811408"></a>KALETRA Tablets, 100 mg lopinavir/25 mg ritonavir and KALETRA Oral Solution</p>
<p><a name="p468841408"></a>Abbott Laboratories, North Chicago, IL 60064 USA </p>
<p><a name="p63266124"></a></p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="GN78467"></a><a name="section-16"></a><p></p>
<p class="First"><a name="p468941408"></a><span class="Bold">MEDICATION GUIDE </span></p>
<br><p><a name="p471061408"></a><span class="Bold">KALETRA<span class="Sup">Â®</span> (kuh-LEE-tra)</span></p>
<p><a name="p471151408"></a> (lopinavir/ritonavir)</p>
<p><a name="p471181408"></a><span class="Bold">Tablets</span></p>
<p><a name="p471231408"></a><span class="Bold">KALETRA<span class="Sup">Â®</span> (kuh-LEE-tra)</span></p>
<p><a name="p471321408"></a> (lopinavir/ritonavir)</p>
<p><a name="p471351408"></a><span class="Bold">Oral Solution</span></p>
<p><a name="p471421408"></a>Read the Medication Guide that comes with KALETRA before you start taking it and each time you get a refill.  There may be new information.  This information does not take the place of talking with your doctor about your medical condition or treatment.  You and your doctor should talk about your treatment with KALETRA before you start taking it and at regular check-ups. You should stay under your doctorâ€™s care when taking KALETRA.   </p>
<p><a name="p471491408"></a><span class="Bold">What is the most important information I should know about KALETRA? </span></p>
<p><a name="p473601408"></a><span class="Bold">KALETRA may cause serious side effects, including:</span><br></p>
<ul class="Disc">
<li>
<span class="Bold">Interactions with other medicines. It is important to <span class="Underline">know the medicines that should not be taken with KALETRA</span>.</span> Read the section "What should I tell my doctor before taking KALETRA?â€?</li>
<li>
<span class="Bold">Changes in your heart rhythm and the electrical activity of your heart.</span>  These changes may be seen on an EKG (electrocardiogram) and can lead to serious heart problems. Your risk for these problems may be higher if you:<ul class="Circle">
<li>already have a history of abnormal heart rhythm or other types of heart disease.</li>
<li>take other medicines that can affect your heart rhythm while you take KALETRA.</li>
</ul>
</li>
</ul>
<p><a name="p58898224"></a>Tell your doctor right away if you have any of these symptoms while taking KALETRA:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span></li>
<li><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span></li>
<li>sensation of abnormal heartbeats</li>
</ul>
<p><a name="p474081408"></a><span class="Bold">See the section below â€œWhat are the possible side effects of KALETRA?â€? for more information about serious side effects.</span></p>
<p><a name="p476221408"></a><span class="Bold">What is KALETRA?</span></p>
<p><a name="p476271408"></a>KALETRA is a prescription anti-human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV) medicine that contains two medicines: lopinavir and ritonavir.  KALETRA is called a protease inhibitor that is used with other anti-HIV-1 medicines to treat people with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.  HIV-1 is the virus that causes AIDS (<span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">Acquired Immune Deficiency Syndrome</span>).  </p>
<p><a name="p476301408"></a><span class="Underline">It is not known if KALETRA is safe and effective in children under 14 days old.</span></p>
<p><a name="p476381408"></a><span class="Bold">Who should not take KALETRA?</span></p>
<ul class="Disc">
<li>Do not take KALETRA if you are taking certain medicines. For more information about medicines you should not take with KALETRA, please see <span class="Bold">â€œCan I take other medicines with KALETRA?â€? and consult with your doctor about all other medicines you take.</span>
</li>
<li>Do not take KALETRA if you have an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to KALETRA or any of its ingredients, including ritonavir and lopinavir. </li>
</ul>
<p><a name="p476561408"></a><span class="Bold">What should I tell my doctor before taking KALETRA?</span></p>
<p><a name="p476611408"></a><span class="Bold">KALETRA may not be right for you. Tell your doctor about all your medical conditions, including if you:</span></p>
<ul class="Disc">
<li>have any heart problems, including if you have a condition called Congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">Long QT Syndrome</span>.</li>
<li>have liver problems, including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C.</li>
<li>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</li>
<li>have <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span>. People who take KALETRA may have increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</li>
<li>have low potassium in your blood.</li>
<li>are pregnant or plan to become pregnant. It is not known if KALETRA will harm your unborn baby. Birth control pills or patches may not work as well while you take KALETRA. To prevent pregnancy while taking KALETRA, women who take birth control pills or use estrogen patch for birth control should either use a different type of birth control or an extra form of birth control. Talk to your doctor about how to prevent pregnancy while taking KALETRA.</li>
<li>take KALETRA during pregnancy, talk with your doctor about how you can take part in an antiretroviral pregnancy registry.  The purpose of the pregnancy registry is to follow the health of you and your baby.</li>
<li>are breastfeeding. <span class="Bold">Do not breastfeed</span>. We do not know if KALETRA can be passed to the baby through your breast milk and whether it could harm the baby. Also, mothers with HIV-1 should not breastfeed because HIV-1 can be passed to the baby in the breast milk. </li>
</ul>
<p><a name="p478981408"></a><span class="Bold">Tell your doctor about all the medicines you take</span>, including prescription and non-prescription medicines, vitamins, and herbal supplements. Many medicines interact with KALETRA. Do not start taking a new medicine without telling your doctor or pharmacist.  Your doctor can tell you if it is safe to take KALETRA with other medicines. Your doctor may need to change the dose of other medicines while you take KALETRA.  </p>
<p><a name="p479041408"></a><span class="Bold">Medicines you should not take with KALETRA.</span></p>
<p><a name="p479091408"></a><span class="Bold">Serious problems or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> can happen if you take these medicines with KALETRA:</span></p>
<ul class="Disc">
<li>ergot containing medicines, including:<ul class="Circle">
<li>ergotamine tartrate (Cafergot<span class="Sup">Â®</span>, Migergot, Ergomar, Ergostat, Medihaler Ergotamine, Wigraine, Wigrettes)</li>
<li>dihydroergotamine mesylate (D.H.E. 45<span class="Sup">Â®</span>, Embolex, Migranal<span class="Sup">Â®</span>)</li>
<li>ergonovine, ergonovine and methylergonovine (Ergotrate, Methergine), ergotamine and methylergonovine</li>
<li>Ergotrate Maleate, methylergonovine maleate (Methergine)</li>
</ul>
</li>
<li>triazolam (Halcion<span class="Sup">Â®</span>), midazolam hydrochloride oral syrup</li>
<li>pimozide (Orap<span class="Sup">Â®</span>)</li>
<li>the <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> lowering medicines lovastatin (Mevacor<span class="Sup">Â®</span>) or simvastatin (Zocor<span class="Sup">Â®</span>)</li>
<li>sildenafil (Revatio<span class="Sup">Â®</span>) only when used for the treatment of <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span>.  (See â€œMedicines that may need changesâ€? and â€œWhat are the possible side effects of KALETRA?â€? for information about the use of sildenafil for erectile problems.)</li>
<li>alfuzosin (Uroxatral<span class="Sup">Â®</span>)</li>
</ul>
<p><a name="p483961408"></a><span class="Bold">Medicines that you should not take with KALETRA since they may make KALETRA not work as well:</span></p>
<ul class="Disc">
<li>the herbal supplement St. John's Wort (hypericum perforatum)</li>
<li>rifampin (Rimactane<span class="Sup">Â®</span>, Rifadin<span class="Sup">Â®</span>, Rifater<span class="Sup">Â®</span>, or Rifamate<span class="Sup">Â®</span>)</li>
</ul>
<p><a name="p484251408"></a><span class="Bold">Medicines that may need changes:</span></p>
<ul class="Disc">
<li>birth control pills that contain estrogen ("the pill") or the birth control (contraceptive) patches</li>
<li>certain anticancer medicines, such as nilotinib (Tasigna<span class="Sup">Â®</span>) and dasatinib (Sprycel<span class="Sup">Â®</span>)</li>
<li>certain <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> lowering medicines, such as atorvastatin (Lipitor<span class="Sup">Â®</span>) or rosuvastatin (Crestor<span class="Sup">Â®</span>)</li>
<li>certain other antiretroviral medicines, such as efavirenz (Atripla<span class="Sup">Â® </span>and Sustiva<span class="Sup">Â®</span>), nevirapine (Viramune<span class="Sup">Â®</span>), amprenavir (Agenerase<span class="Sup">Â®</span>) and nelfinavir (Viracept<span class="Sup">Â®</span>)</li>
<li>anti-<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> medicines, such as phenytoin (Dilantin<span class="Sup">Â®</span>) carbamazepine, (Tegretol<span class="Sup">Â®</span>), phenobarbital</li>
<li>medicines for erectile problems, such as sildenafil (Viagra<span class="Sup">Â®</span>), tadalafil (Cialis<span class="Sup">Â®</span>), or vardenafil (Levitra<span class="Sup">Â®</span>)</li>
<li>medicines for <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> (TB), such as rifabutin (Mycobutin<span class="Sup">Â®</span>)</li>
<li>inhaled steroid medicines, such as fluticasone propionate (Flonase<span class="Sup">Â®</span>)</li>
<li>inhaled medicines such as salmeterol (Serevent<span class="Sup">Â®</span>) or salmeterol in combination with fluticasone propionate (Advair<span class="Sup">Â®</span>). Your doctor may need to change to a different medicine</li>
<li>medicines for <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, such as colchicine (Colcrys<span class="Sup">Â®</span>)</li>
<li>medicines to treat <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span> (PAH), such as bosentan (Tracleer<span class="Sup">Â®</span>) or tadalafil (Adcirca<span class="Sup">Â®</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicines, such as fentanyl (Duragesic<span class="Sup">Â®,</span> Ionsys<span class="Sup">TM</span>, Fentora<span class="Sup">Â®</span>) and methadone</li>
</ul>
<p><a name="p491821408"></a><span class="Bold">If you are not sure if you are taking a medicine above, ask your doctor.</span></p>
<p><a name="p491891408"></a><span class="Bold">How should I take KALETRA?</span></p>
<ul class="Disc">
<li>Take KALETRA every day exactly as prescribed by your doctor.</li>
<li>It is very important to set up a dosing schedule and follow it every day.</li>
<li>Do not change your treatment or stop treatment without first talking with your doctor.</li>
<li>Swallow KALETRA tablets whole. Do not chew, break, or crush KALETRA tablets.</li>
<li>KALETRA tablets can be taken with or without food.</li>
<li>If you are taking both Videx<span class="Sup">Â®</span> (didanosine) and KALETRA:<ul class="Circle">
<li>didanosine can be taken at the same time as KALETRA tablets, without food.</li>
<li>take didanosine either one hour before or two hours after taking KALETRA oral solution.</li>
</ul>
</li>
<li>Do not miss a dose of KALETRA. This could make the virus harder to treat. If you forget to take KALETRA, take the missed dose right away. If it is almost time for your next dose, do not take the missed dose. Instead, follow your regular dosing schedule by taking your next dose at its regular time. Do not take more than one dose of KALETRA at one time.</li>
<li>If you take more than the prescribed dose of KALETRA, call your local poison control center or emergency room right away.</li>
<li>Take KALETRA oral solution with food to help it work better.</li>
<li>If KALETRA is being used for your child, tell your doctor if your childâ€™s weight changes.</li>
<li>KALETRA <span class="Bold">should not</span> be given one time each day in children.  When giving KALETRA to your child, give KALETRA exactly as prescribed. </li>
<li>KALETRA oral solution contains propylene glycol and a large amount of alcohol. KALETRA oral solution <span class="Bold">should not</span> be given to babies younger than 14 days of age unless your doctor thinks it is right for your baby.<ul class="Circle">
<li>If a young child drinks more than the recommended dose, it could make them sick.  Contact your local poison control center or emergency room right away.</li>
<li>Talk with your doctor if you take or plan to take metronidazole or disulfiram. You can have severe <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> if you take these medicines with KALETRA.</li>
</ul>
</li>
<li>When your KALETRA supply starts to run low, get more from your doctor or pharmacy. It is important not to run out of KALETRA.   The amount of HIV-1 virus in your blood may increase if the medicine is stopped for even a short time. The virus may become resistant to KALETRA and become harder to treat.</li>
<li>KALETRA can be taken with acid reducing agents used for <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> or reflux such as omeprazole (Prilosec<span class="Sup">Â®</span>) and ranitidine (Zantac<span class="Sup">Â® </span>) with no dose adjustment.</li>
<li>KALETRA should not be administered once daily in combination with carbamazepine (Tegretol<span class="Sup">Â®</span> and Epitol<span class="Sup">Â®</span>), phenobarbital (Luminal<span class="Sup">Â®</span>), or phenytoin (Dilantin<span class="Sup">Â®</span>).</li>
</ul>
<p><a name="p497081408"></a><span class="Bold">What are the possible side effects of KALETRA?</span></p>
<p><a name="p499221408"></a><span class="Bold">KALETRA can cause serious side effects. </span></p>
<ul class="Disc">
<li>See <span class="Bold">â€œWhat is the most important information I should know about KALETRA?â€?</span><br>
</li>
<li>
<span class="Bold">Liver problems.</span> Liver problems, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, can happen in people who take KALETRA. Blood tests in people who take KALETRA may show possible liver problems. People with liver disease such as <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C who take KALETRA may have worsening liver disease. Tell your healthcare provider right away if you have any of these signs and symptoms of liver problems:<ul class="Circle">
<li>loss of appetite</li>
<li><span class="product-label-link" type="condition" conceptid="4021666" conceptname="Yellow skin">yellow skin</span> and whites of eyes  (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>)</li>
<li>dark-colored urine</li>
<li><span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> colored stools, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy skin</span></li>
<li>stomach area (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</li>
</ul>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> of the pancreas (<span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>)</span>. Some people who take KALETRA get <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the pancreas which may be serious and cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. You have a higher chance of getting <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> if you have had it before. Tell your doctor if you have <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> while taking KALETRA. These may be signs of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</li>
<li>
<span class="Bold">Increases in certain fat (triglycerides and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>) levels in your blood</span>. Large increases of triglycerides and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> can be seen in blood test results of some people who take KALETRA. The long-term chance of getting complications such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> due to increases in triglycerides and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> caused by protease inhibitors is not known at this time.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> and high blood sugar (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>)</span>. Some people who take protease inhibitors including KALETRA get new or more serious <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, or high blood sugar. Tell your doctor if you notice an increase in <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span> or urinate often while taking KALETRA. </li>
<li>
<span class="Bold">Changes in body fat</span>. Changes in body fat in some people who take antiretroviral therapy. These changes may include increased amount of fat in the upper back and neck ("<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>"), breast, and around the trunk. Loss of fat from the legs, arms and face may also happen. The cause and long-term health effects of these conditions are not known at this time.</li>
<li>
<span class="Bold">Increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> for hemophiliacs</span>. Some people with <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> have increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> with protease inhibitors including KALETRA.</li>
<li>
<span class="Bold"><span class="Underline">Increased risk of certain problems when you take medicines used for the treatment of erectile problems such as sildenafil (Viagra<span class="Sup">Â®</span>), tadalafil (Cialis<span class="Sup">Â®</span>), or vardenafil (Levitra<span class="Sup">Â®</span>) with KALETRA:</span></span><ul class="Circle">
<li><span class="Underline"><span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span></span>.  If you get dizzy or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, you need to lie down.  Tell your doctor if you feel dizzy, or have <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> spells.</span></li>
<li><span class="Underline"><span class="Bold">vision changes.</span>  Tell your doctor right away if you have vision changes.</span></li>
<li><span class="Underline"><span class="Bold">penis erection lasting more than 4 hours</span>.  If you are a male and have an erection that lasts longer than 4 hours, get medical help right away to avoid permanent damage to your penis. Your doctor can explain these symptoms to you. </span></li>
</ul>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span>.</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rashes</span>, some of them severe, can occur in people who take KALETRA. Tell your healthcare provider if you had a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> when you took another medicine for your HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or if you notice any <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> when you take KALETRA.</li>
<li>
<span class="Bold">Babies taking KALETRA oral solution may have side effects.</span>  KALETRA oral solution contains alcohol and propylene glycol.  Call your doctor right away if your baby appears too <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span> or their breathing has changed.</li>
</ul>
<p><a name="p504521408"></a>Common side effects of KALETRA include:   </p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li>stomach area (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li>feeling weak</li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span></li>
</ul>
<p><a name="p504791408"></a>These are not all of the possible side effects of KALETRA. For more information, ask your doctor or pharmacist. Tell your doctor about any side effect that bothers you or that does not go away. </p>
<p><a name="p506881408"></a>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </p>
<p><a name="p506931408"></a><span class="Bold">How should I store KALETRA?</span></p>
<p><a name="p506981408"></a><span class="Bold">KALETRA tablets:</span></p>
<ul class="Disc">
<li>Store KALETRA tablets at room temperature, between 59Â°F to 86Â°F (15Â°C to 30Â°C).</li>
<li>Do not keep KALETRA tablets out of the container it comes in for longer than 2 weeks, especially in areas where there is a lot of humidity. Keep the container closed tightly. </li>
</ul>
<p><a name="p507111408"></a><span class="Bold">KALETRA oral solution:</span></p>
<ul class="Disc">
<li>Store KALETRA oral solution in a refrigerator, between 36Â°F to 46Â°F (2Â°C to 8Â°C).  KALETRA oral solution that is kept refrigerated may be used until the expiration date printed on the label.</li>
<li>KALETRA oral solution that is stored at room temperature (less than 77Â°F or 25Â°C) should be used within 2 months.</li>
<li>Keep KALETRA away from high heat.</li>
</ul>
<p><a name="p507271408"></a>Throw away any medicine that is out of date or that you no longer need.</p>
<p><a name="p507301408"></a><span class="Bold">Keep KALETRA and all medicines out of the reach of children.</span></p>
<p><a name="p507371408"></a><span class="Bold">General information about KALETRA</span></p>
<p><a name="p509481408"></a>KALETRA does not cure <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> or AIDS and you may continue to experience illnesses associated with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. You should remain under the care of a doctor when using KALETRA. </p>
<p><a name="p49199324"></a>Avoid doing things that can spread HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. </p>
<ul class="Disc">
<li><span class="Bold">Do not share needles or other injection equipment</span></li>
<li><span class="Bold">Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</span></li>
<li>
<span class="Bold">Do not have any kind of sex without protection.</span> Always practice safe sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood.</li>
</ul>
<p><a name="p509571408"></a>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use KALETRA for a condition for which it was not prescribed. Do not give KALETRA to other people, even if they have the same condition you have. It may harm them.  </p>
<p><a name="p509611408"></a>This Medication Guide summarizes the most important information about KALETRA. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about KALETRA that is written for health professionals.  For more information about KALETRA call 1-800-633-9110 or go to www.KALETRA.com.   </p>
<br><p><a name="p509651408"></a>What are the ingredients in KALETRA? </p>
<p><a name="p509681408"></a>Active ingredients:  lopinavir and ritonavir</p>
<p><a name="p509711408"></a> Inactive ingredients: </p>
<p><a name="p509741408"></a><span class="Bold">KALETRA 200 mg lopinavir and 50 mg ritonavir tablets</span>:  copovidone, sorbitan monolaurate, colloidal silicon dioxide, and sodium stearyl fumarate.  The film coating contains:  hypromellose, titanium dioxide, polyethylene glycol 400, hydroxypropyl cellulose, talc, colloidal silicon dioxide, polyethylene glycol 3350, yellow ferric oxide 172, and polysorbate 80. </p>
<p><a name="p509801408"></a><span class="Bold">KALETRA 100 mg lopinavir and 25 mg ritonavir tablets</span>:  copovidone, sorbitan monolaurate, colloidal silicon dioxide, and sodium stearyl fumarate.  The film coating contains: polyvinyl alcohol, titanium dioxide, talc, polytheylene glycol 3350, and yellow ferric oxide E172. </p>
<p><a name="p509861408"></a><span class="Bold">KALETRA oral solution</span>:  acesulfame potassium, alcohol, artificial cotton candy flavor, citric acid, glycerin, high fructose corn syrup, Magnasweet-110 flavor, menthol, natural and artificial vanilla flavor, peppermint oil, polyoxyl 40 hydrogenated castor oil, povidone, propylene glycol, saccharin sodium, sodium chloride, sodium citrate, and water.</p>
<p><a name="p509921408"></a><span class="Bold">KALETRA oral solution contains 42.4% alcohol (v/v).  â€œSee How should I take KALETRA?â€?</span>.</p>
<br><br><br><br><br><br><p><a name="p512191408"></a>2012, ALL RIGHTS RESERVED</p>
<br><p><a name="p512231408"></a><span class="Sup">*</span> The brands listed are trademarks of their respective owners and are not trademarks of Abbott Laboratories.  The makers of these brands are not affiliated with and do not endorse Abbott Laboratories or its products.</p>
<br><p><a name="p512301408"></a>Rev. 05/2012</p>
<p><a name="p512331408"></a>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p><a name="p586671324"></a>KALETRA Tablets, 200 mg lopinavir/50 mg ritonavir</p>
<p><a name="p49664624"></a>Manufactured by Abbott Pharmaceuticals PR Ltd., Barceloneta, PR 00617</p>
<p><a name="p58927924"></a>for Abbott Laboratories, North Chicago, IL 60064 USA</p>
<br><p><a name="p588861224"></a>KALETRA Tablets, 100 mg lopinavir/25 mg ritonavir and KALETRA Oral Solution</p>
<p><a name="p589191124"></a>Abbott Laboratories, North Chicago, IL 60064 USA </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Ld9819e38-8431-4d26-b778-1a8bda87a523"></a><a name="section-17"></a><p></p>
<h1>Package Label</h1>
<p class="First">NDC 66336-0624-XX</p>
<p>NDC 66336-0624-12</p>
<p><img alt="NDC 66336-0624-XX" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dac2ea61-f5ce-45b8-b4aa-d761c5aecd74&amp;name=NDC%2066336-0624-XX------ABBOTT.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>KALETRAÂ 		
					</strong><br><span class="contentTableReg">lopinavir and ritonavir tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:66336-624(NDC:0074-6799)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LOPINAVIR</strong> (LOPINAVIR) </td>
<td class="formItem">LOPINAVIR</td>
<td class="formItem">200Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>RITONAVIR</strong> (RITONAVIR) </td>
<td class="formItem">RITONAVIR</td>
<td class="formItem">50Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SORBITAN MONOLAURATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STEARYL FUMARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3350</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>COPOVIDONE K25-31</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">KA</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:66336-624-12</td>
<td class="formItem">12  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021906</td>
<td class="formItem">06/18/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Dispensing Solutions, Inc.
							(066070785)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>PSS World Medical, Inc. (101822682)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Dispensing Solutions, Inc.</td>
<td class="formItem"></td>
<td class="formItem">066070785</td>
<td class="formItem">relabel(66336-624), repack(66336-624)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8e2fad31-7e6d-426c-b2f4-487d870f2374</div>
<div>Set id: dac2ea61-f5ce-45b8-b4aa-d761c5aecd74</div>
<div>Version: 1</div>
<div>Effective Time: 20121010</div>
</div>
</div>Â <div class="DistributorName">Dispensing Solutions, Inc.</div></p>
</body></html>
